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ABSTRACT

Kainate receptors (KARs) are glutamate-gated ion channels that mediate synaptic
transmission, modulate transmitter release, and mediate excitation in the brain.
Potentiation in their function predisposes the hippocampus to hyperexcitability and
seizures. These receptors are widely expressed throughout the central nervous system as
tetramers composed of various combinations of GluK1-5 subunits. In the hippocampus (a
brain region commonly associated with seizure initiation), GluK2-, GluK4-, and GluK5containing receptors are highly expressed in the CA3 pyramidal cell layer, whereas
GluK1 is barely detectable. The lack of pharmacological tools hinders identifying the
functional contribution of each kainate receptor subtype in normal CA3 synaptic
transmission. To address this critical obstacle, we used whole cell patch clamp
electrophysiology on HEK-T 293 cells transfected with GluK2 homomers, GluK2/K4 or
GluK2/K5 heteromers. We found that the drug ACET selectively inhibits GluK5 and
GluK4 subunits, whereas the drug kynurenate is an antagonist at all kainate subunits but
was more potent at GluK2 subunits. Furthermore, we were able to discover that binding
of glutamate to either the two GluK2 subunits or two GluK4/K5 subunits in the
heteromeric tetramer was sufficient to open the kainate receptor, albeit to a nondesensitizing current. However, glutamate binding to three or more subunits in the
tetramer was sufficient to enable kainate receptor desensitization. Lastly, using field
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potential electrophysiology to stimulate and record KAR-mediated synaptic transmission
(fEPSPs) at the mossy fiber – CA3 synapse, we found that perfusion of ACET was
sufficient to entirely block KAR-mediate fEPSPs at the mossy fiber – CA3 synapse.
These results suggest that 1) drugs ACET and kynurenate can be used as pharmacological
tools to delineate the functional contribution of specific receptor subtypes, 2) kainate
receptor activation and desensitization depends on the number of subunits bound to an
agonist, and 3) KAR-mediated synaptic transmission at the mossy fiber – CA3 is
conducted through heteromeric GluK4- or GluK5-containing KARs.
Metabotropic receptors, such as muscarinic acetylcholine receptors (mAChRs)
and dopamine receptors (DARs), can also alter the function of glutamate receptors and
have been implicated in epilepsy. Muscarinic acetylcholine receptors also play a critical
role in synaptic plasticity and neuronal excitability. There are five types of mAChR, M1M5, all of which, except m5 mAChRs, are found at different levels of expression in area
CA3 of the hippocampus where they are co-expressed with kainate receptors. Muscarinic
receptors regulated the function of other glutamate receptors, but it is unknown whether
they can interact with KARs. Dysfunctional interactions between KARs and muscarinic
acetylcholine receptors (mAChRs) have been implied in neurological diseases, including
temporal lobe epilepsy. For example, injection of a mAChR agonist (pilocarpine) in
rodents induces prolonged seizures and epilepsy, which can be blocked by a KAR
antagonist. Understanding how KARs and mAChRs interact may unlock novel therapies
for epilepsy. Using field potential electrophysiology, we discovered that mAChR
activation selectively depresses KAR-mediated fEPSPs at the mossy fiber – CA3
synapse. This mAChR depression of KAR fEPSPs is mediated through M1 mAChRs, but
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cannot be totally explained through PKC phosphorylation. Interestingly, M1 mAChR
depression of KAR fEPSP goes away with aging, suggesting this phenomenon is
developmentally regulated.
Lastly, we investigated whether the dopaminergic system is altered in a chronic
model of temporal lobe epilepsy. Similarly to mAChRs, DARs, specifically D1-like
DARs, play a critical role in synaptic plasticity, neuronal excitability, and have been
associated with seizure propagation. We demonstrated that D5 DARs, but not D1 DARs,
expression is significantly depressed in the epileptic hippocampus. Furthermore, we
found that dopamine clearance is reduced, while total dopamine content is unchanged in
the epileptic brain compared to sham-treated controls.
Taken together, we demonstrate the first steps toward discovering a novel
interaction between KARs and mAChRs in the brain. Furthermore, we identified
compensatory changes that occur in the dopaminergic system as a result of chronic
temporal lobe epilepsy. These findings will provide potential targets for therapeutic
interventions for patients with epilepsy.
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CHAPTER 1
GENERAL INTRODUCTION

1.1SIGNIFICANCE
Glutamate receptors mediate fast excitatory transmission in the brain. Particularly,
in the hippocampus they are required for synaptic plasticity that underlies learning and
memory. There are three types of ionotropic glutamate receptors: α-amino-3-hydroxy-5methyl-4-isoxazole propionic acid (AMPA), N-methyl-D-aspartate (NMDA), and kainate
receptors. Of these three types, kainate receptors are the least understood, although the
most interesting of the bunch. Unlike the other receptors, kainate receptors are located at
both presynaptic and postsynaptic sites, where they mediate synaptic transmission and
neurotransmitter release through not only the classical ionotropic mechanism but also
through a metabotropic G-protein mechanism. Additionally, kainate receptors have slow
excitatory postsynaptic potentials (EPSPs), which allows for temporal summation.
Furthermore, kainate receptor subtypes have unique pharmacology based upon the
subunits that compose them, and can undergo posttranslational modification (i.e.
phosphorylation), which allows kainate receptors to have diverse responses to the same
ligand. Overactivation of kainate receptions have been linked to neurological diseases,
such as epilepsy.
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Neurotransmitters, likes acetylcholine and dopamine, can modulate glutamate
receptor function. In the hippocampus, dysfunctional interactions between these
neurotransmitters and glutamate receptors have been linked to several neurological
diseases, including epilepsy. For example, administering a muscarinic acetylcholine
agonist reliably produces seizures in an animal model that remarkably resembles human
temporal lobe epilepsy. These seizures no longer occur when animals are pretreated with
a kainate receptor antagonist. Additionally, administering a dopamine receptor agonist
can precipitate seizures, which can also be blocked by a kainate receptor antagonist.
Interestingly, alternative therapies known to improve brain health and learning and
memory, such as routine physical exercise, have been shown to modulate acetylcholine
and dopamine content in the brain. This demonstrates a dynamic interaction between the
glutamatergic system and other monoamines that are required for optional brain health.
Our goal is to understand the interaction between the glutamatergic system and
monoamines in the brain. Furthermore, we want to understand how disruption in these
interactions could lead to neurological disease, such as in epilepsy, and how alternative
therapies, such as physical exercise, can counteract this disruption. Several studies have
observed how AMPA and NMDA ionotropic glutamate receptors are modulated by
muscarinic and dopamine receptors. However, it is not known whether kainate receptors
are altered by these metabotropic receptors. In this collection of studies we seek to 1)
discover a pharmacological tool that will help us identify KAR subunits involved in
synaptic transmission, 2) determine whether KAR-mediated synaptic transmission is
modulated by muscarinic and/or dopamine receptors, and 3) determine how neurological
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diseases, such as epilepsy, can alter monoamine content and infer how these changes can
impact the hippocampal glutamatergic system.

1.2 THE HIPPOCAMPUS

1.2.1 HIPPOCAMPAL FUNCTION
The hippocampus is a group of millions of cells buried deep within the medial
temporal lobe of the human and other mammalian brain. This structure resembles a
seahorse, and was thus named after the Latin translation “hippocampus” by the
Bolognese anatomist Giulio Cesare Aranzi (circa 1564). Since its discovery, the
functional role of the hippocampus remained heavily debated until the late 1950’s when
scientists William Scoville and Brenda Milner began excising the mesial temporal lobe
from patients with brain damage. The most notable patient, known as H.M., suffered
severely from uncontrollable seizures. He underwent surgery to remove the ‘epileptic
core’, which included removing both hippocampi, in an effort to reduce his seizure
frequency. The studies and observations of H.M. by William Scoville and Brenda Milner
in 1957 (Scoville and Milner, 2000) concluded that while the surgery was successful in
reducing the seizures, the patient was left incapable of developing new memories
(anterograde amnesia) nor had he retained memory of events that occurred immediately
before surgery. This was the first definitive link between memory and the hippocampus.
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Since that initial clinical observation, decades of behavioral research have
accumulated a large body of evidence confirming the hippocampus’s role in acquiring,
maintaining, and recalling memories. However, the hippocampus is not involved in every
type of memory. It is generally accepted that the hippocampus is critical for both
declarative memory and spatial memory (Burgess et al., 2002). Declarative memory
refers to memories that can be consciously recalled, such as facts and verbal knowledge.
These memories can be categorized into two subclasses: sematic memory, which is the
capacity to remember factual knowledge, and episodic memory, which stores
observational memories attached to specific personal experiences. In contrast, spatial
memory is the ability to encode information regarding one’s environment and spatial
orientation, which is necessary for navigation. The hippocampus achieves this with
“place cells”. Place cells are neurons located in the hippocampus that activate in
correspondence to a specific location independent of orientation (O’Keefe, 1976; Wilson
and McNaughton, 1993; Muller et al., 1994). In addition to acquiring and storing
memories, the hippocampus is also involved in memory retrieval. Although this
hippocampal function is still heavily debated due to the complicated nature of
experimental procedures and interpretation, it is believed that the hippocampus is
required for retrieval of detailed contextual memories (generally recent memories)
(Wiltgen et al., 2010). However, memories that lose precision (memories of our distant
past) can be retrieved independently of the hippocampus (Wiltgen et al., 2010). This
theory is also corroborates with clinical observations of patient H.M. and others with
damaged hippocampi, whom found it difficult to recall events just prior to the surgery
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removing their hippocampi, but did not experience deficits in recalling distant memories
(Squire, 1992; Hodges, 1994; Squire and Alvarez, 1995).
In accordance to the hippocampus’s central role in learning and memory, aging
(Scahill et al., 2003; Raz et al., 2004; Rodrigue and Raz, 2004; Du et al., 2006) and
diseases associated with learning and memory impairment, including Alzheimer’s (Wang
et al., 2006), epilepsy (Chang and Lowenstein, 2003) and schizophrenia (Heckers, 2001),
are strongly associated with hippocampal atrophy and sclerosis. Additionally, therapies
that are known to improve learning and memory performance, such as physical exercise,
can reverse and/or delay hippocampal atrophy (Erickson et al., 2011). The ability to
understand diseases that impair learning and memory and develop more effective
treatments for these diseases likely lies within our understanding of the hippocampus.
Fortunately, the anatomical structure and circuitry of this region in the healthy brain has
been well characterized.

1.2.2 HIPPOCAMPAL ANATOMY
Humans and other mammals have two hippocampi, one located on either side of
the brain – deep within the medial temporal lobe. The hippocampus is shaped like a
curved tube, resembling a cashew nut. The hippocampus is intimately connected and
function in coordination with other regions (dentate gyrus (DG), subiculum,
presubiculum, parasubiculum, and entorhinal cortex (EC)), known collectively as the
hippocampal formation. These accessory regions are required for funneling information
from various brain regions into the hippocampus and redistributing information exiting
5

the hippocampus. Particularly, the hippocampus proper itself consists of three Cornu
Ammonis fields (CA): CA1, CA2, and CA3. However, throughout this document and
most commonly in peer reviewed literature, the hippocampus refers to regions CA1,
CA2, CA3 and the DG.
Unlike discovering the function of the hippocampus, early investigations by
neuroanatomists were remarkably accurate in their depictions of the structure and cellular
organization of the hippocampus. In fact, illustrations of the hippocampus produced by
Ramon y Cajal in his book Histologie due Systeme Nerveux (1911) are still widely used
today. This ease in defining the hippocampal neuroanatomy was probably due to the
unique laminar organization of the hippocampus. Principal cells are tightly packed into a
single layer within each hippocampus region. This organization produces a highly
organized unidirectional flow of information known as the ‘trisynaptic circuit’ (See
Figure 1.1 for illustration). Briefly, the first synapse (perforant path) consists of axons
from principal cells in the EC synapsing onto principal cells dendrites in the DG. The
second synapse (mossy fiber pathway) consists of axons from the principal cells in the
DG synapsing onto principal cells in CA3. Finally, the third synapse (Schaffer collateral
path) consists of axons from CA3 principal cells (Schaffer collaterals) synapse onto CA1
principal cell dendrites. Information received by CA1 principal cells is then exited from
the hippocampus proper to the subiculum. Although the ‘trisynaptic circuit’ accounts for
general information flow through principal cells, diversions from this circuit and the
inclusion of non-principal cells makes the hippocampus circuitry more complex and will
be discussed in modest detail in the upcoming sections.
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CA1
3.

CA3

1.

2.

DG

Figure 1.1 Illustration of the trisynaptic circuit: 1) perforant path axons synapse onto
dentate granule cell dendrites, 2) dentate granule cell axons (mossy fibers) synapse onto
CA3 pyramidal cell dendrites, and 3) CA3 pyramidal cell axons synapse onto CA1
pyramidal cell dendrites.
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1.2.3 DENTATE GYRUS ANATOMY AND CIRCUITRY
The dentate gyrus (DG) is the first step in the hippocampus structure to receive
information leading towards the processing and production of memories. The entorhinal
cortex (EC), which accumulates cortical sensory information, projects unidirectionally
mainly to the dentate gyrus through axons called the perforant path. The DG does not
reciprocate axonal projections to the EC.
The DG has three distinct layers. The most superficial layer is called the
molecular layer or stratum moleculare. This layer is relatively cell-free (albeit a small
number of interneurons) and contains predominately dendrites from DG principal cells,
called dentate granule cells (DGCs). The other major occupant of the molecular layer are
the axon fibers projecting from the EC, which make up the perforant path. The layer in
which the principal DGCs are tightly packed and aligned is called the granule cells layer
or stratum granulosum. The cell body of interneurons, called pyramidal basket cells, are
also located on the inner boundary of the granule cells layer and the third layer of the DG,
called the polymorphic layer. The polymorphic layer, also called the hilus, is the most
inner layer of the DG. Numerous cell types are located in the hilus, but the most
prominent are the mossy cells. Mossy cell bodies and dendrites reside in the DG hilus,
and

their

axons

extend

into

the

inner

third

of

the

molecular

layer

(associational/commissural projection) where they synapse onto both granule cells and
GABAergic interneurons. Additionally, the hilus consists of axons from DGCs, called
mossy fibers, projecting towards CA3.
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1.2.4 CA3 ANATOMY AND CIRCUITRY
The CA3 region contains the second synapse in the trisynaptic pathway. This
region can be subdivided into four distinct layers: stratum oriens, stratum pyramidale,
stratum lucidum, and stratum radiatum. The most superficial region is the stratum oriens.
This region contains the basal (downward extending) dendrites of CA3 pyramidal
neurons. Additionally, this region contains axons projecting from CA3 pyramidal neurons
and synapsing onto adjacent CA3 pyramidal neurons (recurrent collaterals), as well as
CA3 pyramidal axons (Schaffer collateral) projecting to CA1 pyramidal neurons. Lastly,
this region contains a plethora of inhibitory interneurons. Just deep of the SO layer, is the
stratum pyramidale (SP), which contains the very densely packed pyramidal cell bodies.
The stratum lucidum is located deep to SP and contains mossy fibers originating from the
DG. Lastly, the stratum radiatum (SR) is the deepest layer and contains CA3 pyramidal
neuron dendrites, EC axons projecting onto CA3 pyramidal dendrites (perforant path),
and various interneuron subtypes.

1.2.5 CA1 & CA2 ANATOMY AND CIRCUITRY
The anatomical organization and nomenclature for regions CA1 and CA2 are
identical. Densely packed pyramidal cells align to form a layer known as the stratum
pyramidale. Superficial to this layer is the stratum oriens, which similarly to area CA3,
contains both the apical dendrites of CA1/CA2 pyramidal cells and axons projecting from
CA1/CA2 pyramidal neurons into mainly the subiculum. Deep to the stratum pyramidale
is the stratum radiatum, which contains basal CA1/CA2 pyramidal neuron dendrites.
9

Additionally, this layer contains Schaffer collateral fibers synapsing onto CA1/CA2
pyramidal dendrites. Various types of interneurons are distributing throughout the
stratum oriens and stratum radiatum and sparsely throughout the stratum pyramidale.
Unlike the CA3 region, the CA1 contains very few recurrent connections, making it less
likely to undergo feed-forward bursting.

1.3 SYNAPTIC PLASTICITY

1.3.1 GLUTAMATE RECEPTORS
Glutamate is the main excitatory neurotransmitter in the brain. At synapses,
glutamate is stored in vesicles, where it is released from presynaptic neurons in response
to nerve impulses. Released glutamate binds to glutamate receptors and produces
neuronal activation, which is essential for brain function. Glutamate receptors come in
two subclasses: ionotropic and metabotropic. Ionotropic receptors contain a channel pore
that opens in response to bound glutamate, allowing the flow of ions and mediating fast
synaptic transmission. Alternatively, metabotropic glutamate receptors couple to a Gprotein and elicit a second-messenger signaling cascade when bound to glutamate. There
are three primary categories of ionotropic glutamate receptors: N-methyl-D-aspartate
receptor

(NMDAR),

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic

receptor

(AMPAR), and kainate receptor (KAR). Each receptor subtype was identified based on
their relative affinity for agonists N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
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methyl-4-isoxazolepropionic acid (AMPA), kainate (KA) respectively. However, recent
pharmacology studies have identified promiscuity among ionotropic glutamate receptors
in their affinity for these agonists.
Ionotropic glutamate receptors are distributed throughout the hippocampus on
principal and non-principal neurons, where they mediate the cellular form of learning and
memory. It is believed that the cellular basis for learning and memory is intimately
related to the ability of a synapse to strengthen or weaken. This phenomenon is called
synaptic plasticity. There are several forms of synaptic plasticity that vary based on their
persistence over time and the mechanisms by which they occur. Generally, synaptic
plasticity is put into two categories: short-term plasticity, in which change in synaptic
strength lasts seconds to minutes, and long-term plasticity, in which the change in
synaptic strength lasts for an hour or more.

1.3.2 LONG-TERM POTENTIATION
Much experimental work has been performed on long-term plasticity, and
specifically

investigating

mechanisms

leading

to

persistent

activity-dependent

enhancement in synaptic strength, long-term potentiation (LTP). Long-term potentiation
can be induced either by strongly stimulating the presynaptic neuron with a nonphysiological relevant high frequency (100Hz, 1sec) train, stimulating the presynaptic
neuron with an activation pattern that closely resembles learning in the awake brain (theta
burst patterns), briefly pairing presynaptic and postsynaptic stimulation, or chemically
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with pharmaceutical agents mimicking other neurotransmitters. All of these protocols for
induction of LTP elicit a similar cascade of events.
Although similar mechanisms of LTP have been identified in several synapses
throughout the brain, much of the studies have been conducted on Schaffer collaterals
projecting to CA1 pyramidal neurons. Electrical stimulation of Schaffer collateral axons
causes a release of stored glutamate from presynaptic vesicle. This released glutamate
binds to various glutamate receptor subtypes located postsynaptically on CA1 pyramidal
neurons. Specifically, AMPA receptors open when bound to glutamate allowing a net
positive flow of Na+ ions into the CA1 pyramidal cells. This causes the cell to become
more depolarized (excitatory postsynaptic potential (EPSP)) and more likely to fire an
action potential. NMDA receptors are also located on postsynaptic CA1 pyramidal
neurons, where they can bind glutamate. However, the NMDAR channel pore is blocked
by Mg2+ ions when the cell is near resting membrane potentials. Thus, if the Schaffer
collaterals are stimulated at low frequencies, the EPSP amplitude will remain constant or
slightly increase. However, if high frequency stimulation is applied to Schaffer
collaterals, more glutamate is released from the presynaptic neuron and repeatedly
activates AMPA receptors. The sustained AMPA receptor activation causes the CA1
pyramidal neuron to become highly depolarized. The Mg2+ block will then withdraw from
the NMDA receptor and allow a high influx of Ca2+ and Na2+ into the CA1 pyramidal
neuron. This increase in Ca2+ elicits signaling cascades with downstream effects of PKC
and PKA phosphorylation of AMPA receptors to facilitate more AMPA receptor
trafficking and insertion in the postsynaptic CA1 synapse. Now, the same stimulus will
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elicit EPSP amplitudes that are increased and remain elevated for several hours. Thus, the
CA1 pyramidal neuron is more likely to fire an action potential.
LTP at the perforant path to dentate gyrus granule cells and Schaffer collaterals to
CA1 pyramidal neurons are NMDAR dependent. Also, LTP at the perforant path
projected onto CA3 pyramidal neurons, and recurrent collaterals interconnecting CA3
pyramidal neurons are also NMDAR dependent. However, the mossy fiber pathway that
synapses onto CA3 pyramidal neurons is not NMDAR dependent. Interestingly, KARs
are highly expressed pre- and post-synaptic at this synapse, and is one of few regions in
the hippocampus where there is a measurable KAR field potential.

1.3.3 MOSSY FIBER LONG-TERM POTENTIATION
Mossy fiber synapses show an unusual form of LTP. Unlike conventional
synapses where LTP is NMDAR dependent, mossy fiber LTP can occur and persists even
when NMDAR function is blocked (Harris and Cotman, 1986; Zalutsky and Nicoll,
1990). Thus, the mechanism by which the mossy fiber – CA3 synapse undergoes
plasticity is fundamentally different than those at most synapses. Similar to classical
(Hebbian) LTP, LTP of the mossy fiber – CA3 synapse can be evoked by various high
frequency stimulation protocols (Zalutsky and Nicoll, 1990; Hirata et al., 1991; Castillo
et al., 1994; Nicoll and Schmitz, 2005) or stimulation patterns that mimic natural granule
cell firing patterns (Mistry et al., 2011). The mechanism contributing to MF-LTP is
thought to occur predominantly presynaptic, by an increase in presynaptic calcium
current causing enhanced glutamate release. Others have suggested that activation of
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presynaptic KARs and/or an increase release of calcium from internal stores also
contribute to MF-LTP. However, the involvement of postsynaptic mechanisms cannot be
ruled out as other studies have demonstrated that a postsynaptic rise in Ca2+ (Kapur et al.,
1998; Yeckel et al., 1999; Wang et al., 2004) and ephrin-mediated kinases (Contractor et
al., 2002; Armstrong et al., 2006) are required for MF-LTP.

1.3.4 LONG TERM DEPRESSION
Long-term depression (LTD) is a persistent weakening in synaptic strength lasting
for at least one hour. This form of plasticity ensures that the postsynaptic neuron is less
likely to fire an action potential (depressed EPSPs). LTD occurs in several brain regions,
including the hippocampus. The discovery of long-term depression (LTD) occurred much
later (1980’s) than LTP (1973) (Bliss and Gardner-Medwin, 1973; Bliss and Lomo, 1973;
Ito and Kano, 1982), which may account for why slightly less is known about the
mechanism of LTD. However, we do know that LTD can be induced by very low
frequency stimulation patterns (1 to 5 Hz) given for prolonged periods of time
(Braunewell and Manahan-Vaughan, 2001). This low stimulation intensity causes only a
modest increase in NMDAR-mediated postsynaptic calcium concentrations, which
subsequently activates calcium-dependent phosphatases (as opposed to protein kinases in
LTP) to remove AMPAR from the postsynaptic cell surface (Lisman, 1989; Mulkey and
Malenka, 1992; Mulkey et al., 1993, 1994). The threshold for determining whether Ca2+
levels will undergo LTD or LTP is dynamic and depends on the previous history of the
synapse.
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1.3.5 MOSSY FIBER LONG-TERM DEPRESSION
Low frequency stimulation of mossy fiber axons evokes long-term depression
(LTD) at mossy fiber – CA3 synapses. This form of LTD is NMDAR-independent
(Kobayashi et al., 1996) and involves activation of presynaptic metabotropic glutamate
receptors (Manzoni et al., 1995; Yoshino et al., 1996), causing a reduction in cAMP and
subsequent protein kinase A (PKA) activity (Tzounopoulos et al., 1998). The end result is
a lower glutamate release probability. Interestingly, the mechanism of MF-LTD is age
and developmentally dependent. Rats 2 – 3 weeks postnatal transiently express calciumpermeable AMPAR (CP-AMPAR) (Pellegrini-Giampietro et al., 1992; Pickard et al.,
2000). As the name suggests, activation of these receptors allows Ca2+ ions to flow into
the cell. At MF synapses expressing CP-AMPAR, the locus of LTD is postsynaptic,
involving selective trafficking of CP-AMPAR away from the CA3 pyramidal cell surface
(Ho et al., 2007). Alternatively, rats older than 3 weeks postnatal express predominantly
calcium-impermeable AMPAR (CI-AMPAR) postsynaptically at mossy fiber – CA3
synapses, and do not undergo MF-LTD after low frequency depolarization of mossy fiber
axons.

1.3.6 SHORT-TERM PLASTICITY
Changes in synaptic strengthening or weakening that lasts for less than 1 hour is
considered short-term potentiation or short-term depression, respectively. Short-term
plasticity is considered to occur predominantly presynaptic, by a change in the release
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probability of glutamate from presynaptic terminals. An increase in glutamate release
probability corresponds to short-term potentiation, whereas a decrease in glutamate
release probability corresponds to short-term depression. The mechanism by which shortterm potentiation occurs is coined the “residual Ca2+ hypothesis”. This theory states that
enhanced transmitter release (facilitation) during a second stimulus is caused by
remaining Ca2+ in the nerve terminal after the initial stimulus (Katz and Miledi, 1968;
Rosenthal, 1969; Erulkar and Rahamimoff, 1978; Kretz et al., 1982).
There are several possible mechanisms for short-term depression. The most
widespread mechanism is use-dependent depletion of release-ready neurotransmitter
(glutamate) in the presynaptic terminal (Liley and North, 1953; Betz, 1970). In detail,
when the presynaptic neuron is depolarized it releases glutamate from vesicles that are
docked and ready to be released into the synapse. With low frequency stimulation, the
released glutamate is re-uptaken back into the nerve terminal where it can be recycled
and/or replaced with other glutamate-containing vesicles waiting “on deck”. However,
with high frequency stimulation, this release-ready pool is not provided enough time to
recycle (Simons-Weidenmaier et al., 2006). The result is less glutamate released and
lower EPSPs recorded from the postsynaptic neuron. Another mechanism for short-term
depression is the reduction of glutamate release mediated by autoreceptors located
presynaptically. Each of the ionotropic and metabotropic glutamate receptors have been
shown to be localized on presynaptic terminals were they regulate glutamate release after
depolarization of the presynaptic neuron (Kerchner et al., 2001; Lee et al., 2002a;
Bardoni et al., 2004). Alternatively, short-term depression can also occur through a
postsynaptic mechanism. Exposure of ionotropic glutamate receptors to glutamate opens
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the receptors and can also put some channels into a nonresponsive (desensitized) state.
Desensitization of glutamate receptors located postsynaptically can make the target
neuron less sensitive to glutamate (Mennerick and Zorumski, 1996; Larkman et al.,
1997). The end result is transiently lower EPSPs.

1.3.7 SYNAPTIC PLASTICITY IN LEARNING AND MEMORY
Virtually every synapse in the brain is dynamically regulated. Mechanisms to
either enhance or depress synaptic transmission can either be short-lived or long lasting.
We previously described that the hippocampus is necessary for acquiring, retaining, and
retrieving new memories. Furthermore, we described how ionotropic glutamate receptors
are the key players in mediating several forms of synaptic plasticity, both long-term and
short-term, in the hippocampus. However, the question prevails whether synaptic
plasticity translates to learning and memory.
It is generally accepted that synaptic plasticity, especially LTP, is a cellular model
for learning and memory. The first studies linking synaptic plasticity with learning and
memory were correlational. Barnes (1979) and Barnes & McNaughton (1985) found that
persistent LTP was statistically correlated with the rate of learning and/or memory
retention (Barnes, 1979; Barnes and McNaughton, 1985). Subsequent studies
accumulated over 20 years have found similar results. This correlation also occurs in the
diseased brain. For example, in the murine model of Alzheimer’s disease overexpressing
mutant amyloid precursor protein, the decline in memory performance was also
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statistically correlated with a decline in LTP, both in vivo and in vitro (Chapman et al.,
1999).
In addition to correlation studies, pharmacological blockage of NMDA receptors
impairs hippocampus-dependent learning. As described above, NMDAR are necessary
for LTP and LTD to occur at most synapses, with the mossy fiber – CA3 synapse being
an exception. Studies have shown that administering a potent NMDAR antagonist
prevents LTP, and impairs hippocampal-dependent spatial memory, but not hippocampalindependent forms of memory (visual discrimination) (Morris et al., 1986). Several
learning paradigm have been used to replicate these findings (Tonkiss et al., 1988;
Danysz et al., 1988; Staubli et al., 1989; Tonkiss and Rawlins, 1991; Bolhuis and Reid,
1992; Shapiro and O’Connor, 1992; Cole et al., 1993; Lyford et al., 1993; Caramanos and
Shapiro, 1994; Fanselow et al., 1994; Li et al., 1997). The impairment in learning
performance is dose dependent and occurs at comparable drug concentrations that impair
LTP in vivo and in vitro (Davis et al., 1992). Interestingly, blocking NDMA receptors
with an antagonist prevents the development of new memories, but does not affect the
retention of memories (Morris, 1989; Staubli et al., 1989; Morris et al., 1990). This
suggests that the ability of a synapse to undergo LTP is necessary for the formation of
new memories, as opposed to retaining or retrieving older memories. Also, drugs that
activate ionotropic glutamate receptors can enhance both LTP and memory. One such
class of drugs are the ampakines, which decrease the speed of AMPAR desensitization
and activation (Arai et al., 1994, 1996). Interesting, this drug shifts the AMPAR kinetics
to those mimicking NMDA and KARs. Ampakines increase both the probability of LTP
and enhance memory encoding (Stäubli et al., 1994; Lynch, 1998).
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Synaptic plasticity also occurs naturally during learning. Spatial exploration
causes a short-term modulation in perforant path EPSPs (Moser et al., 1993). This
increase occurs rapidly at the onset of exploration and gradually declines to baseline over
time (15 min). These observations present two interesting points. One, synaptic plasticity
occurred in the time scale when learning is most likely taking place, and two, short-term
plasticity also has important implications for learning and memory. Indeed, mice with
genetically compromised presynaptic proteins (alpha CaMKII, synapsin II, and both
synapsin I and synapsin II) but normal LTP, demonstrate impaired short-term plasticity
and profound learning difficulties (Silva et al., 1996). However, there have been studies
that also demonstrate natural occurring LTP during learning. For example, Ishihara et al.
(1997) found a positive correlation between CA3 population spikes caused by mossy
fiber stimulation and learning performance in radial arm maze (Ishihara et al., 1997).
Furthermore, studies have proven post-hoc that adult animals raised in an enriched
environment have enhanced perforant path – dentate EPSP compared to adult animals
raised in normal cages (Green and Greenough, 1986). In conclusion, these results
demonstrate that both short-term and long-term forms of synaptic plasticity are critical
for the acquisition of new memories. Thus, any neuromodulator that would impact either
form of synaptic plasticity would have profound effects on our ability to learning and
form memories.
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1.4 MUSCARINIC ACETYLCHOLINE RECEPTOR MODULATION OF GLUTAMATE
RECEPTORS

1.4.1 ACETYLCHOLINE
Glutamate receptors, and consequently synaptic transmission, can be dynamically
regulated by other neurotransmitters and their metabotropic receptors. One example is
acetylcholine (ACh). Acetylcholine was the first neurotransmitter to be synthesized. Its
discovery by Sir Henry Hallett Dole and Otto Loewi awarded them the Noble Prize in
1936. Its name is derived from its chemical structure, an ester of acetic acid and choline.
Acetylcholine has many functions throughout the body. In the brain, acetylcholine is used
as a neurotransmitter and plays important roles in learning and memory, arousal,
attention, and motivation. Aside from its effects in the brain, ACh is also a primary
neurotransmitter at the neuromuscular junction where ACh activates muscles and is a
major neurotransmitter in the autonomic nervous system.
The hippocampus receives acetylcholine from cholinergic fibers projecting from
the medial septum of the basal forebrain (Dutar et al., 1995). In fact, the human
hippocampus contains one of the highest densities of cholinergic fibers (Mesulam et al.,
1992). Acetylcholine is synthesized from choline and acetyl coenzyme A by the enzyme
choline acetyltransferase and becomes packaged into membrane bound vesicles in the
axons of cholinergic fibers. After an action potential propagates down the cholinergic
terminal, acetylcholine is released into the synaptic cleft. Released acetylcholine can
then bind to acetylcholine receptors located postsynaptically. Alternatively, acetylcholine
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is rapidly degraded by acetylcholinesterase into choline and acetate. The choline product
can be re-uptaken into the presynaptic terminal and recycled into acetylcholine.

1.4.2 ACETYLCHOLINE RECEPTORS
Like other neurotransmitters ACh exerts its effects by binding to receptors. There
are two categories of ACh receptors: nicotinic acetylcholine receptor (nAChR) and
muscarinic acetylcholine receptor (mAChR). Similarly to glutamate, they were identified
and named after their affinity for the selective agonists: nicotine and muscarine. The
nicotinic receptors act as ligand-gated ionotropic receptors, meaning they undergo a
conformation change and open a channel pore to allow the flow of ions (Na+, K+, and
Ca2+) when ACh is bound. Alternatively, mAChRs are G-protein coupled (metabotropic)
receptors and have a slower response when activated. mAChRs can have either an
inhibitory or excitatory effect based upon the mAChR activated and the G-protein in
which the mAChR couples.

1.4.3 MUSCARINIC RECEPTORS
As stated earlier, mAChRs are metabotropic receptors that couple to G-proteins
and elicit a second-messenger signaling cascade. mAChRs have seven transmembrane
regions. There are five types of mAChRs (M1 – M5), each encoded by the gene with
corresponding names (m1 – m5). M1, M3, and M5 couple to Gq proteins and stimulate a
phospholipase C/ inositol trisphosphate/ intracelluclar calcium-signaling pathway
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(Caulfield and Birdsall, 1998; Lanzafame et al., 2003). The M2 and M4 mAChRs couple
Gi/o protein and inhibits cAMP activity by downregulating adenylate cyclase. However,
mAChRs occasionally vary in the G-protein in which they are bound.
Each of the mAChRs have distinct subcellular localization in the hippocampus
(Levey et al., 1995). M1 mAChRs are the most abundantly expressed mAChRs in the
human and rodent hippocampus (Cortes et al., 1984; Cortés et al., 1986; RodríguezPuertas et al., 1997; Scarr et al., 2007), where it is expressed widely in the cell body and
dendrites of principal neurons (CA1, CA2 and CA3 pyramidal neuron and dentate
granule neurons). M2 is expressed predominantly in non-principal neurons and discrete
bands and puncta surrounding pyramidal neuron soma in CA3 more than CA1, but not
expressed in the pyramidal neurons (Rouse et al., 1997). M3 is expressed in pyramidal
neurons, neuropil in stratum lacunosum-moleculare, and the outer third of the molecular
layer of dentate gyrus. M4 is enriched in non-principal neurons and the inner third of the
molecular layer. Additionally, a subset of M2 and M4 mAChRs were localized
presynaptically. In conclusion, only the M1 and M3 receptors are predominantly located
on postsynaptic principal neurons, where they can modulate synaptic plasticity by
directly interacting with postsynaptic ionotropic glutamate receptors, while M2 and M4
mAChRs are predominately located on interneurons. The M5 receptor is the least
abundant of the muscarinic receptors and is expressed at low levels throughout brain. At
the mossy fiber – CA3 synapse, mAChRs are located both pre- and postsynpatically
where they alter synaptic neurotransmission.

22

1.4.3 FUNCTION OF MUSCARINIC RECEPTORS IN THE HIPPOCAMPUS
The cholinergic system is crucial for learning and memory. Perhaps the best
behavioral illustration is in Alzheimer’s disease, where degeneration of these cholinergic
projections in the hippocampus is the hallmark symptom for deficits in learning and
memory, working memory, and attention (Bartus et al., 1982). Additionally,
scopolamine, a mAChR antagonist, induces memory deficits (delirium and amnesia) in
healthy volunteer (Drachman and Leavitt, 1974). Still today, several pharmaceutical
therapies for AD are aimed at inhibiting cholinesterase activity or enhancing cholinergic
signaling (Lane et al., 2006). Indeed, enhanced cholinergic signaling has shown to
improve LTP and memory deficits in vivo and in vitro (Caccamo et al., 2006; Chen et al.,
2006). Furthermore, ablation or inhibition of M1 mAChRs impairs spatial memory
encoding, demonstrating a critical role for mAChRs in hippocampal-dependent learning.
Muscarinic acetylcholine receptors are located at both presynaptic and
postsynaptic sites where they modulate synaptic plasticity. Presynaptic mAChRs on
principal neurons suppress glutamate release, and thereby reducing hippocampal activity
(a form of short-term depression) (Valentino and Dingledine, 1981). Meanwhile,
postsynaptic mAChR inhibit K+ conductance, which enhances hippocampus activity (a
form of short-term potentiation) (Cole and Nicoll, 1983). Thus, the same muscarinic
agonist can have bidirectional affects on short-term synaptic plasticity. Additionally,
presynaptic muscarinic receptors have been shown to suppress GABA release onto CA3
hippocampal pyramidal neurons, which is mediated predominantly through M2 mAChRs
(Szabó et al., 2010).
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Cholinergic activity can also facilitate LTP in various brain regions, including the
hippocampus. Application of a cholinergic agonist (Blitzer et al., 1990; Auerbach and
Segal, 1996) or stimulation of the medial septum in vivo can induce hippocampal LTP
(Galey et al., 1994; Markevich et al., 1997). Indeed, when a muscarinic agonist is
perfused onto a brain slice prior to a high frequency stimulus, it can enhance LTP in CA1
without affecting baseline EPSPs (Blitzer et al., 1990; Auerbach and Segal, 1994;
Sokolov and Kleschevnikov, 1995; Adams et al., 2004; Shinoe et al., 2005). This
phenomenon also occurs in the dentate gyrus and shown to be mediated through M1
mAChRs at both synapses. A recent study using newly developed M1 mAChR selective
agonist and congenital knockout mice elegantly corroborates previous literature by
demonstrating that M1 mAChR activation produces a robust potentiation of
glutamatergic synaptic transmission onto CA1 pyramidal neurons and NMDA-dependent
LTP (Dennis et al., 2015). However, M1 mAChRs seem not to be necessary for LTP to
occur, since congenital M1 knockout mice demonstrates only mild deficits in CA1 LTP.
Interestingly, these mice did experience significant memory deficits in tasks requiring
both the cortex and hippocampus to interact (Anagnostaras et al., 2003). In conclusion,
significant evidence supports that M1 mAChRs activation enhances synaptic plasticity at
CA1 and the dentate gyrus and facilitates the ability to learn.
In contrast to its effects on tetanus-induced LTP (LTP induced by a high stimulus
train), mAChR activation by itself can induce LTP (Auerbach and Segal, 1994, 1996) or
LTD (McCutchen et al., 2006). Interestingly, the expression mAChR-induced LTP or
LTD is dependent on the mAChR agonist concentration. A low dose of mAChR agonist
induces mAChR-induced LTP. The mechanism mimics LTP induced by a high frequency
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stimulus train, with postsynaptic increase in intracellular calcium and initiation of protein
kinases activity is required (Auerbach and Segal, 1994, 1996). Whether mAChR LTP is
NMDA-dependent is controversial. However, at higher concentrations muscarinic
agonists can induce synaptic depression and LTD following prolonged exposure
(Auerbach and Segal, 1996; McCutchen et al., 2006; Dickinson et al., 2009). The
mechanism by which this effect is thought to occur is predominantly mediated through
M1 and M3 receptors and involves the loss of surface AMPA receptors (NMDAR
independent) via a calcium-independent signaling cascade involving dephosphorylation
by protein tyrosine phosphatases (Dickinson et al., 2009).
Although significant studies have found that M1 mAChR play a major role in
synaptic plasticity and learning and memory, M2/M4 mAChRs also have an important
role in synaptic plasticity and learning and memory. An M2 receptor knockout
demonstrates significant impairments in working memory, behavioral flexibility, and
LTP (Seeger et al., 2004). Moreover, an M2/M4 specific antagonist can induce LTP in
CA1 in vivo, albeit requires coactivation of M1/M3 receptors. These studies suggest that
presynaptic and postsynaptic mAChRs, including specific mAChR subtypes, work in
conjunction to modulate learning and synaptic plasticity.

1.4.4 MUSCARINIC MODULATION OF GLUTAMATE RECEPTORS
NMDA receptors
As described in the previous sections, neuronal excitability and synaptic
transmission can be altered by interactions between the glutamatergic and cholinergic
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systems. The mechanism for this interaction requires crosstalk between the two receptors.
For example, NMDARs (specifically the NMDARs containing the GluN1 subunit) colocalize with M1 mAChRs on CA1 pyramidal neurons (Marino et al., 1998). Activation
of M1 mAChRs elicits a protein kinase C (PKC) signaling cascade, which proceeds to
phosphorylate PYK2 and in turn phosphorylates and activates Src kinase (Lu et al.,
1999). Phosphorylation of ionotropic glutamate receptors is subunit and amino acid site
specific. For example, the molecular targets of Src are postulated to be three tyrosines on
the C-terminus of the NMDA subunit, GluN2A (Zheng et al., 1998). Phosphorylation of
this subunit by the Src kinase increases NMDAR trafficking to the cell surface and
thereby increased NMDA responses at CA1 synapses. In contrast to M1 receptor
activation enhancing NMDAR responses at hippocampal CA1 synapse, M1 receptor
activation depresses NMDAR responses at the mossy fiber – CA3 synapse (Grishin et al.,
2005). The mechanism proposed involves calmodulin-activated tyrosine phosphatases.
These findings demonstrate that GPCR, specifically mAChRs, can interact with
NMDARs through second messenger signaling cascades and that phosphorylation of
glutamate receptors are subunit and amino acid site specific.
AMPA Receptors
Muscarinic acetylcholine receptors have also been shown to modulate AMPAR
activity. Muscarinic receptors (mainly M1) induce long-term depression (LTD) at CA1 in
the hippocampus and cerebellum mainly through changes in AMPA receptor trafficking
(Dickinson et al., 2009; Nomura et al., 2012). Interestingly, the mechanism eliciting M1
facilitation of NMDAR activity and M1 LTD of AMPAR activity require similar
signaling cascades. mACh receptor-induced LTD at CA1 pyramidal neurons is mediated
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by PKC activation leading to phosphorylation of the AMPAR specific GluA2 subunit
(Dickinson et al., 2009). PKC phosphorylation of this subunit causes it to dissociate from
glutamate receptor-interacting protein 1 (GRIP1), which is a protein involved in the
regulation of glutamate receptor trafficking. Dissociation from GRIP1 allows the GluA2containing AMPAR to diffuse laterally out of the synapse, and undergo endocytosis
mediated by an AMPAR receptor auxiliary protein. These results show that mAChRs can
also interact with AMPARs through phosphorylation cascades to alter their function at
the synapse.
Alternatively, a study by Grishin et al. (2005) demonstrated that activation of M1
mAChRs had no affect on AMPAR current at CA3 pyramidal neurons, but reliably
depressed NMDA receptor current at the same synapse (Grishin et al., 2005). This
muscarine-induced depression of NMDA receptors was found to be mediated through a
signaling cascade involving tyrosine phosphatase.
Kainate Receptors
While previous studies have demonstrated that mAChRs crosstalk with NMDAR
and AMPAR, little is known about whether mAChRs can crosstalk with KARs. To date
there has been one study directly investigating this interaction. Benveniste et al. (2010)
demonstrated that activation of M1 and M3 mAChRs with pilocarpine potentiated
GluK2-containing (GluK2/K4 and GluK2/K5) KAR heteromers, but not homomeric
GluK2 KARs (Benveniste et al., 2010). This suggests that the subunits, GluK4 and
GluK5, are necessary for mAChR potentiation of KARs. Benveniste et al. (2010)
furthermore demonstrated that mAChR activation with pilocarpine increased kainate-
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induced mossy fiber axon excitability. The mechanism responsible this interaction was
not investigated.
This study presents a successful initial step in identifying that crosstalk between
the mAChRs and KARs can potentially occur. However, it misses in demonstrating
physiological relevance for this interaction. First, the experiments demonstrating
mAChRs potentiating heteromeric KARs were performed in Xenopus oocytes. Although
this model is ideal in deciphering the pharmacology of ligand-gated and voltage-gated
ionotropic receptors, the relevance of this model diminishes when used to compare
intracellular signaling mechanisms in oocytes to those in humans. Additionally, their
experiments in brain slices that showed pilocarpine, a mAChR agonist, enhanced KARinduced mossy fiber excitability were performed measuring antidromic spikes. An
antidromic spike in an electrical impulse that originates in the axon and travels toward the
cell body (soma), opposite the conventional action potential direction. Thus, the
physiological relevance of these results is also left to be determined. More research is
required to determine whether mAChRs can induce physiological relevant changes to
KARs and to elucidate the corresponding signaling mechanism by which this interaction
occurs.
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1.5 DOPAMINERGIC MODULATION OF GLUTAMATE RECEPTORS

1.5.1 DOPAMINE
Dopamine (DA) in the central nervous system acts as a neurotransmitter and
belongs to the catecholamine family (Carlsson et al., 1962). Its name is derived from its
chemical structure, an amine formed by removing a carboxyl group from a molecule of
L-DOPA. Dopamine is produced in several areas in the brain, including the substantia
nigra and ventral tegmental area. DA neurons project to many areas throughout the brain
through pathways categorized based upon the territories they innervate: mesolimbic,
mesocortical, nigrostriatal, and tuberoinfundibular (Vallone et al., 2000). The
hippocampus receives dopaminergic innervation from the mesolimbic pathway projecting
from the VTA (Gasbarri et al., 1994a, 1994b, 1997). Some fibers from the substantia
nigra also innervate the temporal (ventral and caudal) hippocampus.
DA neurons synthesize dopamine through a specific metabolic pathway. Briefly,
phenylalanine is converted into tyrosine by the enzyme phenylalanine hydroxylase.
Tyrosine is then converted into L-DOPA by the enzyme tyrosine hydroxylase (TH). In
the final step, L-DOPA is converted into dopamine by the enzyme aromatic L-amino acid
decarboxylase. Dopamine is then stored in vesicle in DA neurons terminals where it
awaits release. When an action potential terminates at the axon terminal, dopamine is
then released from the presynaptic vesicles into the synaptic cleft. Upon release,
dopamine can either undergo 1) degradation by enzymes, such as catechol-O-methyl
transferase (COMT), 2) reabsorbtion back into the presynaptic terminal by dopamine
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transporter (DAT), or 3) binding to dopamine receptors (DAR) located on the
postsynaptic neurons.

1.5.2 DOPAMINE RECEPTORS
Dopamine released from DA neuron terminals bind to receptors with a high
affinity for dopamine. Dopamine receptors (DARs) are composed of seven
transmembrane domains. They are metabotropic in function, meaning that they couple to
G-proteins and elicit their action through second messenger signaling cascades. However,
recent studies have demonstrated that dopamine receptors can directly bind (proteinprotein interaction) to several other types of metabotropic and ionotropic receptors and
alter their function (Liu et al., 2000; Lee et al., 2002b). There are five distinct types of
dopamine receptors: D1, D2, D3, D4, and D5. D1 and D5 dopamine receptors (D1-like
dopamine receptors) couple to the Gs protein, which stimulates adenylyl cyclase activity
and increases cyclic adenosine monophosphate (cAMP) concentration. The D2, D3, and
D4 dopamine receptors (D2-like dopamine receptors) couple to the Gi protein, which
inhibits adenylyl cyclase activity and subsequently reduces cAMP production.
Increasing evidence suggests that dopamine, and specifically D1 and D5 DARs,
play critical roles in learning and memory in the hippocampus. However, the anatomical
data demonstrating the localization of specific dopamine subtypes are lacking. This gap
in knowledge is due to the lack of antibodies that can convincingly distinguish between
D1 and D5 DARs. In an effort to solve this problem, an elegant study performed by
Gangarossa et al. (2012) used BAC transgenic mice expressing EGFP (a green
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fluorescent protein) tagged under the promoter of either DRDI (D1 gene) or DRD2 (D2
gene) (Gangarossa et al., 2012). D1 dopamine receptors were found scattered on
interneurons in the CA1 and CA3 regions. In the DG, D1 DARs were highly expressed
throughout the outer and medial molecular layer. In contrast, D2 DARs were expressed
almost exclusively in hilar mossy cells (Gangarossa et al., 2012; Etter and Krezel, 2014).
D5 dopamine mRNA is highly abundant in the rat hippocampus (Tiberi et al.,
1991), where they are located on principal cell (pyramidal and dentate granule cells)
soma, spines, and apical dendrites (Ciliax et al., 2000; Khan et al., 2000; Medin et al.,
2011, 2013). Interesting, D5 dopamine receptors have a tenfold higher affinity for
dopamine than the D1 dopamine receptor (Sunahara et al., 1991). Thus, older studies
using radioligands to investigate D1 DAR expression may have inadvertently detected
both D1 and D5 dopamine receptors (Boyson et al., 1986; Dawson et al., 1986; Dubois et
al., 1986; Mansour et al., 1990). In conclusion, D1 and D5 dopamine receptors have
strikingly different expression patterns in the hippocampus that do not appear to colocalize.

1.5.3 FUNCTION OF DOPAMINE RECEPTORS IN THE HIPPOCAMPUS
DA has many functions in the brain, including regulating memory, mood,
motivation, and motor activity. Due to its diverse roles in brain function, dysregulation of
dopamine has been link to several neurological disorders, including Parkinson’s disease
(Ehringer and Hornykiewicz, 1960), drug addiction (Robinson and Berridge, 1993),
schizophrenia (Goto and Grace, 2007; Lodge and Grace, 2011), and attention deficit
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hyperactivity disorder (Del Campo et al., 2011). Specifically in the hippocampus, DA is
released after novel (Ljungberg et al., 1992), salient (Ungless, 2004), aversive
(Bromberg-Martin et al., 2010), or rewarding stimuli (Schultz et al., 1993), suggesting
that dopamine is necessary for giving context to encoded information (Ihalainen et al.,
1999; Bethus et al., 2010). In contrast to the basal ganglia, there is relatively limited
DAergic input into the hippocampus. Thus, it is thought that DA’s role in hippocampal
signaling is more of a tonic nature (Shohamy and Adcock, 2010), although this has yet to
be verified.
Both D1-like dopamine receptors and D2-like dopamine receptors mediate critical
functions in the brain. However, D1-like dopamine receptors have gained increasing
attention for their significant role in regulating both hippocampus-dependent memory and
hippocampus-dependent synaptic plasticity (Huang and Kandel, 1995; Lemon and
Manahan-Vaughan, 2006; Bethus et al., 2010; Clausen et al., 2011; da Silva et al., 2012).
In the dentate gyrus, D1-like dopamine receptors are thought to regulate the threshold for
LTP and consequently determine which encoded information becomes a lasting memory
(Heinemann et al., 1992; Hamilton et al., 2010). Indeed, in freely moving animals, D1like dopamine receptors activate during a “novel” or “rewarding” signal, and
consequentially increases DG excitability (Hamilton et al., 2010). Furthermore, inhibition
of D1-like dopamine receptors also inhibits LTP in the DG (Yanagihashi and Ishikawa,
1992; Kusuki et al., 1997; Swanson-Park et al., 1999). In the CA1 region, D1-like
dopamine receptors have been shown to facilitate synaptic plasticity. Briefly, LTP at the
Schaffer collateral – CA1 synapse is enhanced with D1-like receptor activation
(Otmakhova and Lisman, 1996), while antagonizing D1-like receptors reduces or
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prevents LTP both in vitro (Frey et al., 1991; Huang and Kandel, 1995; Otmakhova and
Lisman, 1996; Swanson-Park et al., 1999) and in freely behaving rats (Lemon and
Manahan-Vaughan, 2006). Interestingly, LTD is also facilitated by activation of D1-like
dopamine receptors in CA1 (Chen et al., 1995; Liu et al., 2009) and hindered by D1-like
dopamine receptor antagonism (Chen et al., 1995). These results are corroborated by an
in vivo study (Lemon and Manahan-Vaughan, 2006).
Another form of synaptic plasticity in which D1-like dopamine has effects is
depotentiation. Depotentiation occurs when a low frequency stimulation is delivered soon
(maximum 30 minutes) after LTP has occurred, resulting in the ablation of LTP (Staubli
and Lynch, 1990; Kulla et al., 1999). Depotentiation is suggested to be a mechanism for
forgetting. Activation of D1-like dopamine receptors reduce depotentiation in the DG and
CA1 (Otmakhova and Lisman, 1998; Kulla and Manahan-Vaughan, 2000), whereas
antagonizing D1-like dopamine receptors prevented this effect (Kulla and ManahanVaughan, 2000).
In contrast to the plethora of research done in the CA1 and DG, relatively few
studies have investigated the effect of D1-like receptors on synaptic plasticity in the CA3
region. More so than at any other hippocampal synapse, the mossy fiber – CA3 synapse
is highly sensitive to intracellular cAMP concentrations (Weisskopf et al., 1994), and
cAMP-dependent pathways have been implicated in its induction of LTP (Weisskopf et
al., 1994) and LTD (Tzounopoulos et al., 1998). Also, as stated above, D1-like dopamine
receptors are expressed on dentate granule cells and CA3 pyramidal neurons. Thus, it is
conceivable that dopamine receptors, which modulate cAMP concentrations, would
mediate plasticity at this synapse. Indeed, one study demonstrated that mossy fiber LTP
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is reduced in guinea pigs in which dopamine is depleted (Ishihara et al., 1991). Also,
another study by Kobayashi and Suzuki (2007) demonstrated that application of
dopamine induced acute synaptic potentiation at the mossy fiber – CA3 synapse, which
was mediated through a cAMP cascade by presynaptic D1-like receptors (Kobayashi and
Suzuki, 2007). This potentiation was shown to affect AMPA and NMDA receptors.
Although KARs play a critical role in synaptic plasticity at this synapse, KAR function
was not investigated. Thus, more studies are required to elucidate the functional role of
dopamine, specifically D1-like dopamine receptors, at the mossy fiber – CA3 synapse
and corresponding KAR function.

1.5.4 DOPAMINERGIC MODULATION OF GLUTAMATE RECEPTORS
D1-like dopamine receptors alter synaptic transmission and learning and memory
by interacting with glutamate receptors. Several studies have investigated the effects of
D1-like dopamine receptor activation on NMDAR and AMPAR function and trafficking.
However, no study has investigated whether D1 dopamine receptors can affect KAR
function or trafficking.
D1-like dopamine receptors interact with NMDAR through both phosphorylation
cascades and direct protein-protein interactions. D1-like dopamine activation enhances
NMDAR surface expression (Hallett et al., 2006; Paoletti et al., 2008) and localization in
the synapse through stimulation of the tyrosine kinase Fyn (Dunah et al., 2004; Tang et
al., 2007). Notably, several studies have demonstrated that D1-like dopamine receptors
can also interact with NMDAR through direct protein-protein receptor binding (Lee et al.,
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2002b). Interestingly, this physical interaction is dynamic. Activation of D1 dopamine
receptors reduces formation of this D1-like/NMDA receptor complex (Lee et al., 2002b;
Luscher and Bellone, 2008). Interfering with the D1-like/NMDA receptor formation
allows NMDAR to traffic (diffuse laterally) to the synapse, thereby increasing NMDAR
mediated currents and facilitating long-term potentiation (Argilli et al., 2008; Ladepeche
et al., 2013). Furthermore, formation of the D1/NMDAR receptor complex stabilizes D1like dopamine receptors to the synapse. In conclusion, activation of D1-like dopamine
receptors predominately enhances NMDAR currents.
Surprisingly few studies have investigated whether D1-like receptors can interact
with AMPARs. However, we do know that D1-like dopamine receptors can also
modulate AMPAR activity and trafficking. Early studies demonstrated that D1-like
dopamine receptor activation both increased AMPAR phosphorylation through a PKA
signaling cascade and potentiated AMPAR current amplitude (Price et al., 1999). Indeed,
application of a D1-like agonist increases AMPAR surface expression (Snyder et al.,
2000; Gao et al., 2006; Vastagh et al., 2012). These data suggests that D1-like dopamine
receptors in general work to enhance AMPAR function.
No study to date has investigated whether D1 dopamine receptors can interact
with KARs. Metabotropic receptors, such as muscarinic acetylcholine receptors and
dopamine receptors have been shown to interact with both NMDA and AMPA receptors.
However, KARs have been neglected. There are several reasons for why KARs should be
investigated, including that they are unique to the other ionotropic receptors because not
only do they mediate fast synaptic transmission, but they also modulate the amount of
neurotransmitters released from presynaptic terminals, and alter neuronal excitability.
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1.6 KAINATE RECEPTORS

Kainate receptors were the last of the three ionotropic glutamate receptors to be
discovered. Like other ionotropic glutamate receptors, KARs are tetrameric, meaning that
they are formed by the combination of four distinct subunits, and share a common
subunit structure. Each subunit contains an extracellular N-terminus domain (NTD),
followed by four membrane domains (M1, M2, M3, and M4) and a cytoplasmic Cterminus domain (CTD). M1, M3, and M4 are transmembrane domains, named TMD 1,
TMD 2 and TMD 3 respectively. The M2 domain is a re-entrant pore loop, which
penetrates and exits the cell membrane intracellularly. The ligand-binding domain (LBD)
is composed of a segment of the NTD (deemed S1) and a segment of the extracellular
loop between TMD2 and TMD3. KARs assemble by two subunits (dimers) binding to an
identical dimer, which is referred to as ‘dimer of dimers’. There are five kainate receptor
subtypes: GluK1, GluK2, GluK3, GluK4, and GluK5 (formerly GluR5 – GluR7, KA1
and KA2). Subunits GluK1, GluK2, and GluK3 can form functional homomers, meaning
that each of the four subunits in the KAR can be entirely GluK1, GluK2, or GluK3.
However, GluK4 and GluK5 subunits must combine with GluK1, GluK2, or GluK3
subunits to form a functional KAR The structural repertoire of KAR subunits is further
diversified by Q/R editing of the GluK1, GluK2, and GluK3 subunits, which alter the
KAR permeability to Ca2+, and alternative splicing of GluK1 – GluK3 subunits.
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Evidently, the GluK4 nor GluK5 subunits do no undergo such post-transcriptional
modifications.

1.6.1 LOCALIZATION
Determining the subcellular localization of KARs have been particularly elusive
due to the absence of KAR subunit-specific antibodies. Several in situ hybridization
studies have revealed tissue specific localization, but this method does not have the
resolution to distinguish subcellular level localization (Wisden and Seeburg, 1993;
Bureau et al., 1999). Currently, GluK2/K3 and GluK5 specific antibodies are available,
although their reliability in immunohistochemistry is debatable. Nevertheless,
corroborating evidence can be extracted from these results. The GluK2 and GluK5
subunits are the most robustly expressed subunits (Perrais et al., 2010). The GluK5
subunit is expressed abundantly throughout the brain on principal cells and interneurons
(Wisden and Seeburg, 1993). Meanwhile, GluK2 subunits are mostly expressed on
principal neurons throughout the brain, including pyramidal neurons and dentate granule
cell in the hippocampus (Paternain et al., 2003). In contrast, GluK1 subunits are
predominantly expressed on interneurons (Paternain et al., 2003). The GluK3 subunit is
expressed at few synapses in the brain, including the hippocampal dentate gyrus (Wisden
and Seeburg, 1993). However, the GluK4 subunit has the most restricted expression,
mainly express in CA3 pyramidal neurons (Bahn et al., 1994).
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1.6.2 PHARMACOLOGY
Each KAR subunit contains a binding site and contributes to the channel pore.
The only known KAR agonist that is present in the brain is glutamate. Glutamate
activates homomeric GluK1 and GluK2 receptors with a 50% effective concentration
(EC50) value in the 100 and 200 micromole (μM) range (Alt et al., 2004; Fisher and
Fisher, 2014). However, the EC50 value for GluK3 in in the 5mM range (Schiffer et al.,
1997; Perrais et al., 2009). Although GluK4 and GluK5 subunits are non-functional as
homomers, when expressed in recombinant HEK-293 cells they bind to glutamate. In
contrast, the EC50 glutamate concentrations for the GluK4 and GluK5 subunits are in the
30μM and 10μM range respectively (Fisher and Mott, 2011; Fisher and Fisher, 2014).
Thus, the GluK4 and GluK5 subunits are given the distinction as being “high-affinity”
subunits.
Kainate receptors were identified based upon their high binding affinity to the
neurotoxin kainate acid, compared to the other ionotropic glutamate receptors (NMDA
and AMPA receptors). Kainate acid (KA) is a naturally occurring analog of glutamate,
which was isolated from the seaweed Digenea simplex (Nitta et al., 1958). Injection of
kainate acid in the brain causes lesions in brain regions with abundant kainate receptors
expression, such as the CA3 region. Similar to glutamate, KA activates the KARs
subunits with diverse potency. The GluK1 – GluK3 subunits have a “lower” affinity for
KA (KDs near 50nM) than the “high-affinity” subunits GluK4 and GluK5 (KDs 5 –
15nM) (Werner et al., 1991; Herb et al., 1992; Sommer et al., 1992).
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The heteromeric kainate receptors predominate in the central nervous system. The
abundant co-expression of the GluK2 and GluK5 subunits throughout the brain suggests
that the GluK2/K5 heteromeric KARs compose majority of the expressed functional
KARs. Interestingly, incorporation of the high-affinity subunits into KAR assemblies
alters the pharmacology of the KAR. GluK2/K5 and GluK2/K4 heteromeric KARs are
more sensitive to glutamate than GluK2 homomers due to the incorporation of the highaffinity subunits GluK5 and GluK4 (EC50: GluK2/K5 = 10 μM, GluK2/K4 = 50 μM,
GluK2 = 200 μM) (Heckmann et al., 1996; Paternain et al., 1998; Barberis et al., 2008;
Fisher and Mott, 2011, 2013). Additionally, the GluK4 and GluK5 subunits can also bind
to ligands that the other KAR subunits cannot. For example, agonists AMPA, ATPA, and
willardiine compounds do not activate GluK2 homomeric receptors, but can bind and
activate heteromeric GluK2/K5 receptors (Alt et al., 2004).

As expected, these

compounds also have an affinity for AMPA receptors, making interpretation from earlier
studies misleading.
The lack of KAR subunit specific antagonist has been the Achilles heel of the
KAR field. The development and functional characterization of such compounds is
essential in understanding the functional contribution of KARs subtypes. Recently, an
intense effort was made to synthesize and characterize subunit-selective KAR antagonist
against GluK1 (Dargan et al., 2009). They developed a series of KAR antagonist based
upon the structure of the willardiine compound, which is thought to be a GluK1 specific
agonist. Among this series of compounds were UBP310, UBP302, and UBP316 (also
named ACET). However, recent evidence suggests that these compounds are not as
specific as initially thought, as the drug UBP310 inhibits GluK2/K5 heteromeric receptor
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current in recombinant cells and inhibits postsynaptic KAR transmission at mossy fiber –
CA3 synapses where GluK1 and GluK3 expression is limited (Pinheiro et al., 2013).
Another antagonist distinguished as being subunit selective is kynurenic acid.
Kynurenic acid is a product of normal metabolism and has neuroprotective properties
(Chmiel-Perzyńska et al., 2014). Recent studies have shown that kynurenic acid can
discriminate between homomeric GluK2 and heteromeric GluK2/K5 receptors.
Kynurenic acid antagonizes the glutamate-induced current through GluK2 homomers at
low concentrations (IC50 = 0.3mM), but virtually has no effect on GluK2/K5 heteromer
current at concentrations up to 3mM (Alt et al., 2004; Fisher and Mott, 2011).

1.6.3 ACTIVATION AND DESENSITIZATION
When a ligand binds to an ionotropic receptor, it can either elicit a conformation
change in the receptor that allows the receptor to open its channel pore (activation), or it
can have no effect. A ligand that binds to the receptor and has an effect is an agonist, and
a ligand that binds to a receptor but has no effect is called an antagonist. Once the ligand
leaves the binding site, the receptor will undergo another conformational change to close
the channel pore (deactivation). Alternatively, some receptors (including KARs) will
decrease its response to the agonist even while the agonist is still bound (desensitization).
Each KAR subunit contains a binding site and contributes to the channel pore.
Thus, there are four possible ligand-binding sites on each functional KAR. Previous
studies demonstrate that, in heteromeric KARs receptors, glutamate binding to the higher
affinity GluK4 or GluK5 subunits is sufficient to activate the channel, albeit to a non40

desensitizing current. Desensitization occurred when the glutamate concentration
increased to allow binding to the lower affinity GluK2 subunit (Mott et al., 2010; Fisher
and Mott, 2011). These papers concluded that the high-affinity subunits had the
distinguished role in opening the KAR, while the low affinity subunit’s role was to
desensitize the receptor. However, these papers did not test whether binding to only the
GluK2 subunit is sufficient to open the receptor, and does subsequent binding to the high
affinity subunits ensue desensitization. More recent work with subunit-selective agonists
or antagonist (Swanson et al., 2002; Fisher and Mott, 2011; Pinheiro et al., 2013; Fisher
and Fisher, 2014) and tethered ligands (Reiner and Isacoff, 2014), suggest that partial
occupancy of the KAR binding sites is sufficient to activate the receptor, and the onset of
desensitization in heteromeric receptors is determined more by the number of subunits
bound to the agonist than by the identity of those subunits.

1.6.4 INTERACTING PROTEINS
Kainate receptors interact with proteins on the plasma membrane that transiently
regulate their location and function. For example, KARs can interact with PDZ motifcontaining proteins such as postsynaptic density protein 95(PSD-95), protein interacting
with C kinase-1 (PICK-1), and glutamate receptor interacting protein (GRIP), which
regulate trafficking of KARs to the cell surface and stabilizing KARs to the synapse
(Hirbec et al., 2003). It is important to note that these interacting proteins are not specific
to KARs and also regulate the function of AMPARs. Interestingly, the apparent
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regulation differs between KARs and AMPARs, as these proteins prevent AMPAR
internalization, but facilitate KAR internalization (Hirbec et al., 2003).
Two proteins have been identified as true auxiliary proteins to KARs: neuropilin
tolloid-like 1 and neuropilin tolloid-like 2 (Neto1 and Neto2) (Zhang et al., 2009; Straub
et al., 2011a, 2011c; Tang et al., 2011). Neto1 and Neto2 are single transmembrane
proteins that co-localize and associate with KAR in the brain. Neto1 is predominantly
located in the hippocampus and is almost completely absent in the cerebellum, whereas
Neto2 is almost completely absent in the hippocampus, but is abundantly expressed
throughout the cerebellum (Straub et al., 2011b). Neto1 was initially discovered as an
auxiliary protein to NMDA (Ng et al., 2009), although it arguably has a more pronounced
effect on KAR function. Neither Neto1 nor Neto2 appear to associate with AMPA
receptors. Co-expression of Neto1 or Neto2 with KARs in recombinant cells radically
alters KAR gating. The most pronounced effect is the reduction in KAR receptor
deactivation and desensitization, while recovery from desensitization accelerates (Copits
et al., 2011; Straub et al., 2011a; Fisher and Mott, 2013). Thus, the glutamate-induced
KAR current persists for longer periods in the presence of Neto. Indeed, this effect is
conserved for all KAR subtypes (Fisher and Mott, 2013). Most importantly, the discovery
of the Neto-KAR complex corroborates recombinant cell data with brain slice data
demonstrating slow deactivation kinetics of KARs.
Current results are conflicting about whether Neto affects KAR trafficking to the
synapse (Ng et al., 2009; Zhang et al., 2009; Copits et al., 2011; Straub et al., 2011a;
Tang et al., 2011, 2012; Wyeth et al., 2014). Neto knockout mice demonstrate
dramatically reduced localization of GluK2 and GluK5 subunits in the synapse (Tang et
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al., 2011; Wyeth et al., 2014). Indeed, genetic ablation of Neto1 (but not Neto2) has
effects on KAR EPSCs (Straub et al., 2011a; Tang et al., 2011) by showing faster decay
and reduced amplitudes. However, KAR EPSCs can still occur. Thus, Neto1 may
function more as a regulator of KAR kinetic properties in addition to targeting KARs to
the synapse.
1.6.5 PHOSPHORYLATION
Although relatively few studies have investigated whether KARs can be
modulated by GPCRs mACh and dopamine receptors, several studies have shown that
KARs can undergo protein kinase C (PKC), CaMKII, and PKA phosphorylation.
Activation of PKC inhibits KAR currents in recombinant cells (Dildymayfield and
Harris, 1994) and brain slices (Selak et al., 2009). Also in the perirhinal cortex, PKC and
PICK1 interacts with KARs to cause KAR-EPSC LTD (Park et al., 2006). These studies
suggest that the mechanism for this KAR LTD is that activation of KARs causes an
increase in postsynaptic Ca2+, which encourages the uncoupling of the PKC-PICK1mediated maintenance of KAR EPSC (Staudinger et al., 1997; Park et al., 2006). In the
hippocampus, PKC was also shown to induce KAR-EPSC LTD, albeit through a
interacting with SNAP-25, PICK1, GRIP, and the KAR subunit GluK5 co-localized
postsynaptically (Selak et al., 2009). Furthermore, blocking SNAP-25 activity causes a
GluK5-dependent increase in KAR-EPSCs, suggesting a role for SNAP-25 in the PKCdependent internalization of GluK5. However, these results are not without controversy,
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as other studies demonstrate an PKC-dependent increase in KAR EPSCs (Cho et al.,
2003).
In contrast to PKC, PKA phosphorylation potentiates kainate-evoked currents in
recombinant cells (Raymond et al., 1993; Wang et al., 1993; Kornreich et al., 2007).
Furthermore, the phosphatase calcineurin reverses PKA phosphorylation of GluK2
receptors (Traynelis and Wahl, 1997; Coussen et al., 2005), and causes an NMDA
receptor and voltage-sensitive Ca2+ channel-dependent depression of KAR current
(Ghetti and Heinemann, 2000; Rebola et al., 2007).
KARs activity can also be modulated by CaMKII phosphorylation. A stimulation
protocol known to induce AMPAR LTP also induces CaMKII phosphorylation of
GluK5-containing receptors and depression in KAR-mediated synaptic transmission at
the mossy fiber – CA3 synapse (Caporale and Dan, 2008; Carta et al., 2013). However,
instead of internalizing the KAR, CaMKII phosphorylation causes the GluK5-containing
receptor to uncouple from PSD-95 and laterally diffuse out of the synapse (Carta et al.,
2013).

1.6.6 KAINATE RECEPTOR FUNCTION
Postsynaptic
Unlike NMDA and AMPA receptors, KAR-mediated postsynaptic current is
found at only few synapses in the hippocampus, including the mossy fiber – CA3 synapse
(Castillo et al., 1997; Vignes and Collingridge, 1997) and the Schaffer collateral – CA1
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hippocampal interneurons (Cossart et al., 1998; Frerking et al., 1998). At these synapses,
KARs EPSCs are small in amplitude (Castillo et al., 1997) and have slow deactivation
kinetics when compared to NMDA and AMPA receptors (Frerking and Ohliger-Frerking,
2002; Pinheiro et al., 2013). The slow deactivation kinetics allows the synaptic response
to temporally summate and increase spike transmission, thereby facilitating LTP
induction (Sachidhanandam et al., 2009).
Also unlike NMDA and AMPA receptors, KARs can influence neuronal
excitability of postsynaptic neurons through metabotropic signaling by affecting the slow
hyperpolarization (IsAHP) of postsynaptic neurons (Melyan et al., 2002, 2004). The IsAHP is
activated in response to an action potential. Voltage sensitive-Ca2+ dependent K+
channels open to hyperpolarize the neuron and prevent further bursting. Thus, the IsAHP is
instrumental in spike timing adaptation. Activation of kainate receptors suppresses the
IsAHP, thus increasing spike-firing frequency and neuron excitability. Evidence suggests
that the mechanism for KAR inhibition of the IsAHP is mediated through KARs directly
coupling the Gi/o protein, activating PKC (Melyan et al., 2002) and probably PKA, and
downstream activation of MAP kinases (Grabauskas et al., 2007). Interestingly, KARs
can simultaneously elicit both ionotropic and metabotropic actions at the mossy fiber –
CA3 synapse (Fisahn et al., 2005; Ruiz et al., 2005).
Presynaptic
Kainate receptors are also localized both postsynaptic and presynaptic. Kainate
receptors can act presynaptically to regulate neurotransmitter release at both inhibitory
and excitatory synapses (Lerma, 2003). Presynaptic kainate receptors have been
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extensively studied at the mossy fiber – CA3 synapse, where they have been implicated
in the large paired-pulse facilitation characteristic of this synapse (Contractor et al., 2001;
Lauri et al., 2001; Schmitz et al., 2001; Pinheiro et al., 2007). Indeed, a blocker of Ca2+
permeable KARs reduces this synaptic facilitation at the mossy fiber – CA3 synapse
(Lauri et al., 2003; Scott et al., 2008). Interestingly, activation of presynaptic kainate
receptors can have a bidirectional effect on transmitter release, either enhancing or
inhibiting release, dependent upon the concentration of kainate receptor agonist used.
Exogenous application of a low concentration of KAR agonist facilitates glutamate
release (Kamiya and Ozawa, 2000; Schmitz et al., 2000), while a high dose of KAR
agonist produces a depression in glutamate release at mossy fiber – CA3 synapse and
Schaffer collateral – C1 pyramidal synapse (Chittajallu et al., 1996; Kamiya and Ozawa,
1998; Vignes et al., 1998; Frerking et al., 2001). Depression of glutamate release by a
KAR agonist is sensitive to G proteins blockers, and is thus thought to be through a novel
metabotropic function (Frerking et al., 2001; Negrete-Díaz et al., 2006; Salmen et al.,
2012). Thus, these data suggest that KAR facilitation of glutamate release is mediated
through ionotropic actions, whereas KAR depression of glutamate release is mediated
through metabotropic G-protein actions.
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1.7 IMPLICATIONS FOR EPILEPSY

1.7.1 KAR IN EPILEPSY
The disease most prominently associated with KARs is epilepsy. Overactivation
of kainate receptors can cause seizures. In fact, intraperitoneal injection of kainate acid
has served as a reliable animal model of temporal lobe epilepsy (TLE) that mimics
several behavior and anatomical changes that occur in human epilepsy. Both human and
rodent models of temporal lobe epilepsy demonstrate recurrent mossy fiber synapses onto
dentate granule cells (Artinian et al., 2011). These synapses have aberrant kainate
receptor EPSCs and thereby alter the activity pattern of dentate granule cells (Epsztein et
al., 2005). It is thought that this positive feedback loop could be the epicenter for seizure
generation in TLE patients. Indeed, Human tissue from patients with pharmacoresistant
TLE demonstrated an upregulation of GluK1 subunit expression, potentially contributed
by the mossy fiber sprouting (Li et al., 2010). Additionally, genetic ablation of the GluK2
subunit prevents the development of seizures (Mulle et al., 1998). Conversely,
overexpressing GluK2-containing KARs exhibit spontaneous seizures (Telfeian et al.,
2000). As a result of the previous data demonstrating an association between KARs and
epilepsy, significant effort have been attributed to demonstrating the therapeutic benefits
of GluK1 antagonist to prevent the development of epileptiform bursting in the
hippocampal CA3 region in vitro and in vivo (Khalilov et al., 2002; Smolders et al.,
2002).
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1.7.2 MUSCARINE AND EPILEPSY
Several lines of evidence support a role for mAChRs in epilepsy. For example,
pirenzepine, a mAChR antagonist, significantly retards the development of kindled
seizures (Eşkazan et al., 1999). Alternatively, in hippocampal slices, when inhibition is
removed, the anitcholinesterase, eserine, evokes spontaneous epileptiform discharges that
are blocked by pirenzepine (Gruslin et al., 1999; Potier and Psarropoulou, 2004). Perhaps
the strongest evidence for an association between epilepsy and mAChRs is the
epileptogenic effect of the muscarinic agonist, pilocarpine (Cavalheiro et al., 1991).
Pilocarpine produces sustained seizures (status epilepticus, SE) by acting on M1
mAChRs (Maslanski et al., 1994; Hamilton et al., 1997; Bymaster et al., 2003). However,
the role played by the M1 mAChRs in producing SE in the pilocarpine model, the
subsequent neurodegeneration and the development of spontaneous seizures, is not
known.
Interestingly, the role played by M1 mAChRs in the induction of SE appears to be
critical but limited. Thus, the muscarinic antagonist, atropine suppresses the induction of
lithium-pilocarpine-induced SE in rats if injected before pilocarpine, but will not block
ongoing lithium-pilocarpine-induced SE (Jope et al., 1986; Morrisett et al., 1987). Given
the role of KARs in this model, this observation suggests that mAChR activation induced
a KAR-dependent process required for the induction and maintenance of SE. It is further
suggested that M1 mAChR activation stimulates KARs by both directly depolarizing
pyramidal cells causing glutamate release and by directly potentiating KAR function.
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Several studies have demonstrated a synergistic effect of subconvulsant doses of
pilocarpine and kainate on the induction of seizures. For example, Millan et al. (1988)
reported that a subconvulsant dose of kainate induces motor limbic seizures only when
injected into the prepiriform cortex after a subconvulsant dose of pilocarpine (Millan et
al., 1988). Similar results were found by De Sarro et al. (1992) in the lateral habenula and
pedunculopontine nucleus and by Patel et al. (1988) in the entopeduncular nucleus and
doral striatum (Patel et al., 1988; De Sarro et al., 1992). These epilepsy models are
thought to be predictive of partial complex seizures, suggesting that the interaction
between muscarinic and KARs may contribute to the evolution of seizures of this type. In
contrast, KARs do not appear to be involved in models of more generalized seizures such
as picrotoxin or bicuculline, since KAR antagonists do not block epileptiform activity in
these models.

1.7.3 DOPAMINE AND EPILEPSY
The dopaminergic system has been associated with epilepsy and seizures for over
a century. The basal ganglia (primary source of dopamine in the brain) are significantly
involved in seizure initiation and determining seizure threshold (Trimble, 1977; Toone,
1991). Forty years ago, epilepsy was thought to be a disease of dopaminergic
hypoactivity (Lamprecht, 1977; Starr, 1996). This theory was conceived as a result of
studies demonstrating that application of a general dopamine receptor agonist reduces
seizure susceptibility (Lamprecht, 1977; Lal, 1988), whereas blockage of dopamine
receptors induced seizures (Laird et al., 1984; Jann et al., 1993). Indeed, it was
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discovered that a class of antipsychotic drugs that were known to precipitate seizures
were general dopamine receptor antagonist (Seeman, 1981). We now known that there
are two subtypes of dopamine receptors: D1-like and D2-like. These dopamine receptors
have opposite effects on seizure susceptibility. D1-like dopamine receptor activation
precipitates seizures (Starr et al., 1987; al-Tajir et al., 1990a, 1990b), while D2-like
dopamine receptors reduce seizure susceptibility (al-Tajir et al., 1990a; Al-Tajir and
Starr, 1991).
These studies demonstrate a long withstanding association between the
dopaminergic system and epilepsy. Although we have now identified two subclasses of
dopamine receptors and their opposing roles in seizure generation, the mechanism for
how the interaction occurs is not known, nor is it known how the dopaminergic system is
altered in chronic models of temporal lobe epilepsy. Further studies are needed to
elucidate these mechanisms.

1.8 IMPLICATIONS FOR EXERCISE

1.8.1 EPILEPSY AND PHYSICAL EXERCISE
Over the past decade, physical activity has been noted as a powerful tool in the
battle against cognitive impairment. In healthy adults, physical activity has been shown to
improve performance on memory test and counterbalance the age-related decline in
hippocampal volume and learning and memory performance tasks (Erickson et al., 2011).
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These results are indiscriminant on the type of physical activity, but are predicated on the
intensity of the exercise, with greater cognitive benefits occurring following acute or
repetitive (chronic) moderate to vigorous physical activity.
Exercise has also been shown to prevent the development and reduce the
progression of neurological diseases. Several reviews exist outlining the beneficial effects
of exercise on Alzheimer’s disease and Parkinson’s disease (Paillard et al., 2015).
However, in this document we will focus our attention on exercise’s benefits on epilepsy.
The stigma of exercise being harmful for people with epilepsy was prevalent until
recent years. It was recommended by the American Medical Association in 1968, that
people with uncontrolled epilepsy should not be allowed to participate in physical activity
for the fear of inducing seizure and increased risk of injury for the person with seizures
and others within the vicinity (American Medical Association Committee on the Medical
Aspects of Sports, 1968). Due to much controversy, this recommendation was relaxed six
years later to allow the participation of exercise when it was deemed beneficial for social
integration (Corbitt et al., 1974).
Recent evidence in human and animal models demonstrates that physical activity
can prevent the development in seizures. In animal models, prior exposure to exercise can
reduce brain cell loss and neuronal damage secondary to brain insults (Arida et al., 2013).
One study investigating the effects of physical exercise during post-natal development
showed that when submitted to daily exercise for forty days, rats presented delayed onset
and reduced intensity of pilocarpine-induced seizure during midlife (Gomes da Silva et
al., 2011). Additionally, another study demonstrated that animals exposed to acute and
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chronic physical exercise required more electrical stimulus to the limbic brain region
(kindling) to provoke seizures than controls (Arida et al., 2008). Although there are
several studies in animal models demonstrating physical activity can prevent seizures and
the development of epilepsy, the possible preventative effects of exercise on epilepsy in
humans are still uncertain. There is only one study that has tested this question directly.
According to a Swedish population-based cohort of 6,796 individuals examined for 40
years, participants who presented low cardiovascular fitness at the age of 18 had an
increased risk of developing epilepsy later in life (Nyberg et al., 2013). Thus, this study
suggests that engaging in physical activity early in life has protective effects on the
development of epilepsy later in life. Although more studies in humans are needed to
answer the question whether physical activity can protect the brain from developing
epilepsy, the consensus among several animal studies and one human study suggest that
physical exercise can be used as a powerful tool to protect the brain against the
development of repetitive seizures.
As opposed to the development of epilepsy, more human studies have sought to
answer the question whether exercise can reduce seizure frequency in individuals who
have already been diagnosed with epilepsy. People who practice regular physical exercise
report fewer seizures than inactive individuals (Roth et al., 1994). However, human
intervention studies have rendered mixed results. One study examining fifteen women
with pharmacologically intractable epilepsy were administered aerobic activity for fifteen
weeks and presented a decrease in seizure frequency (Eriksen et al., 1994). However,
another study including twenty-one patients with uncontrolled epilepsy experienced no
change is seizure frequency two weeks before, during, or after a four-week exercise
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program (Nakken et al., 1990). Although these studies provide contradictory results about
whether exercise reduces seizure frequency in people with epilepsy, they both support the
notion that engaging in physical exercise is not a seizure precipitant. Furthermore, other
studies examining acute bouts of maximal and sub-maximal physical exercise in people
diagnosed with epilepsy demonstrated reduced epileptiform discharges after physical
exertion compared to before the exercise bout (Camilo et al., 2009; Vancini et al., 2010;
de Lima et al., 2011). Animal studies demonstrate a more definitive role of epilepsy
reducing seizure frequency. Rats with pilocarpine-induced epilepsy who submitted to a
physical training program presented a lower frequency of spontaneous seizures than
controls (Westerberg et al., 1984; Arida et al., 1999, 2004, 2009a, 2013). Other animal
models of epilepsy have demonstrated similar results (Rambo et al., 2009; Reiss et al.,
2009; Tutkun et al., 2010).
Lastly, physical activity can also reduce the comorbid mental disorders associated
with epilepsy. As stated earlier, people with epilepsy are more like to suffer from other
mental and psychosocial disorders, such as mood and personality disorders and
behavioral problems. Depression, deficits in learning and memory, stress and anxiety are
among the most common. In physically healthy adults, engaging in regular physical
exercise has shown to consistently improve emotional well-being (Roth et al., 1994).
Similarly, people with epilepsy who practice physical exercise present lower levels of
depression independently of other factors like age, gender, seizure frequency or stressful
life experience (Eriksen et al., 1994; Roth et al., 1994; de Lima et al., 2013). Other
studies have reported positive effects of physical exercise training on mental state, selfesteem, social integration, several anxiety scales, fatigue, sleep problems, and overall
53

quality of life (Nakken et al., 1990; Eriksen et al., 1994; McAuley et al., 2001; Arida et
al., 2009b). Thus, physical exercise can improve overall mental health and emotional
wellbeing in people with epilepsy. In individuals with managed epilepsy, physical
activity’s benefits of improving mental health may prove more beneficial than the
possible reduction of seizure frequency.
Mental health disorders in people with epilepsy may result from the complicated
interactions between the antiepileptic medications, epilepsy surgery, and social
interventions (such as restricted license to drive and fear of seizure in public).
Interestingly, epilepsy and mood disorders share dysfunctions in neurotransmitter
systems (dopamine, acetylcholine, glutamate, GABA, etc.), which might contribute to
their coexistence and bidirectional relationship (Kanner, 2007; Thapar et al., 2009; Arida
et al., 2012).
Several theories for how exercise mediates benefits on cognition in the healthy
and diseased brain exist. The most prevalent theory is that an increase in cardiovascular
blood flow that occurs during physical activity initiates the synthesis of several growth
neurotrophic factors and neurotransmitters, which ultimately results in increased
neurogenesis, angiogenesis, and synaptogenesis. The alteration of the human brain
caused by acute and chronic exercise leads to a change in the fundamental network and
structure in the brain compared to the sedentary brain. Thus, this new brain is efficient at
preventing the development of seizure, reducing seizure frequency, and ameliorating
psychosocial comorbidities associated with epilepsy (such as depression, learning and
memory deficits, anxiety, stress, and schizophrenia).
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1.8.2 ACETYLCHOLINE AND EXERCISE
The cholinergic system and exercise have a close interconnected relationship.
First, exercise alters the cholinergic system in the brain. Particularly in the hippocampus,
acetylcholine release increases 2-fold during moderate intensity walking in young
(Nakajima et al., 2003) and aged adult rats (Uchida et al., 2006). Because depletion of
acetylcholine is causal for memory impairment, this increase can be beneficial when
applied to diseased brains. In addition to an increase in acetylcholine release, exercise can
also reduce degradation of released acetylcholine. One study demonstrated that
acetylcholinesterase was inhibited in the whole brain by 30 – 50% 2hr to 5hr post forced
swimming exercise (Tsakiris et al., 2006). Thus, these studies show that exercise can
modulate the amount of acetylcholine in the extrasynaptic space by both increasing the
amount of acetylcholine release and inhibiting the amount of acetylcholine degraded,
which seems to have beneficial effects in the diseased brain.
A theoretical mechanism for how exercise mediates its beneficial effects in the
brain is thought to be triggered by an increase in cerebral blood flow. Several studies
have shown that acetylcholine is necessary for the exercise-induced increase in cerebral
blood flow. For example, acetylcholine released in the cerebral cortex and hippocampus
can increase regional blood flow in the cerebral cortex and hippocampus in anesthetized
rats (Biesold et al., 1989; Cao et al., 1989; Kurosawa et al., 1989; Adachi et al., 1992;
Sato and Sato, 1992, 1995; Sato et al., 2004). Thus, independent of periphery stimulation,
an increase in acetylcholine can increase cerebral blood flow. Furthermore, walking at
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moderate speed can increase cerebral blood flow in the hippocampus and cerebral cortex
independent of systemic arterial pressure via activation of intracranial cholinergic fibers
and release of ACh from these nerves. Thus, physical exercise stimulates the central
cholinergic system to increase cerebral blood flow independent of periphery stimulation.
Lastly, the cholinergic system is involved in the regulation of adult hippocampus
neurogenesis. Selective lesioning of the medial septum system negatively affects the
proliferation of neural stem cells (NSCs) and neuronal progenitor cells (Cooper-Kuhn et
al., 2004; Mohapel et al., 2005; Van Der Borght et al., 2005), whereas the administration
of acetylcholine esterase (AChE) inhibitor promotes NSC/neuronal progenitor cell
proliferation (Mohapel et al., 2005; Narimatsu et al., 2009). Specifically, M1 muscarinic
receptors are necessary for cholinergic-induced NSCs proliferation. Furthermore,
exercise-induced promotion of aged NSC proliferation was abolished by specific
lesioning of the septal cholinergic system, demonstrating the cholinergic system is
necessary for exercise-induced neurogenesis (Itou et al., 2011). Thus, the cholinergic
system also mediates exercise-induce increase in neurogenesis.

1.8.3 DOPAMINE AND EXERCISE
The effects of exercise on dopamine levels in the hippocampus have rendered
mixed results. Some studies find that exercise significantly increases dopaminergic
content (Chaouloff et al., 1986). For example, De Castro et al. confirmed an increase in
dopaminergic metabolism in the whole brain of rats sacrificed 48 hours after an 8-week
running training period (de Castro and Duncan, 1985). A related study used a 1-week
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training model to examine brain dopamine metabolism and found that the sum of
DOPAC and homovanillic acid was increased with running and remained elevated
throughout the first hour of recovery (Chaouloff et al., 1987). Indeed, more recent studies
have demonstrated increases in dopamine concentration and dopamine receptor binding
(Greenwood et al., 2011). These results may be a result of increased bursting/activation
of dopamine neuron in the VTA due to wheel running (Wang and Tsien, 2011).
Additionally, chronic voluntary and forced wheel running demonstrate increase tyrosine
hydroxylase and well as dopamine in several brain areas (Dishman et al., 1997; Sutoo and
Akiyama, 2003; Droste et al., 2006; Foley and Fleshner, 2008; Greenwood et al., 2011).
Thus, exercise seems to mediate an increase in dopamine production and release in the
brain.
Other studies have found no change or a decrease in dopamine levels after acute
or chronic physical exercise (Brown and Van Huss, 1973; Lukaszyk et al., 1983; Sudo,
1983; Acworth et al., 1986). Notably, no study has found a significant decrease in
dopaminergic content specifically in the hippocampus after an acute or chronic physical
exercise-training plan, although several studies report a significant increase in dopamine
content in the hippocampus (Chaouloff et al., 1987; Bailey et al., 1992). Thus, it seems
that exercise, when it does have an effect, tends toward increasing dopaminergic content
in the hippocampus.
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1.9 SIGNIFICANCE REVISITED

As discussed above, interplay between the glutamatergic system and
cholinergic/dopaminergic system in the hippocampus are required for learning and
memory. Specifically, kainate receptors play an important role in the physiology and
pathophysiology of synaptic transmission. However, there have been no studies that have
systematically examined whether mAChRs or D1 DARs in the brain alters kainate
receptor function. To fill this significant knowledge gap, we first needed to identify
pharmacological tools that can be used to identify specific kainate receptor subtypes. This
tool will be useful to differentiate which kainate receptor subtypes are responsible for
mediating KAR synaptic transmission in the normal hippocampus. After identifying
which kainate receptor subtypes are responsible for KAR synaptic transmission, we must
determine whether mAChRs and/or D1-like DARs can alter KAR synaptic transmission
in the normal hippocampus. Several lines of evidence suggest that interaction between
KARs and muscarinic/dopaminergic receptor may occur; however, this will be the first
directly tested proof of concept. Understanding whether this interaction occurs and
identifying which receptors are responsible, will reveal a novel mechanism by which the
normal brain undergoes synaptic plasticity. Additionally, it will provide newfound
mechanisms by which neurological disorders, such as epilepsy, and neurological
therapies, such as exercise, may illicit their effects. Lastly, we will determine how the
dopaminergic system is altered in the chronically epileptic brain. Understanding longterm changes in dopaminergic content in the epileptic brain will provide us with a
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comprehensive view of where the dysfunctional interaction between the glutamatergic
and dopaminergic system exists. These studies are important, because they can shed light
on a novel mechanism that occurs in the brain, which are necessary for brain health.
Furthermore, understanding these mechanisms can unlock targets for therapies for
neurological diseases.
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CHAPTER 2
GENERAL METHODS

2.1 INTRODUCTION TO ELECTROPHYSIOLOGY
Electrophysiology is the study of the flow of ions through a cell or group of cells,
and it also refers to the specific techniques required to measure this flow of ion. Every
thought, every nerve impulse, every movement, and every heartbeat is controlled by
highly specific and precisely timed flow of ions through cell membranes. Interfering with
this flow could have a wide range of effects, from beneficial (as in exercise) to fatal (such
as a prolonged seizure). Thus, having a detailed understanding of the ions and the
transporters/receptors that mediate their passage through the cell membrane is
indispensable when deciphering neurological disorders and developing novel therapies to
remedy them.
Electrophysiologists use the basic physical laws of electricity to understand the
electrical activity of cells and the receptors inhabiting them. By far, the most useful law
of electricity in electrophysiology is Ohm’s law. Ohm’s law states that voltage (V) or
electrical potential (ΔV) is equal to current (I) multiplied by resistance (R): V=IR. In a
cell, voltage is a measure the electrical potential difference across the cell membrane,
which in most cells in negative a rest. The current is a measure of the amount of charged
particles flowing through the cell membrane. Last, but certainly not least, resistance is a
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measure of the friction or resistance on ion flow, which is primarily a function of
technical access to the cell. Electrophysiology equipment allows us to measure and
modify eACh electrical component of the cell, as the experimental procedure sees fit.

2.1.1 ELECTRICAL POTENTIAL
Ions flow through plasma membranes because there is a difference in electrical
potential (volts, V or ΔV) between the interior and exterior of cells. The ability of every
cell to maintain an electrical potential is derived from two main characteristics. First, the
distribution of ions inside the cell differs from those outside the cell. Most cells have a
higher concentration of potassium (K+) and a lower concentration of sodium (Na+) and
calcium (Ca2+) inside the cell than in the extracellular space. Ion specific pumps that
require energy maintain this ionic gradient. Furthermore, the cell’s interior contains
negatively changed proteins that are impermeable to the cell membrane. Taken together,
the interior electrical potential of most cells at rest is negative, compared to the
extracellular space.
Secondly, the plasma membrane itself has selective ion permeability. Every cell is
enveloped by a plasma membrane consisting of lipids and proteins. Lipids are
hydrophobic (repel water), which causes them to arrange into a phospholipid bilayer that
is impermeable to ions. Ions are transported through this otherwise impermeable layer
through specialized proteins, ion channels and transporters. The selective permeability of
the cell membrane for each ion depends on the amount and states of its varied ion
channels. During rest, most cells are highly permeably to K+, moderately permeable to
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Cl-, and only slightly permeable to Na+ and Ca2+. These two properties of the cell, the
varied distribution of ions and the selective permeability of ions, are necessary for a cell
to maintain its electrical potential.

2.1.2 VOLTAGE CLAMP
Voltage clamp is an experimental paradigm used by electrophysiologists to
measure ion currents through a cell membrane by holding (“clamping”) the electrical
potential inside the cell constant. In theory, when ionotropic channels, such as kainate
receptor, bind to glutamate, they open and allow Na+ ions to flow into the cells and K+
ions to flow out of the cell, and thereby mediating an inward current of positive ions. By
holding voltage constant, a change in current is directly related to the function of the
receptors and channels expressed on the cell. Thus, we can reliably measure and
confidently interpret KAR kinetics by measuring the current produced by ions flowing
across the cell membrane at a given voltage.

2.2 WHOLE CELL PATCH-CLAMP ELECTROPHYSIOLOGY
In patch clamp electrophysiology, we are measuring the flow of ions across a
single cell or single channel. This technique was first demonstrated by Erwin Neher and
Bert Sakmann (Neher and Sakmann, 1976) in 1976, and later won the Nobel Prize in
Physiology or Medicine in 1991. Changes in current and voltage are sensed by an
electrode. Several different configurations of this technique exist, one of which is whole62

cell recording. To acquire a whole-cell configuration a glass electrode is placed on the
surface of a cell and mild suction is applied to rupture the membrane, allowing for the
contents of the cell cytoplasm to diffuse and exchange with the internal solution inside
the glass pipette. The whole-cell configuration produces a convenient method to directly
apply substances into the cell in order to study the electrical currents and properties from
the entire cell, or we may perfuse agonist or antagonist on the extracellular space of the
cell to measure changes in ions flow (current) through receptors.
Whole-cell electrophysiology is used to study the movement of electrically
charged ions, commonly through voltage-gated or ligand-gated channels. Glutamatergic
receptors, such as kainate receptors, are permeable to Na+ and K+ ions. When these
receptors open, Na+ enters the cell and creates a more positive intracellular environment
(depolarizes). In an effort to maintain the cell electrical potential at -70mV (in voltage
clamp), a negative current is applied to the cell. Thus, a KAR response from voltageclamped data is negative.

2.2.1 EXPERIMENTAL PROTOCOL FOR WHOLE-CELL PATCH CLAMP RECORDINGS
HEK-293T cells (GenHunter, Nashville, TN, USA) were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100
IU ml-1 penicillin and 100 µg ml-1 streptomycin. Cells were passaged with a 0.025%
trypsin/0.01% EDTA solution in phosphate-buffered saline (10 mM Na2HPO4, 150 mM
NaCl, pH 7.3). Full length cDNAs for the GluK or Neto1 subunits in mammalian
expression vectors were transfected into cells using calcium phosphate precipitation as
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previously described (Mott et al. 2010). Plasmids encoding rat GluK2 (Q), GluK4 or
GluK5 were provided by S. Heinemann (Salk Institute, San Diego, CA, USA). Human
Neto1 was provided by S. Tomita (Yale University, New Haven, CN, USA). Plasmids
were transfected at ratios of 1:3:4 (GluK2: GluK4 – GluK5: Neto1), previously shown to
optimize formation of heteromeric receptors (Barberis et al. 2008) and Neto1 assembly
with KARs (Fisher & Mott, 2012). To identify transfected cells, we co-transfected 1 µg
of a cDNA encoding a single-chain antibody recognizing the hapten 4-ethoxymethylene2-phenyl-2-oxazoline-5-one (phOx; Chesnut et al. 1996). Positively transfected cells
were isolated using phOx-coated beads 18 – 28 hr after transfection and plated onto glass
coverslips treated with poly-L-lysine and collagen.
Whole-cell recordings were performed on isolated HEK-293T cells 40 – 52 h
after transfection under voltage-clamp conditions. Patch pipettes were pulled from
borosilicate glass with an internal filament (World Precision Instruments, Sarasota, FL,
USA) on a two-stage puller (Narishige, Japan) to a resistance of 5 – 10 MΩ and filled
with a solution containing (in mM): 130 CsGluconate, 5 CsCl, 10 Hepes, 5 CsBAPTA, 2
MgCl2, 2 MgATP, 0.3 NaGTP (pH 7.3, 290-300 mosmol l-1). Cells were continually
perfused with an external solution containing (in mM): 150 NaCl, 3 KCL, 10 Hepes, 1
CaCl2, 0.4 MgCl2 (pH 7.4, 295-305 mosmol l-1). For whole-cell recordings glutamate and
antagonists (ACET and kynurenate) were applied to cells using a stepper solution
changer (SF-77B, Warner Instruments, Hamden, CT, USA). The time course of drug
application was <50 ms in the whole-cell recording configuration as determined using a
diluted external solution applied to the electrode. Rise times (10 – 90%) of the junction
potential at the open tip were consistently faster than 400 µs and were tested using a
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diluted external solution. All antagonists were applied to cells before glutamate per
sweep. Current recordings were amplified (Axopatch 200B; Molecular Devices, Foster
City, CA, USA), filtered (1kHz) and digitized at 10 kHz using a Digidata 1320 analog to
digital board (Molecular Devices) and stored on a computer hard drive for off-line
analysis.

2.3 FIELD POTENTIAL ELECTROPHYSIOLOGY
Field-potential electrophysiology is performed extracellularly, as opposed to
whole cell record which is recorded intracellularly. Once the tissue is prepared a
stimulating electrode is placed into the tissue to depolarize a population of neurons. Field
potential electrophysiology allows electrophysiologists to record activity of a population
of neurons by placing the recording electrode within a cell body region or within the
dendrites or axons of the neuronal population. Activation of these neurons results in a
summation of the extracellular potentials creating either a field inhibitory postsynaptic
potential (fIPSP) or a field excitatory postsynaptic potential (fEPSP).
Because these recordings are extracellular and measures collective cell activity,
the placement of the recording electrode and stimulation electrode is critical to ensure
proper interpretation of the data. Relative to the electrode, neuronal activation can create
what is denoted as an extracellular sink or source. The flow of positively charged ions
into a cell or dendrite leaves the extracellular space more negative, creating an
extracellular sink, while a positive waveform (source) is created by the current that leaves
the cell (generally at the cell body) to complete the local circuit. Field potential
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recordings in the mossy fiber – CA3 synapse are at particular risk for improper electrode
placement, as the CA3 region contains mossy fibers input as well as the
associational/commissural fibers. Pure stimulation of the mossy fibers, elicited through
activation of dentate granule cells, would evoke an extracellular sink in area CA3 stratum
lucidum. However, if the placement of the recording electrode was not precise an
extracellular source evoked from the CA3 A/C fibers would contaminant the response.
The overall response would be a fEPSP comprised of both a downward sink and upward
source. Thus, in experiments involving the mossy fiber – CA3 synapse, steps are taken to
ensure pure mossy fiber stimulation and recording.

2.3.1 EXPERIMENTAL PROTOCOL FOR FIELD POTENTIAL RECORDINGS
Hippocampal slices were made from postnatal day (P) 21 – P28 and P45 – P60
Sprague-Dawley rats as described previously (Iyengar and Mott, 2008). Briefly, animals
were deeply anesthetized with isoflurane and decapitated with a guillotine. The brain was
removed under ice-cold (4ºC), sucrose-based ‘cutting’ artificial cerebrospinal fluid
(aCSF) that contained (in mM): 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 248
sucrose, 0.5 CaCl2, and 5 MgSO4 (350mOsm). The use of this solution during the cutting
process enhances neuronal survival by limiting excessive excitation. Transverse slices
were made with a vibratome (Leica VT1000S, Nussloch, Germany) at 500 µM and
incubated for at least one hour at room temperature in aCSF containing (in mM): 125
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2, 5 MgSO4, 20 µM D-
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AP-5, and 1 mM kynurenate (305 mOsm; pH=7.4). Both the sucrose-based and standard
aCSF were oxygenated with 95% O2 / 5% CO2.
After 1 hour, individual slices were transferred to a submersion chamber
maintained at 32 – 34 ºC, held in place by a bent piece of platinum wire resting on the
surface of the slice, and perfused continuously at 3 – 4 ml/min with recording aCSF
containing (in mM): 125 NaCl, 2.01 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 2
CaCl2, 1 MgSO4. Glass electrodes were pulled from borosilicate glass to achieve 2 – 3
MΩ and filled with recording aCSF. Extracellular dendritic field potentials recording
were made from the stratum lucidum of the CA3 region of the hippocampus, which was
visually identified with a light microscope (See Figure 2.1). Synaptic currents were
evoked with a monopolar platinum-iridium glass electrode positioned in the stratum
lucidum. For AMPA-fEPSPs recordings, we recorded composite MF-fEPSPs, which
were primarily composed of AMPA-fEPSPs (~ 93%) (Contractor et al., 2003), with aCSF
containing 10 µM MK-801, 50 µM picrotoxin, and 1 µM CGP 55845 to block NMDA,
GABAA, and GABAB receptors, respectively. We defined synaptic currents as MFfEPSPs if they showed characteristically large paired-pulse facilitation (Salin et al.,
1996), had a rapid rise time and short latency, and were inhibited by >70% by the group
II-selective metabotropic glutamate receptor (mGluR) agonist (2S,2’R,3’R)-2-(2’3’Dicarboxycyclopropyl) glycine (DCG-IV, 1 µM), which was bath applied at the end of
some experiments. To isolate KA-fEPSPs recordings, we recorded from CA3 pyramidal
cells in the presence of the aCSF containing the AMPA antagonist GYKI53655 (50 µM)
in addition to the GABAA, GABAB and NMDA receptor antagonist cocktail. Once KARfEPSPs were isolated, a four pulse train stimuli (100 Hz, 0.1 ms/stumulus, cathodal,
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monophasic, rectangular constant current pulses) were delivered every 30 sec through
monopolar, platinum-iridium stimulating electrodes (FHC Inc., Bowdoin, ME) referenced
to the bath ground. KAR-fEPSPs were stable for a minimum of 20 min. prior to
pilocarpine (300 nM) perfusion onto the slice for 10 – 15 min. to activate predominately
M1 mAChRs. In experiments were M1 mAChRs or PKC were inhibited, telenzepine
(100 nM) or chelerythrine (5 µM) respectively were applied concurrently with AMPA,
GABAA, GABAB, and NMDA antagonists. To resolve small KAR-fEPSPs that were
obscured by stimulation artifacts, we digitally subtracted a “template” stimulation trace
that was acquired after application of an AMPA/KAR antagonist (CNQX, 50 µM) at the
end of the recordings.

Figure 2.1 Illustration of the mossy fiber – CA3 synapse and field recording
configuration.
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2.4 PILOCARPINE MODEL OF SE
The use of animal models in investigation potential therapies for epilepsy is
indispensable. These models, and specifically the pilocarpine model, closely resembles
distinct anatomical and physiological alterations seen in the human disease, including
sclerosis and cell loss and mossy fiber sprouting. Additionally, the pilocarpine model
develops spontaneous seizures, chronic hyperexcitability, appropriate responsiveness to
AEDs, and develop comorbidities, such as anxiety and learning and memory deficits, that
are strongly associated with chronically epileptic patients. Without these models would
not be able to elucidate the mechanism precipitation or preventing seizures. The current
study will utilize a pilocarpine to initiate status epilepticus followed by a period of
epileptogenesis (30 days) and eventually the development of spontaneously recurring
seizures.

2.4.1 ANIMAL CARE AND USE
All animal care and use procedures were carried out in accordance with protocols
written under the guidance of the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and approved by the institutional Animal Care and Use
Committee at the University of South Carolina. Male Sprague-Dawley rats were
purchased from Harlan, and housed at 1 – 3 rats per cage with ab libitum access to food
and water. Rats were housed in a climate-controlled facility with a light/dark cycle of
12/12 hours.
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2.4.2 PILOCARPINE MODEL OF STATUS EPILEPTICUS
Adult male Sprague-Dawley rats (42 – 50 days; Harlan, Indianapolis, IN)
received intraperitoneal (i.p.) injections of scopolamine methyl bromide, to block
peripheral muscarinic receptors, and terbutaline hemisulfate (2 mg/kg) to activate
peripheral β2-adrenergic receptors to act as a bronchodilator and prevent respirator
depression associated

with

SE. Pilocarpine hydrochloride (390 mg/kg) was

intraperitoneally injected 30 – 40 minutes after scopolamine and terbutaline injection.
Following pilocarpine injection, rats were observed continuously for the occurrence of
behavioral seizures and were scored on the Racine scale (Racine, 1972) (Table 2.1).
Approximately 70% of rats experienced class V seizures. Animals that did not exhibit SE
after 45 minutes were given an additional ‘booster’ of pilocarpine (200 – 300 mg/kg).
Nearly 90% of animals receiving a pilocarpine ‘booster’ experienced sufficient SE.
Animals that successfully had a stage V seizure were allowed to seize 2 hours (status
epilepticus) before the seizures were suppressed by intraperitoneally injected diazepam
(DZP, 25 mg/kg). This group of animals served as the ‘pilo’ group. In order to limit
physical distress and any peripheral effects of pilocarpine, animals received additional
doses of the scopolamine/terbutaline cocktail approximately one-hour into SE as well as
upon termination of SE with DZP. A separate group of animals were treated identically,
but received saline (390 mg/kg) instead of pilocarpine hydrochloride. This group of
animals served as the ‘sham’ group. Approximately 1 – 2 hours after seizures were
terminated, animals received a subcutaneous dose of the scopolamine/terbutaline cocktail
(2 mg/kg), lactate Ringer’s solution (2 mL), and rat chow that had been softened and
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sweetened in high sucrose water. Animals that did not enter SE were excluded from the
study.
All animals were housed overnight in the animal facility and their health status
was checked as early as possible on the following day to determine if they successfully
recovered from treatment. Animals still experiencing side effects from treatment
(lethargy, immobility) were given additional subcutaneous injections of lactated Ringer’s
solution and the scopolamine/terbutaline cocktail and placed on a heating pad. For
animals who endured the first night post-treatment the survival rate was nearly 100%.
Animals in our “pilo” group were video monitored a minimum of 30 days post-treatment
to ensure the appearance of spontaneously occurring seizures. This experimental protocol
was used in Chapter 5 to explore alterations in the dopaminergic system in the epileptic
brain.

Table 2.1 Racine scale of epileptic seizures
Score
0
1
2
3
4
5
6
7

Observed Rat Motor Behavior
Normal behavior (exploring, walking, grooming, etc.)
Immobility, staring ‘curled up’ posture
Automatisms
(Chewing, head bobbing, twitching, wet-dog shakes)
Forelimb/hindlimb myoclonic jerking, head tremor
Rearing and whole body clonus
Rearing and falling over; loss of posture
Tonic-clonus seizures with tonic forelimb flexion/extension, wholebody clonus
Wild-running with bouncing; death
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2.5 WESTERN BLOT ANALYSIS
Western blotting is a widely used tool to detect the presence and measure the
abundance of specific proteins (MacPhee, 2010). Western blotting begins with successful
extraction and isolation of a particular lysate. Proteins are then separation by molecular
weight through electrophoresis onto a polyacrylamide gel. The proteins are then
transferred onto a membrane and probed with antisera to detect the presence of the
specific protein. During application of the appropriate primary and secondary antibody,
the membrane undergoes blocking to prevent non-specific binding between antibody and
membrane. Blocking usually consists of submerging the membrane in a non-fat milk or
bovine serum albumin solution. Once the appropriate antisera is bound to the protein, its
relative

expression

can

be

determined

through

process

such

as

enhanced

chemiluminescence (ECL). The peroxidase conjugated secondary antisera serves to
oxidize the luminol substrate within the ECL to emit light. This light is then captured
onto film and measured using densitometry. The following sections describe in detail the
western blotting protocol utilized in Chapter 5 to determine differences in dopamine
D1/D5 receptor, DAT, and COMT protein abundance within specific brain regions in the
hippocampus following pilocarpine-induces temporal lobe epilepsy.

2.5.1 MEMBRANE PREPARATION
Immunoblot analysis was performed as described in a previous study (Grillo et
al., 2011). Briefly, the hippocampus was rapidly extracted and processed ‘whole’ or
microdissected into CA1, CA3, and dentate gyrus. Tissue was homogenized in ice cold
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homogenization buffer (mM: 2 EDTA, 2 EGTA, 20 HEPES, 0.32M sucrose, 1%
phosphatase inhibitor, and 1% protease inhibitor). The samples were then homogenized
and centrifuged for 10 min at 500 x g at 4C to remove nuclear fraction. The supernatant
containing the total membrane fraction was centrifuged at 31,000 x g for 30 min at 4C.
The resulting crude plasma membrane fraction was resuspended in phosphate buffered
saline (PBS) and stored at -80ºC until used for analysis. A Bradford protein assay was
used as a simple and accurate way to measure protein concentration in the crude plasma
membrane, and used to ensure equal protein is loaded across all lanes.

2.5.2 SDS-PAGE AND ANTIBODY DEVELOPMENT
Aliquots of 20 μg of crude plasma membrane proteins were denatured by diluting
them in a 1:1 ratio with BioRad Laemmli Sample Buffer with 5% β-mercaptoethanol.
Samples were then heated at 95C for 5 min and loaded into pre-cast polyacrylamide gels
(4 – 15%). Running buffer (in mM: 25 Tris, 240 Glycine, 0.1% SDS) was added to the
appropriate tank, BioRad mini PROTEAN-Tetra, and ran using the BioRad Power Pack
HC for at least 30 min at 175 – 200 V. Following sodium dodecyl sulfate polyacrylamide
gel polyvinylidene fluoride (PVDF) membranes using the BioRad Trans-Blot SD SemiDry Transfer Cell. Protein transfer was completed using the BioRad Power Pack HC for
30 min at 25V. Transfer buffer contained (in mM): 25 Tris, 192 Glycine, and 20%
methanol. All equipment was acquired from Bio-Rad Laboratories, Inc.
PVDF blocked in TBS plus 5% nonfat dry milk for 60 min. PVDF
membranes were incubated with primary antisera in TBS/5% nonfat dry milk. After an
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overnight incubation at 4°C, blots were washed with TBS plus 0.05% Tween 20 (TBS-T)
and incubated with peroxidase labeled species-specific secondary antibodies. PVDF
membranes were then washed with TBS-T and developed using enhanced
chemiluminescence reagents (ECL, Amersham) as described by the manufacturer.
Normalization for protein loading was performed using a mouse monoclonal primary
antibody selective for actin (Sigma Chemical Company).

Table 2.2 Primary antibodies for western blot analysis
Ligand
D1
D5
TH
COMT
DAT

Manufacturer;
Catalog number
Millipore; AB1765P
Santa Cruz; sc-1441
Millipore; AB152
Millipore AB5873
Millipore: AB2231

Primary Concentration
1:200
1:250
1:1,000
1:1,500
1:2,000

2.6 IMMUNOHISTOCHEMISTRY
Immunohistochemistry is a power tool used to visualize the localization and
distribution of specific protein the fixed tissue. Thus, much care should be taken to
preserve the original architecture and connectivity in the brain. Immunostaining
techniques use a combination of immunology and histology. Immunology is used to
produce protein-specific antibodies from the serum of animals. Antibodies bind to
corresponding antigens presented on the cell surface. We use an indirect method of
immunohistochemistry to amplify the labeled signal. Antibodies for the specific protein is
applied to the tissue, where they bind to corresponding antigen, while excess and
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unbound antibody is washed off (primary). To identify the location of the antibody and
consequently the location of the antigen, an additional antibody is applied to tissue. This
antibody was developed in another species to recognize and bind to the species from
which the primary antibody was developed (secondary). Lastly, another antibody
conjugated with a peroxidase enzyme will bind to the antibody complex. This peroxidase
enzyme recognizes peroxide and allows us to visualize the location of the antibodies and
consequently the location of the antigen.
Histology is used because we observe the structure and preservation of tissue.
Generally, brains are fixed with formaldehyde and can either be sectioned immediately or
undergo cryoprotecting, which allows longer preservation of the tissue morphology in the
freezer. In many cases, this fixative can prevent sufficient antibody/antigen binding.
Thus, a popular detergent, Triton X can be used to improve penetration of the antibody
and improve labeling. We employed such techniques in this study. The following sections
describe in detail the immunohistochemistry protocol used in Chapter 5 to determine
alterations in dopamine D1/D5 receptor expression within the hippocampus following
pilocarpine-induced chronic temporal lobe epilepsy.
Free-floating sections were incubated with a mouse anti-glutamic acid
decarboxylase 67 (GAD-67, 1:1000; Millipore; product No. MAB5406), goat antidopamine D5 receptor (D5, 1:500; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA; product No. sc-1441), rat anti-dopamine D1 receptor (D1, 1:100; Sigma, St. Louis,
MO, USA; product No. D2944), or rabbit anti-tyrosine hydroxylase (TH, 1:2000;
Millipore; product No. AB152) antibodies for 24 hours at room temperature (RT) or 48
hours at 4°C. The GAD-67 antibody was used for cell body labeling as well as
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quantification of GABAergic neurons. These steps were followed by secondary antibody
incubation with either biotinylated donkey anti-mouse, anti-rabbit, anti-goat, or anti-rat
(1:400, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; product
Nos. 715-065-151, 711-065-152, 705-065-003, 712-065-150) for 1.5 hours at RT, and
horseradish peroxidase conjugated streptavidin (1:1600; Jackson ImmunoResearch
Laboratories, Inc.; product No. 016-030-084) for 1 hour at RT. Immunoreactivity was
developed using nickel sulfate-cobalt chloride intensified diaminobenzidine with
hydrogen peroxide, yielding blue-black immunopositive cells.

2.6.1 PERFUSION OF TISSUE FIXATION
All tissue was processed according to previously described protocols (Stanley et
al., 2012). Briefly, rats were deeply anesthetized using isoflurance and transcardially
perfused with phosphate-buffered saline and 4% paraformaldehyde. Briefly, once
anesthetized, a lateral incision to the lower abdomen was made which extended upwards
to expose the chest cavity and the heart. A hemostatic clamp was placed on the
descending vena cava to prevent perfusate flow to the lower extremities. A 20 x ½ gauge
needle attached to the perfusion pump was inserted through the apex of the left ventricle
and held firmly in place with a hemostat. Once inserted, the right atrium was clipped to
allow perfusate flow. Ice cold, oxygenated (95% O2 / 5% CO2) 0.05 M PBS (pH 7.4)
was perfused at approximately 60 mL/min for 4 – 5 min, followed by the ice cold fixative
(0.1 M phosphate buffer / 4% paraformaldehyde), for approximately 20 min. Whole
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brains were removed and postfixed overnight followed by cryoprotection in 30% sucrose.
Tissue was coronally sectioned at a 45 µm thickness on a crystat.

2.6.2 IMMUNOPEROXIDASE
Free-floating sections were incubated with primary antibodies (Table 2.2)
antibodies for 24 hours at room temperature (RT) or 48 hours at 4°C. The GAD-67
antibody was used for cell body labeling as well as quantification of GABAergic neurons.
These steps were followed by secondary antibody incubation for 1.5 hours at RT, and
horseradish peroxidase conjugated streptavidin (1:1600; Jackson ImmunoResearch
Laboratories, Inc.; product No. 016-030-084) for 1 hour at RT. Immunoreactivity was
developed using nickel sulfate-cobalt chloride intensified diaminobenzidine with
hydrogen peroxide, yielding blue-black immunopositive cells.

Table 2.3 Primary antibodies for immunohistochemistry analysis
Ligand
GAD-67
D5
D1
TH

Manufacturer;
Catalog Number
MAB5406
sc-1441
D2944
AB152
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Primary Concentration
1:1,000
1:500
1:100
1:2,000

2.6.3 SLIDE PREPARATION AND ANALYSIS
Stained and free floating tissue sections were mounted on slides with a 0.15%
gelatin solution and allowed to dry overnight. Once dry, tissue were serial dehydration
step with increasing concentrations of ethanol (50%, 70%, 95%, 100%, 100%; 3
min/bath) followed by two, 10 min incubations in xylene. Slides were immediately coverslipped using cover glass and DPX mounting solution (Sigma, St. Louis, MO) and
allowed several days to dry prior to analysis and long-term storage. Analysis on
immunohistochemical data was performed using cell counts.

2.6.4 CELL COUNTS & PHOTOMICROGRAPHS
Immunopositive cells were counted using a Nikon ECLIPSE 80i microscope
equipped with a CX900 camera (Nikon; Tokyo, Japan) using Neurolucida software (v.10;
MicroBrightField, Inc.; Williston; VT, USA). Minor adjustments to color, contrast, and
brightness were made using Adobe Photoshop 7.0 (San Jose, CA, USA).

2.7 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
High performance liquid chromatography (HPLC) is a technique that can be used
to identify, quantify and purify individual analytes of a given solution. Typically, HPLC
involves a high pressure pump used to carry analytes suspended in a mobile phase
through an analytical column. The column contains densely packed silica beads that
facilitate the separation of analytes based on polar interactions. After being separated,
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analytes are detected by an electrochemical detector. Retention times can be varied based
on mobile phase flow rate, composition or pH, as well as ambient temperature in some
cases. All HPLC products were purchase from BASi.
Rats were deeply anesthetized with isoflurane. Their hippocampi were rapidly
extracted and immediately weighted and chilled. Hippcampal tissue was homogenized
using individual plastic disposable pestles and 1.5mL centrifuge tubes. The tissue was
homogenized in a 0.1M perchloric acid (HClO4) solution containing 0.02% sodium
metabisulfite (Na2S2O5) and dihydroxybenzylamine (DHBA, 146.5 ng/mL, as an internal
standard for monamines) in a proportion of 15 µL solution for each milligram of tissue.
The homogenized tissue was then centrifuges at 11,000g at 4ºC for 40 min. After
centrifugation, the sample supernatant was filtered using 0.2 µM nylon disposable
syringe filters and stored at -80ºC until analyzed. Centrifuged tubes containing the tissue
pellet was also stored at -80ºC to use as a post hoc control to normalize for protein
concentration. We analyzed hippocampal tissue homogenates from “control” and
“epileptic” rats using high performance liquid chromatography (HPLC) with
electrochemical detection for the analytes dopamine, DOPAC, and norepinephrine (NE).
Elution times for these monoamines and their metabolites are displaying in Table 2.2
(Cavalheiro et al., 1994).

Table 2.4 Chromatographic parameters for monoamines and monoamine
metabolites
Neurotransmitter

Retention time (min)

4-hydroxy-3-methoxy-mandelic acid (VMA)

3.60
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4-hydroxy-3-methoxyphenly glycol (MPHG)

4.20

Norepinephrine (NE)

4.60

Dihydroxybenzylamine (DHBA)

7.30

Dihydroxyphenylacetic acid (DOPAC)

8.00

Dopamine (DA)

11.00

4-hydroxy-3-methoxy-phenylacetic acid
(HVA)

20.00

2.7.1 DOPAMINE CHROMATOGRAPHY
Dopamine, DOPAC, and NE were separated by a C18 carbon polymer column
using a mobile phase (pH 3.4) containing 14.5 mM NaH2PO4. A post-column
immobilized enzyme reactor containing covalently bound dopamine, DOPAC, and NE
oxidase generated stoichiometric quantities of hydrogen peroxide, which were detected
by a “peroxidase wired” glassy carbon electrode (Huang et al., 1995; Fadel et al., 2001).
Dopamine peak areas were quantified by comparison with a daily three-point standard
curve defining the range of dopamine values. Dopamine, DOPAC, and NE levels in
epileptic hippocampi were normalized as a percent of the average control hippocampi
dopamine, DOPAC, and NE content.

2.8 STATISTICAL ANALYSIS
Electrophysiological data was analyzed using pClamp10 (Molecular Devices,
Sunnyvale, CA) and Origin7.5 (OriginLab, Northampton, MA). Data collected from
western blot analysis and immunohistochemistry was analyzed using ImageJ 1.47V
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(National Institute or Health, USA) or cell counts. Data depicting changes in DAR, DAT,
and COMT protein expression were obtained by averaging data collected from a
minimum of two separate western blots.
All cell counts, electrophysiological data, and immunoblot data were analyzed
using independent samples Student’s t-test for significant main effects. All values are
expressed as the mean ± standard error of the mean (SEM). P <0.05 defined significant
main effects.
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CHAPTER 3
SUBUNIT DEPENDENT PHARMACOLOGY OF KAINATE RECEPTORS

3.1 INTRODUCTION

Kainate receptors (KARs) are ionotropic glutamate receptors composed of
tetrameric assemblies of GluK1-5 subunits (Pinheiro and Mulle, 2006). GluK2, GluK4,
and GluK5 are thought to compose postsynaptic KARs at mossy fiber (MF) to CA3
pyramidal cell synapses (mossy fiber-CA3 synapses) (Mulle et al., 1998; Contractor et
al., 2003; Fernandes et al., 2009), where they contribute with small amplitude, slowly
decaying currents (Castillo et al., 1997; Vignes and Collingridge, 1997). Despite their
small amplitude, KAR-excitatory postsynaptic currents (EPSCs) were hypothesized to be
important for the integration of information because they summate temporally (Frerking
and Ohliger-Frerking, 2002). Furthermore, kainate receptors are composed of subunits
that demonstrate distinct pharmacology, kinetics, and localization, thus, providing a
higher level of complexity to deciphering the role of kainate receptor subunits in the
brain. Although we know that each subunit can bind to glutamate and open the receptor,
we do not know whether each subunit contributes equally to receptor activation,
desensitization, and subsequently the KAR current at postsynaptic MF-CA3 synapses.
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The lack of pharmacological tools that selectively block KAR subunits known to
be located on CA3 pyramidal cells hampers clarifying the physiological relevance of
postsynaptic KARs at mf-CA3 synapses. Recently, an intense effort was made to
synthesize and characterize subunit-selective KAR antagonists, mainly against GluK1
(Jane et al., 2009). However, no selective antagonist of GluK5 or GluK4 subunits yet
exists, although they likely represent a major population of KARs in the brain (Wenthold
et al., 1994). Previous papers hint at how other GluK1 antagonists can be promiscuous in
also inhibiting heteromeric GluK2/K5 receptors (Pinheiro et al., 2013). The implication
of KAR-EPSCs at hippocampal MF synapses has only been addressed by comparing
wild-type and GluK2-/- mice, which display loss of postsynaptic KARs (Mulle et al.,
1998; Sachidhanandam et al., 2009). This was followed by demonstrations showing that
KAR-EPSCs are eliminated when GluK4 and GluK5 subunits are knocked out
(Fernandes et al., 2009). Thus, these two experiments can be explained by the latter,
suggesting that GluK2 is necessary for integration of GluK4 and GluK5 into the synapse.
However, it is the GluK2/GluK4 and/or the GluK2/GluK5 heteromers that are necessary
for KAR-EPSCs at the MF-CA3 synapses. Interestingly, the GluK4-/- demonstrated the
most diminished KAR-EPSCs at MF-CA3 synapses compared with the GluK5-/(Contractor et al., 2003; Fernandes et al., 2009). However, these results are not
conclusive that the GluK4 subunit is more important for postsynaptic KAR transmission
than the GluK5 subunit, because receptor compensation from congenital knockouts
cannot be ruled out. In addition to the previous research demonstrating a need for the
GluK4 and GluK5 subunits to produce postsynaptic KAR current, new research has
implicated a novel role for the auxiliary protein Neto1 in trafficking of KARs to the
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synapse and altering the properties KAR postsynaptic current at mf-CA3 synapses
(Copits et al., 2011; Straub et al., 2011a).
In search for antagonists of KARs at mf-CA3 synapses, we reevaluated the
efficacy of willardiine derivatives (Jane et al., 2009) on native KARs. ACET was
originally developed as a GluK1 selective antagonist (Dolman et al., 2007). We found
that ACET blocks postsynaptic KARs at mf-CA3 synapses. We further show that ACET
is also an antagonist of recombinant GluK5 and GluK4 subunits, the subunits required for
postsynaptic KAR current. Using this tool and the drug kynurenate, which was previously
demonstrated to antagonize the GluK2 subunit, we directly investigated the relative
contribution of the GluK2 and GluK5 subunits to KAR current in recombinant cells and
the brain.

3.2 MATERIALS AND METHODS

3.2.1 CULTURE AND TRANSFECTION OF HEK-293T CELLS
HEK-293T cells (GenHunter, Nashville, TN, USA) were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100
IU ml-1 penicillin and 100 µg ml-1 streptomycin. Cells were passaged with a 0.025%
trypsin/0.01% EDTA solution in phosphate-buffered saline (10 mM Na2HPO4, 150 mM
NaCl, pH 7.3). Full-length cDNAs for the GluK or Neto1 subunits in mammalian
expression vectors were transfected into cells using calcium phosphate precipitation as
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previously described (Mott et al. 2010). Plasmids encoding rat GluK2 (Q), GluK4 or
GluK5 were provided by S. Heinemann (Salk Institute, San Diego, CA, USA). Human
Neto1 was provided by S. Tomita (Yale University, New Haven, CN, USA). Plasmids
were transfected at ratios of 1:3:4 (GluK2: GluK4 – GluK5: Neto1), previously shown to
optimize formation of heteromeric receptors (Barberis et al. 2008) and Neto1 assembly
with KARs (Fisher & Mott, 2012). To identify transfected cells, we co-transfected 1 µg
of a cDNA encoding a single-chain antibody recognizing the hapten 4-ethoxymethylene2-phenyl-2-oxazoline-5-one (phOx; Chesnut et al. 1996). Positively transfected cells
were isolated using phOx-coated beads 18 – 28 hr after transfection and plated onto glass
coverslips treated with poly-L-lysine and collagen.

3.2.2 WHOLE-CELL RECORDING
Whole-cell recordings were performed on isolated HEK-293T cells 40 – 52 h
after transfection under voltage-clamp conditions. Patch pipettes were pulled from
borosilicate glass with an internal filament (World Precision Instruments, Sarasota, FL,
USA) on a two-stage puller (Narishige, Japan) to a resistance of 5 – 10 MΩ and filled
with a solution containing (in mM): 130 CsGluconate, 5 CsCl, 10 Hepes, 5 CsBAPTA, 2
MgCl2, 2 MgATP, 0.3 NaGTP (pH 7.3, 290-300 mosmol l-1). Cells were continually
perfused with an external solution containing (in mM): 150 NaCl, 3 KCL, 10 Hepes, 1
CaCl2, 0.4 MgCl2 (pH 7.4, 295-305 mosmol l-1). For whole-cell recordings glutamate and
antagonists (ACET and kynurenate) were applied to cells using a stepper solution
changer (SF-77B, Warner Instruments, Hamden, CT, USA). The time course of drug
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application was <50 ms in the whole-cell recording configuration as determined using a
diluted external solution applied to the electrode. Rise times (10 – 90%) of the junction
potential at the open tip were consistently faster than 400 µs and were tested using a
diluted external solution. All antagonists were applied to cells before glutamate per
sweep. Current recordings were amplified (Axopatch 200B; Molecular Devices, Foster
City, CA, USA), filtered (1kHz) and digitized at 10 kHz using a Digidata 1320 analog to
digital board (Molecular Devices) and stored on a computer hard drive for off-line
analysis.

3.2.3 ANALYSIS OF WHOLE-CELL CURRENTS
Whole-cell currents were analyzed using the programs Clampfit (pClamp9.2
suite, Molecular Devices, Foster City, CA, USA) and Origin (MicroCal, Northampton,
MA, USA). Concentration-response data were fit with a four-parameter logistic equation:
Current = [Minimum current + (Maximum current – Minimum current)]/1 + (10^(log
EC50 – log [Glutamate]) x n), where n represents the Hill number. All fits were made to
normalized data with current expressed as a percentage of the maximum response to
glutamate for each cell. Peak currents and log EC 50 values were compared using unpaired
Student’s t tests with a significance level of P = 0.05.
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3.3 RESULTS

3.3.1 ACET INHIBITION OF HETEROMERIC KAINATE RECEPTORS
ACET is a williardine compound previously described to be a GluK1 antagonist
(Dargan et al., 2009; Jane et al., 2009). Studies have confirmed that ACET does not
inhibit the activation of GluK2 homomeric currents (Dargan et al., 2009). However,
doubts about the specificity of ACET to inhibit only GluK1 receptors were raised when it
was demonstrated that ACET could inhibit KAR currents at mossy fiber-CA3 synapses
(Dargan et al., 2009), a synapse in which few if any postsynaptic GluK1 receptors are
located (Paternain et al., 2003). To examine the selectivity of ACET, we transfected
HEK-293T cells with heteromeric and homomeric kainate receptors known to be
predominantly expressed on CA3 pyramidal cells (GluK2, GluK2/K4 and GluK2/K5)
and evaluated the efficacy of ACET to inhibit their glutamate-induced current.
Using whole cell patch-clamping electrophysiology, we gained access to the
internal milieu of the cell and clamped the voltage inside the cell at -70 mV. An EC50
glutamate dose was applied to each cell as a reference for maximum current activation.
Glutamate was applied at the beginning and end of each experiment to 1) receive a
reference for maximum current activation, and 2) as a way to determine receptor
rundown throughout the experiment. In cells transfected with GluK2/K4 KAR subtypes,
a 5 sec application of 30 µM glutamate produced a rapid on and fast desensitizing current
(Figure 3.1A). These receptor kinetics are similar to those reported in other papers (Fisher
and Fisher, 2014). Co-application of 1 µM ACET with 30 µM glutamate reliably reduced
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the peak current amplitude by 54 ± 6.3% (Figure 3.1A). In cells transfected with
GluK2/K5 KAR subtypes, an EC50 glutamate dose of 10 µM produced a rapidly activated
but slowly desensitizing current (Figure 3.1A). This receptor kinetic was similar to those
reported in other papers (Fisher and Mott, 2011; Fisher and Fisher, 2014). Co-application
of 1 µM ACET with 10 µM glutamate reliably reduced the peak current by 92 ± 0.85%
(Figure 3.1A). However, in cell transfected with GluK2 KAR subtypes, and EC50
glutamate dose of 300 µM glutamate produced a rapidly activating and desensitizing
current (Figure 3.1B). Co-application of 1 µM ACET with 300 µM glutamate did not
inhibit the peak current amplitude (Figure 3.1B).
Interestingly, our results demonstrate that 1µM ACET is not sufficient to inhibit
GluK2 when expressed alone. However, 1 µM ACET is sufficient to inhibit peak currents
when GluK2 is expressed with either GluK4 or GluK5 subunits. Thus, we designed
further experiments to test whether the GluK4 or GluK5 subunits contribute to the
appearance of ACET inhibition. To test whether GluK4 or GluK5 subunits contribute to
ACET inhibition of heteromeric KAR currents, we co-transfected GluK4 or GluK5
subunits with a mutated GluK2, in which the 738th glutamate (E) amino acid was
replaced with a aspartate (D) amino acid. This mutation reduces the GluK2 subunit
sensitivity to glutamate 1,000 fold (Fisher and Mott, 2011), resulting in the lack of GluK2
activation at glutamate concentrations less than 1 mM. Now, when GluK4 and GluK5 is
expressed with the mutated GluK2 subunit (GluK2E738D), the receptor kinetics change
from a rapid on and desensitizing current to a non-desensitizing current. This was
reported and elucidated in other papers, where they described this phenomenon was due
to activation of only two identical subunits in the tetramer (Fisher and Mott, 2011).
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Desensitization requires that activation of at least three or more subunits. By removing
the sensitivity of the GluK2 subunit to glutamate, only the GluK4 or GluK5 subunits in
the tetramer can bind to glutamate, and thus produces a non-desensitizing current.
Application of 1 µM ACET was sufficient to block activation induced by EC50 dose of
glutamate (Figure 3.1B)
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Desensitization requires that activation of at least three or more subunits. By
removing the sensitivity of the GluK2 subunit to glutamate, only the GluK4 or GluK5
subunits in the tetramer can bind to glutamate, and thus produces a non-desensitizing
current. Application of 1 µM ACET was sufficient to block activation induced by EC50
dose of glutamate (Figure 3.1B)

3.3.2 ACET SIMILAR INHIBITS THE GLUK4 AND GLUK5 SUBUNITS
The GluK4 and GluK5 subunits can have drastically different pharmacology from
the other KAR subtypes. They can be activated by ligands, such as AMPA, that GluK1 –
GluK3 subunits cannot bind (Alt et al., 2004). Also, GluK4 and GluK5 are more sensitive
to glutamate, given them the name of ‘high affinity’ KAR subunits (Heckmann et al.,
1996; Paternain et al., 1998; Barberis et al., 2008; Fisher and Mott, 2011, 2013). Thus,
their incorporation into KAR subtypes can have drastic effects on the pharmacology of
the whole KAR receptor. We previously, demonstrated that 1 µM of ACET was
sufficient to reduce EC50 glutamate activation of GluK2-containing heteromers, although
the inhibition of GluK2/K5 wildtype KARs current was more than in GluK2/K4 KARs.
This difference in current inhibition in GluK4 versus K5 KARs was occluded when coexpressed with a mutant GluK2, which lacked sensitivity to the EC50 glutamate dose.
Next, we sought to determine whether the sensitivity of the GluK4- and GluK5containing KARs to ACET was similar. To test this, we conducted an ACET
concentration curve, where increasing concentration of ACET were co-applied with an
EC50 concentration of glutamate. Peak current responses were recorded for each
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concentration in each cell. All data was normalized to the EC50 glutamate concentration
alone. Results are reported as a measure of how much a particular drug (ACET or
kynurenate) is needed to inhibit current amplitude by half (IC50). Analyses of wildtype
GluK2, GluK2/4 and GluK2/5 receptors demonstrated that the IC50 of ACET was very
different across the KAR subtypes (GluK2, IC50 = 126 ± 3 nM, n = 4; GluK2/K4, IC50 =
71 ± 5 nM, n = 8; and GluK2/K5, IC50 = 29 ± 7 nM, n = 10, respectively) (Figure 3.2A).
As shown above, wildtype GluK2/K5 heteromers have the highest sensitivity to ACET
inhibition, followed by wildtype GluK2/K4 heteromers. As expected, GluK2 homomers
were non-responsive to ACET inhibition until concentrations exceeding 1 µM. It is also
important to note that ACET inhibition of the GluK2/K4 peak current plateaued at ~45%
of the maximum glutamate response irrespective of increased ACET concentrations
(Figure 3.2A). Thus, the difference in wildtypes GluK2/K4 and GluK2/5 sensitivity to
ACET inhibition is more pronounced with higher concentrations of ACET (Figure 3.2A).
Interestingly, the difference between GluK2/K4 and GluK2/K5 sensitivity to
ACET inhibition was abolished when co-expressed with the mutated GluK2 subunit
(GluK2(E738D)). ACET concentration-response curves for GluK2(E738D)/K4 and
GluK2(E738D)/K5 were not statistically different. This was also supported by the
similarities of their ACET IC50s: GluK2(E738D)/K4, IC50 = 112 ± 1 nM, n = 6;
GluK2(E738D)/K5, IC50 = 64 ± 1 nM, n = 7 (Figure 3.2C).
Steady-state current is achieved when there is equilibrium between the amount of
receptors in the desensitized state and the open state. Thus, the amount of current remains
constant in the presence of glutamate. ACET did not inhibit the steady-state current in
wild-type GluK2/K4 and GluK2/K5 KARs (Figure 3.2B). However, the steady-state
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current in GluK2(E738D)-containing heteromers was sensitive to ACET inhibition
(Figure 3.1B).
GluK2 homomeric KARs with a glutamine (Q) residue in the pore domain are
subject to voltage dependent block by intracellular polyamines, which cause inward
rectification of their current – voltage relationship. The ending result is that positive ions
are hindered from leaving the cell even when the cell is depolarized to higher voltages.
Cell that express heteromeric KARs do not experience inward rectification and allow ions
to flow freely in or out of the cell in response to hyperpolarization or depolarization,
respectively. To ensure that heteromeric receptors were expressed when we transfected
with GluK2 and GluK4 or GluK5, we test for the lack of inward rectification. To test for
the presence of rectification, we took the cell through a range of voltage steps (-90 mV +70 mV) and measured the peak current in response to the EC50 glutamate. Results were
plotted on a current (I) – volts (V) curve, where peak current for each step is averaged
and normalized to the peak current at -90 mV. The presence of positive current indicates
the lack of inward rectification and the successful expression of functional heteromeric
KARs. In cell transfected with GluK2/K5 and GluK2/K4, we saw the presence of
positive current when the cells were depolarized above 0 mV (Figure 3.2C). However, we
saw a lack of positive current at higher voltage potential in cell transfected with GluK2
homomers (Figure 3.2C).
The glutamate EC50 for GluK2-containing homomers and heteromers and
GluK2(E738D) have been previously described (Fisher and Fisher, 2014). Our glutamate
concentration curve agrees with this published data (Figure 3.2D).
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Figure 3.2 The efficacy of ACET is similar at GluK4 and GluK5 KAR subunits.
However this similarity is occluded when these subunits are incorporated with the GluK2
subunit.
A. Graph illustrating an ACET concentration curve. Peak amplitude of each current
to concentration of ACET was normalized to the peak current response to
glutamate application alone. The difference in ACET inhibition of wildtype
GluK2/K4 to GluK2/K5 was abolished when the GluK2 subunit was mutated to
be 1,000-fold less sensitive to glutamate.
B. ACET (1 µM) does not inhibit steady state currents at wildtype GluK2/K4 or
GluK2/K5 KAR receptors.
C. Graph illustrating the I-V curve for cells transfected with GluK2 homomers and
GluK2/K4 and GluK2/K5 heteromers. Cells transfected with heteromers
GluK2/K4 and GluK2/K5 demonstrated reduced inward rectification compared to
GluK2 homomers, and thus, confirms expression of heteromeric receptors.
D. Glutamate EC50s are 330 µM (GluK2) and 8 µM (GluK2/K5). GluK2(E738D) is
less sensitive to glutamate than wildtype (GluK2).
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3.3.3 NETO1 ALTERS ACET INHIBITION
Neto1 is an auxiliary protein to KARs. Neto1 alters the kinetics of GluK2containing receptors (Copits et al., 2011; Straub et al., 2011a; Fisher and Mott, 2013). As
previously

described,

co-expressing

Neto1

with

GluK2/K5

KARs

removes

desensitization of the glutamate-induced current (Figure 3.3A). Co-application of ACET
inhibited peak current amplitude in GluK2/K5 cells expressing Neto1 similarly to those
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Figure 3.3 Neto1 enhances ACET inhibition of steady state GluK2/K5 currents
A. Sample waveforms demonstrating that ACET (1 µM) inhibits steady state current
at GluK2/K5 receptors only when Neto1 is present.
B. Averaged data demonstrating that co-transfecting with Neto1 enhances ACET
inhibition of steady state, but not peak current at GluK2/K5 receptors. We suggest
that the steady state current remaining in the presence of ACET is mediated by
activated GluK2 subunits.

not expressing Neto1. Alternatively, we previously demonstrated that ACET did not
inhibit the steady-state current in cells not expressing Neto1. However, when Neto1 is coexpressed with GluK2/K5 receptors, ACET now inhibits the steady-state current (Figure
3.3A, B).

3.3.4 KYNURENATE INHIBITION OF GLUK2-CONTAINING KAINATE RECEPTORS
Kynurenate (KYN) is a non-selective glutamate antagonist. Among GluK2containing KARs, kynurenate preferentially inhibits the GluK2 subunit (Fisher and Mott,
2011). Thus, when co-expressed with GluK2/K5 kainate receptors, coapplication of
kynurenate with an EC50 concentration of glutamate yielded a non-desensitizing current.
Representative waveforms illustrate that KYN dose-dependently inhibits the peak current
amplitude of GluK2, GluK2/K4, and GluK2/K5 KARs induced by an EC50 dose of
glutamate. In GluK2 homomers, the rapidly activating and desensitizing current is
progressively inhibited by increasing concentrations of KYN (Figure 3.4A). GluK2/K4
currents, although desensitizing slight slower, responded to KYN inhibition similarly to
GluK2 homomers (Figure 3.4A). A difference remained in that at higher KYN
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Figure 3.4 Kynurenate has distinct effects on GluK2/K4 and GluK2/K5 receptors
A. Sample waveforms demonstrating that with increasing kynurenate (KYN)
concentration, glutamate-activated current at GluK2 homomeric receptors is
progressively inhibited. Increasing concentrations of kynurenate had a similar
effect on GluK2/K4 receptors. Alternatively, at GluK2/K5 receptors, kynurenate
inhibits peak current and strongly removes desensitization.
B. Reduced inward rectification in IV-curves confirms expression of heteromeric
GluK2/K4 and GluK2/K5 receptors.
C. Graph illustrating a kynurenate concentration curve. Kynurenate inhibition of
glutamate-induced currents was normalized to the peak current amplitude of
glutamate application alone. Peak glutamate current at GluK2/K5 receptors is less
sensitive to kynurenate inhibition than GluK2 or GluK2/K4 receptors.
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concentrations, GluK2/K4 currents adopted a non-desensitizing receptor kinetic (Figure
3.4A). KYN application had a distinguishing different effect on GluK2/K5 KAR kinetics.
Increasing concentrations of KYN did inhibit the peak current amplitude, however, it
more so removed desensitization (Figure 3.4A). A KYN concentration-curve, further
demonstrates that GluK2 (IC50 = 345 ± 50 µM, n = 8) and GluK2/K4 (IC50 = 162 ± 15
µM, n = 5) have similar sensitivities to KYN inhibition (Figure 3.4C). However,
GluK2/K5 KARs (IC50 = 3857 ± 163 µM, n = 9) were less sensitive to KYN inhibition
than the other GluK2-containing KARs (Figure 3.4C). These results agree with
previously published data (Fisher and Mott, 2011). Additionally, the presence of
heteromers in GluK2/K4 and GluK2/K5 transfected cells was confirmed by the lack of
inward rectification (Figure 3.4B).

3.3.5 NETO1 ALTERS KYNURENATE INHIBITION
As described previously, incorporation of Neto1 into GluK2/K5 preparations
removes desensitization of the glutamate-induced current. In wildtype GluK2/K5
receptors, coapplication of 1 mM KYN with an EC50 dose of glutamate moderately
suppresses the peak current amplitude (Figure 3.5A, B). However, the steady-state current
is significantly increased (Figure 3.5A, C). When Neto1 is expressed with GluK2/K5
KARs, KYN inhibits the peak current amplitude similarly to preparations without Neto1
(Figure 3.5A, B). However, the steady-state current is now inhibited by 3 mM KYN.
Thus, KYN reduces desensitization of GluK2/K5 receptors not expressed with Neto1 and
thereby alters the ratio of the steady-state amplitude to the peak amplitude. However,
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KYN does not alter this steady-state/peak amplitude ratio when applied to GluK2/K5
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Figure 3.5 Neto1 occludes the effect of kynurenate on desensitization, but not
inhibition
A. Representative traces illustrating that co-transfected cells containing GluK2/K5
with Neto1 occludes kynurenate removal of desensitization and allows inhibition
of the steady-state current.
B. Concentration curve comparing the relative kynurenate inhibition of GluK2/K5 ±
Neto1 peak current amplitude. Co-transfection with Neto1 does not alter
inhibition of GluK2/K5 peak current by kynurenate.
C. Concentration curve illustrating the relative inhibition of GluK2/K5 ± Neto1
steady state current. Co-transfection with Neto1 prevents inhibition of GluK2/K5
steady state current by kynurenate.
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3.3.6 USING ACET AND KYNURENATE AS PHARMACOLOGICAL TOOLS
In the previous sections, we demonstrated that ACET inhibits the GluK5 and
GluK4 KAR subunits in heteromers. Additionally, we confirmed that KYN preferentially
does not inhibit the GluK5 KAR subunit in heteromers. Thus, we can use these drugs as
pharmacologic tools to selectively activate or inhibit specific receptors subunits in the
GluK2/K5 heteromer. To test the effectiveness of these tools, we sought to verify the
receptor occupancy model for KARs. The receptor occupancy model states that
desensitization occurs when three or more subunits are activated. If only two or less
KARs are activated, the receptor can open, but will not desensitize (Fisher and Mott,
2011; Fisher and Fisher, 2014; Reiner and Isacoff, 2014). Application of an EC50
glutamate dose allowed GluK2/K5 receptors to rapidly open and desensitize, as
illustrated previously. Co-application with 3 mM kynurenate, preferentially inhibits the
GluK2 subunits, leaving the GluK5 subunits to open the receptor to a non-desensitizing
current. Consecutively, co-applying 1 µM ACET inhibited the remaining predominately
GluK5-mediated current (Figure 3.6A). Steady-state was measured across conditions (10
µM glutamate alone, 3 mM KYN, and 3 mM KYN + 1 µM ACET) and normalized to the
condition with the maximum steady-state current (KYN). Averaged data demonstrates
that the steady-state current was significant reduced in the glutamate alone (26 ± 1%, n =
5) and KYN + ACET (1 µM: 23 ± 4.5%, n = 5; 10 µM: 8.3 ± 1.7%, n = 5; p < 0.05)
condition compared to the KYN condition.
We determined that activation of the GluK5 subunit is sufficient to open the
receptor. Next, we wanted to determine whether activation of the GluK2 subunit is
sufficient to open the heteromeric receptor. We applied the EC50 dose of glutamate (300
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Figure 3.6 Occupancy of either the GluK2 or GluK5 subunits can activate
GluK2/K5 receptors
A. Sample waveforms (left) and bar graph (right) illustrating that kynurenate (3 mM)
removed desensitization at GluK2/K5 receptors, and consequently enhances the
steady state current. ACET (1 µM) inhibits this steady state current. Bar graph
(right) illustrates the amplitude of the steady state current for each condition
normalized to the condition with the maximum steady state amplitude (3mM
kynurenate alone).
B. Sample waveform (left) and bar graph (right) illustrating that co-application of
ACET (10 µM) with glutamate (300 µM) enhances the steady state current and
the addition of KYN (3 mM) inhibits this steady state current. Bar graph (right)
illustrates the steady state current amplitude for each condition normalized to the
condition with the maximum steady state current (10μM ACET).

µM) to ensure sufficient activation of the GluK2 subunits. The GluK2 subunit is less
sensitive to glutamate activation than the GluK2/K5 subunit. Thus, more glutamate is
needed to ensure sufficient binding of the GluK2 subunit. Perfusion of 300 µM glutamate
opened and rapidly desensitized the GluK2/K5 KARs. Co-application of 10 µM ACET (a
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dose chosen to maximally inhibit the GluK5 subunits with minimal inhibition of the
GluK2 subunits), open the GluK2/K5 KAR to a non-desensitizing current. Consecutive
application of 3 mM KYN with 10 µM ACET completely inhibited GluK2/K5 current.
The steady-state current was significantly reduced in the 300 µM glutamate alone (14 ±
7%, n = 5, p < 0.05) and 10 µM ACET + 3 mM KYN condition (26 ± 1%, n = 5, p <
0.05) compared to the ACET condition.
3.3.7 ACET INHIBITS KAINATE – MEDIATED SYNAPTIC TRANSMISSION
The GluK4 and GluK5 subunits are necessary for kainate receptor synaptic
transmission at the mossy fiber – CA3 synapse (Fernandes et al., 2009). Thus, we
hypothesized that ACET will inhibit kainate receptor fEPSPs at this synapse. Field
EPSPs were evoked by stimulating mossy fibers extending from the dentate gyrus
pyramidal cell layer and recording synaptic field potentials in CA3 stratum lucidum. The
KAR component of the fEPSP was isolated with an antagonist cocktail: 50 µM GYKI
53655, 10 µM MK801, 50 µM picrotoxin, and 1 µM CGP 5585, and resembled the slow
fEPSPs as previously described (Castillo et al., 1997) (black trace, Figure 3.7A,B).
Concurrent perfusion of 1 µM ACET significantly and completely blocked the KAR
fEPSP (red trace, 6.6 ± 4.8%, n = 8 p < 0.05), Figure 3.7A,B). Averaged data was
represented as a bar graph, where the peak amplitude was normalized to the fEPSPs
amplitude with the antagonist cocktail alone.
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Figure 3.7 ACET blocks kainate receptor synaptic transmission at mossy fiber –
CA3 synapses.
A. Sample waveform of KAR fEPSPs (black trace) isolated by perfusing an
antagonist cocktail (50 µM GYKI 53655, 10 µM MK801, 50 µM picrotoxin, and
1 µM CGP 55845). Adding 1 µM ACET to the perfusing antagonist cocktail
completely inhibited the KAR EPSPs.
B. Bar graph of averaged data normalized to the KAR fEPSPs. ACET significantly
inhibited the KAR fEPSPs.

3.4 DISCUSSION

In the present study, we used whole cell electrophysiology on cells transfected
with various GluK2-containing KARs to determine whether ACET and/or kynurenate can
be used as pharmacological tools to delineate specific subunit contribution to KAR
current. We found that ACET inhibits current at heteromeric KARs by binding to the
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GluK4 and GluK5 subunits, and KYN preferentially does not inhibit the GluK5 subunit.
Furthermore, we demonstrated that ACET inhibits KAR – mediated synaptic current in
the brain, specifically the mossy fiber – CA3 synapse. These drugs can be used as
pharmacological tools to distinguish GluK2 subunit contribution from KAR current from
the GluK5 subunit.

3.4.1 INHIBITION OF GLUK2-CONTAINING KAINATE RECEPTORS BY ACET
ACET is a willidarine compound originally characterized as a GluK1 antagonist
(Jane et al., 2009). However, doubts about ACET being a selective drug for GluK1 has
surfaced. One reason for recent suspicion is that other compounds within the ACET
family and with a similar structure, have demonstrated a more promiscuous ligand
affinity than for the GluK1 subunit alone. One such compound was the drug UBP310
(Pinheiro et al., 2013). Pinheiro et al., described quite convincingly that UBP310 can
inhibit current at GluK2/K5 currents in cultured cells and acute brain slices (Pinheiro et
al., 2013). Here we describe that ACET, similar to UBP310, also has a more promiscuous
ligand affinity than previously thought and inhibits glutamate current at GluK2/K5
receptors. We took it a step further and characterized another GluK2-containing
heteromer, GluK2/K4. Our results demonstrated that not only is the GluK2/K5 receptor
sensitive to ACET inhibition, but also GluK2/K4 receptors. Furthermore, by mutating the
GluK2 subunit, we determined that ACET inhibition of GluK2-containing heteromers
was due to ACET inhibiting specifically the GluK4 and GluK5 subunits.

103

Interestingly, ACET inhibition at GluK2/K4 wildtype receptors plateaued around
45% of the maximum glutamate response, such that higher concentrations of ACET did
not produce additional inhibition of the GluK2/K4 current. The reason for the plateau
could be that the GluK4 is fully inhibited (as indicated by the GluK2(E738D)/K4
concentration-curve), however the remaining current is mediated by the GluK2 subunit.
An alternative explanation is that ACET may act as a partial agonist. Partial agonists
have partial efficacy at the receptor relative to a full agonist. They are often confused
with competitive antagonists because partial agonists can compete with full agonists for
receptor binding sites and produce a net reduction in receptor activation. Future studies
are needed to determine whether ACET is in fact a partial agonist. Our results suggest
that ACET is not a specific GluK1 antagonist, but should be considered more of an
inhibitor of most KARs (there is no data available on ACET inhibition of GluK3 KARs)
except at GluK2 subunits.
We also examine the impact of the auxiliary subunit Neto1 on the ACET
inhibition of GluK2/K5 current. Neto1 is an auxiliary protein known to bind to KARs in
the brain and recombinant cells (Tang et al., 2011). Neto1 has a role in incorporation of
KARs to the synapse and alters for KAR synaptic transmission (Copits et al., 2011;
Straub et al., 2011a). In recombinant cells, Neto1 has little impact on surface expression
of recombinant KARs. However, Neto1 does change receptor kinetics (Fisher and Mott,
2012, 2013). Co-expression of Neto1 shifts the concentration dependent for the onset of
desensitization towards higher levels of glutamate, but does not change the glutamate
EC50 for GluK5-containng subunits (Fisher and Mott, 2013). Thus, at the glutamate EC50
for GluK2/K5 (10 µM) the presence of Neto1 changed the receptor kinetics from a
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rapidly desensitizing current to a non-desensitizing current, as previously reported (Fisher
and Mott, 2013). In the present study, we demonstrate that the presence of Neto1 does not
significantly change ACET inhibition of GluK2/K5 peak current. However, the presence
of Neto1 did alter how ACET inhibited the heteromeric current. ACET did not inhibit the
remaining steady-state current in the absence of Neto1. However, in the presence of
Neto1, ACET inhibited the steady-state current. It is our suggestion that ACET does not
bind to the desensitized conformation of GluK2/K5 heteromeric receptor. Thus, in
preparations when Neto1 is absent and the GluK2/K5 receptors are allowed to undergo a
desensitized conformation, ACET will inhibit the GluK2/K5 peak current when the
receptors are predominantly in an open/activated conformation. However, ACET did not
inhibit the steady state GluK2/K5 current when majority of the GluK2/K5 receptors are
in the desensitized conformation. Alternatively, when Neto1 is co-expressed with
GluK2/K5 receptors, the GluK2/K5 receptor is prevented from undertaking a
desensitized conformation, and now ACET can inhibit both the peak and steady state
current. These results suggest that ACET may have bias towards the physical
conformation of GluK5-containing kainate receptors.
Another cause for suspicion on the subunit selectivity of ACET, is that ACET
produced inhibition of kainate mediated mossy fiber – CA3 EPSPs (Dargan et al., 2009).
Interestingly, GluK1 is not expressed at detectably levels on CA3 pyramidal cells, and
thus, does not contribute to kainate mediated mossy fiber – CA3 EPSPs (Bahn et al.,
1994; Bureau et al., 1999; Paternain et al., 2000). These results produced confusion about
the function of KARs in the brain. We submit that the previous confusion was stemmed
from the misunderstanding about the subunit selectivity of ACET. Our results from
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recombinant cells demonstrate that ACET inhibits current at heteromeric receptors
containing either GluK4 or GluK5 subunits. Both GluK4 and GluK5 subunits are
expressed at high level postsynaptically on CA3 pyramidal cells (Bahn et al., 1994), and
they are required for kainate-mediate current at that synapse (Fernandes et al., 2009).
Thus, our results provide further reasoning that postsynaptic KARs located on CA3
pyramidal neurons are composed of GluK4 and GluK5 subunits.
Additionally, we discovered in our own hands that ACET completely blocks
kainate mediated EPSPs at mossy fiber – CA3 synapses. This was quite interesting to us,
because although we expected ACET to reduce KAR EPSPs at this synapse, we did not
expect a complete blockage of this KAR EPSPs. Glutamate released from presynaptic
terminals can reach concentrations of ~ 1mM before rapidly declining (Clements et al.,
1992; Clements, 1996; Diamond and Jahr, 1997). Majority of our data in this paper used
the EC50 dose of 10 µM glutamate. This concentration is sufficient to activate the GluK5
subunits; however, it is 30 fold less than the EC50 glutamate concentration for the GluK2
subunit. Thus, most of the current is produced as a result of glutamate binding to the
GluK5 subunit, in which 1 µM ACET produced a pronounced inhibition of the current.
However, when glutamate concentration was increased (300 µM glutamate) equivalent to
the EC50 for the GluK2 subunit and allowing sufficient activation of the GluK2 subunit, 1
µM ACET produced much less inhibition of the peak GluK2/K5 current (Figure 3.6B).
We suggest that these seemingly contradictory data between ACET inhibition of the
recombinant and brain slice KAR responses is an extension of ACET bias for the
open/activation confirmation over the desensitized conformation. At the synapse,
released glutamate is rapidly removed before kainate receptors can undergo a
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desensitized conformation (deactivation). However, in our preparations the onset and
duration (5 seconds) of applied glutamate is slow compared to the synapse, and allows
sufficient time for KAR desensitization. Indeed, other studies have demonstrated with
similar antagonist to ACET (UBP310), that rapidly applying glutamate allows UBP310 to
inhibit the GluK2/K5 response significantly more than with prolonged application of
glutamate (Pinheiro et al., 2013). Another potential explanation is that higher-affinity
GluK5 subunits contribute to the rapid activation of GluK2/K5 heteromeric receptors
even at high glutamate concentrations, while during prolonged glutamate application the
binding of lower-affinity GluK2 subunits (which are insensitive to ACET and UBP310)
to glutamate contributes more to the GluK2/K5 heteromeric current.

3.4.2 INHIBITION OF GLUK2-CONTAINING KAINATE RECEPTORS BY KYNURENATE
Kynurenate is a nonselective competitive antagonist of glutamate receptors.
Previous studies have reported that kynurenate has a substantially higher affinity for
GluK2 than GluK5 subunits (Fisher and Mott, 2011). However, it is not known whether
kynurenate can inhibit currents at GluK2/K4 heteromers nor whether the presence of
Neto1 alters kynurenate inhibition of KAR current. At a concentration that blocked
current at GluK2 homomers, our findings demonstrate that kynurenate produced little
inhibition of peak current and removed desensitization from GluK2/K5 receptors. These
results are consistent with previously reported data (Fisher and Mott, 2011). We further
characterized kynurenate inhibition of GluK2/K4 receptors. Kynurenate dose
dependently inhibited GluK2/K4 heteromers. Unlike kynurenate inhibition of GluK2/K5
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receptors, kynurenate did not substantially increase the steady-state current. The resulting
kinetics of kynurenate inhibition resembled kynurenate inhibition of GluK2 homomers.
We do not know why there is such qualitative difference in receptor kinetics between the
GluK2/K4 and GluK2/K5 receptors when kynurenate is applied. One suggestion is that
the GluK4 subunit appears to make greater contribution to desensitization (Mott et al.,
2010), and can desensitize to glutamate activation in and of itself (Fisher and Fisher,
2014).
We also examined whether co-expression with Neto1 alters kynurenate inhibition
of KAR current. Similarly to our previous data with ACET, the presence of Neto1 did not
alter GluK2/K5 sensitivity to kynurenate inhibition. However, it did alter the kinetics of
the receptor once kynurenate was applied. As reported earlier, kynurenate potentiated the
GluK2/K5 steady-state current (Fisher and Mott, 2011). Co-expression of Neto1 removed
desensitization and allowed kynurenate to inhibit the steady-state current.

3.4.3 FUNCTIONAL

SIGNIFICANCE OF PHARMACOLOGICAL TOOLS FOR KAINATE

RECEPTORS

KARs contribute to synaptic integration at glutamate synapses (Frerking and
Ohliger-Frerking, 2002). Specifically, GluK2/K5 receptors are known to constitute a
major population of KARs in the brain: both subunits are abundantly co-expressed in the
cerebellum, neocortex, striatum, amygdala, and hippocampus, at higher levels than other
KAR subunits (Bureau et al., 1999). The lack of pharmacological tools has hindered our
understanding of KARs and their function in the brain. Recent studies, using congenital
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knockout animals, have shown that GluK5 subunits are required for proper function of
synaptic KARs and contribute to their slow kinetics (Contractor et al., 2003; Barberis et
al., 2008; Fernandes et al., 2009). However, congenital knockouts are not site or region
specific and remove presynaptic KARs. Additionally, congenital knockouts may undergo
receptor compensation and not represent KAR function in the normal brain. It would
therefore be of great value to be able to directly test the implication of KARs in synaptic
integration and information transfer in CA3 pyramidal cells.
Based on our results we identified ACET and kynurenate as potential
pharmacological tools to elucidate the relative function of GluK2 and GluK5 receptors at
GluK2/K5 heteromers. Previous studies observed that glutamate binding of GluK5
subunits activated GluK2/K5 channels and subsequent activation of the GluK2 subunit
desensitizes the receptor (Fisher and Mott, 2011). They concluded that the GluK2 subunit
intrinsically desensitized the receptor. However, it is not known whether the GluK2
subunit can open the GluK2/K5 receptor to a non-desensitizing current. We identified
ACET as a drug selective for the GluK4 and GluK5 subunits in GluK2-containing
heteromers. Additionally, we identified kynurenate as a glutamate antagonist that
preferentially inhibits the GluK2 subunits. Thus, we used both ACET and kynurenate to
determine whether the GluK2 or the GluK5 subunits are intrinsically unique in their
functional role in desensitizing the receptor. Applying 10 µM ACET inhibited glutamate
binding to the GluK5 subunits, and thus glutamate binding to only the GluK2 subunits
was sufficient to open the heteromeric receptor to a non-desensitizing current. The
remaining current was sensitive to 3 mM kynurenate inhibition, suggesting the remaining
current was predominantly mediated by glutamate binding to the GluK2 subunit.
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Furthermore, applying 3 mM kynurenate to GluK2/K5 receptors exposed to 300 µM
glutamate (an EC50 for the GluK2 subunit) produced a non-desensitizing current as
previously described in this study and other publications (Fisher and Mott, 2011).
Concurrent application of 1 µM ACET inhibited the remaining current, suggesting that
the remaining current was mediated predominantly by glutamate binding to the GluK5
subunit. Our results indicate that either GluK2 or GluK5 subunits can open the KAR
channel, while binding of the other can initiate desensitization. Thus, we propose that
KAR desensitization requires three or more subunits to bind to glutamate regardless of
the subunits activated. Additionally, we observed that glutamate binding to either the
GluK2 or the GluK5 subunits is sufficient to open KAR receptors. Thus, ACET and
kynurenate can be used as pharmacological tool to differentiate subunit contribution to
the KAR current.
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CHAPTER 4
MUSCARINIC AND DOPAMINERGIC RECEPTOR REGULATION OF KAINATE
RECEPTOR NEUROTRANSMISSION AT THE MOSSY FIBER – CA3 SYNAPSE

4.1 INTRODUCTION

Muscarinic acetylcholine receptors (mAChRs) play a critical role in synaptic
plasticity and neuronal excitability (Dodd et al., 1981). In the hippocampus, they are
important for modulating learning and memory in the hippocampus (Power et al., 2003).
There are five types of mAChR, M1 – M5 (Bonner, 1989), all of which, except M5
mAChRs, can be found at different levels of expression in area CA3 in the hippocampus
(Volpicelli and Levey, 2004) where they are co-expressed with kainate receptors. One
way mAChRs influence the synaptic network is by modulating the function of glutamate
receptors. Both NMDA and AMPA receptors have been shown to be susceptible to
mAChR modulation (Marino et al., 1998; Lu et al., 1999; Grishin et al., 2005; Dickinson
et al., 2009; Nomura et al., 2012). Specifically, NMDA receptor currents in CA3
pyramidal neurons are reduced by activation of M1 mAChRs through a mechanism
proposed to involve a calmodulin-activated tyrosine phosphatase (Grishin et al., 2005).
Additionally, M1 mAChRs induce long-term depression of hippocampal AMPA receptor
activity through protein kinase C (PKC) mediated phosphorylation of specific AMPAR
subunits, which cause AMPAR dissociation from GRIP1 (a postsynaptic domain
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localization protein) and subsequent removal of AMPARs from the synapse (Dickinson
et al., 2009). Although we know that NMDAR and AMPARs can be modulated by M1
mAChRs, it is not known whether M1 mAChRs can alter KAR activity in the brain.
There are several lines of evidence to suggest that M1 mAChRs can modulate
KAR activity in the brain. Dysfunctional interactions between KARs and mAChRs have
been demonstrated in a number of neurological diseases, including temporal lobe
epilepsy (Frucht et al., 2000). For example, injection of a mAChR agonist (pilocarpine)
in rodents induces prolonged seizures and epilepsy (Cavalheiro et al., 1991), which can
be blocked by a KAR antagonist (Smolders et al., 2002). Also, previous studies have
reported that M1 mAChRs can increase KAR current in recombinant cells (Benveniste et
al., 2010). Although these studies were not conducted in brain tissue, it does validate the
potential for KAR and M1 mAChR interaction. As stated earlier, M1 mAChRs are
GPCRs and elicits modulatory effects through phosphorylation cascades and second
messenger systems (Felder, 1995). KAR subunits can be phosphorylated, which can
affect both KAR channel conductance and KAR trafficking to and away from the synapse
(Cho et al., 2003; Park et al., 2006; Selak et al., 2009; Rojas et al., 2013).
Phosphorylation sites for PKC have been found on the GluK2 and GluK5 subunits (Rojas
et al., 2013). However, it remains unclear whether M1 mAChRs can alter KAR activity in
the hippocampus or whether this can be mediated through a PKC phosphorylationsignaling cascade.
In this study we sought to determine whether M1 mAChRs alters KAR activity in
the hippocampus. We evaluated this question at the mossy fiber – CA3 synapse because
it contains a reliable and well-characterized postsynaptic KAR activity. Our hypothesis is
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that, similarly to NMDAR at the same synapse, activation of M1 mAChRs will depress
KARs at the mossy fiber – CA3 synapse. Furthermore, we suspect this M1 mAChR
mediated depression will be mediated through a PKC phosphorylation signaling cascade.

4.2 MATERIALS AND METHODS

4.2.1 BRAIN SLICES PREPARATION
Hippocampal slices were made from postnatal day (P) 21 – P28 and P45 – P60
Sprague-Dawley rats as described previously (Iyengar and Mott, 2008). Briefly, animals
were deeply anesthetized with isoflurane and decapitated with a guillotine. The brain was
removed under ice-cold (4ºC), sucrose-based ‘cutting’ artificial cerebrospinal fluid
(aCSF) that contained (in mM): 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 248
sucrose, 0.5 CaCl2, and 5 MgSO4 (350mOsm). The use of this solution during the cutting
process enhances neuronal survival by limiting excessive excitation. Transverse slices
were made with a vibratome (Leica VT1000S, Nussloch, Germany) at 500 µM and
incubated for at least one hour at room temperature in aCSF containing (in mM): 125
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2, 5 MgSO4, 20 µM DAP-5, and 1 mM kynurenate (305 mOsm; pH=7.4). Both the sucrose-based and standard
aCSF were oxygenated with 95% O2 / 5% CO2.
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4.2.2 FIELD POTENTIAL ELECTROPHYSIOLOGY
After 1 hour, individual slices were transferred to a submersion chamber
maintained at 32 – 34 ºC, held in place by a bent piece of platinum wire resting on the
surface of the slice, and perfused continuously at 3 – 4 ml/min with recording aCSF
containing (in mM): 125 NaCl, 2.01 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 2
CaCl2, 1 MgSO4. Glass electrodes were pulled from borosilicate glass to achieve 2 – 3
MΩ and filled with recording aCSF. Extracellular dendritic field potentials recording
were made from the stratum lucidum of the CA3 region of the hippocampus, which was
visually identified with a light microscope. Synaptic currents were evoked with a
monopolar platinum-iridium glass electrode positioned in the stratum lucidum. For
AMPA-fEPSPs recordings, we recorded composite MF-fEPSPs, which were primarily
composed of AMPA-fEPSPs (~ 93%) (Contractor et al., 2003), with aCSF containing 10
µM MK-801, 50 µM picrotoxin, and 1 µM CGP 55845 to block NMDA, GABAA, and
GABAB receptors, respectively. We defined synaptic currents as MF-fEPSPs if they
showed characteristically large paired-pulse facilitation (Salin et al., 1996), had a rapid
rise time and short latency, and were inhibited by >70% by the group II-selective
metabotropic

glutamate

receptor

(mGluR)

agonist

(2S,2’R,3’R)-2-(2’3’-

Dicarboxycyclopropyl) glycine (DCG-IV, 1 µM), which was bath applied at the end of
some experiments. To isolate KA-fEPSPs recordings, we recorded from CA3 pyramidal
cells in the presence of the aCSF containing the AMPA antagonist GYKI53655 (50 µM)
in addition to the GABAA, GABAB and NMDA receptor antagonist cocktail. Once KARfEPSPs were isolated, a four pulse train stimuli (100 Hz, 0.1 ms/stumulus, cathodal,
monophasic, rectangular constant current pulses) were delivered every 30 sec through
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monopolar, platinum-iridium stimulating electrodes (FHC Inc., Bowdoin, ME) referenced
to the bath ground. KAR-fEPSPs were stable for a minimum of 20 min. prior to
pilocarpine (300 nM) perfusion onto the slice for 10 – 15 min. to activate predominately
M1 mAChRs. In experiments were M1 mAChRs or PKC were inhibited, telenzepine
(100 nM) or chelerythrine (5 µM) respectively were applied concurrently with AMPA,
GABAA, GABAB, and NMDA antagonists. To resolve small KAR-fEPSPs that were
obscured by stimulation artifacts, we digitally subtracted a “template” stimulation trace
that was acquired after application of an AMPA/KAR antagonist (CNQX, 50 µM) at the
end of the recordings.

4.3 RESULTS

4.3.1 KAINATE RECEPTOR SYNAPTIC TRANSMISSION IS DEPRESSED BY MACHR
ACTIVATION

Muscarinic receptors have been shown to affect the function of AMPA and
NMDA glutamate receptors. However, it is not known whether muscarinic receptors can
regulate the function of kainate receptors. To test this question, we used the drug
pilocarpine. Pilocarpine is a M1 preferring mAChR agonist. Previous studies have
demonstrated that mAChR activation with pilocarpine can alter KAR currents in oocytes
and KAR-dependent excitability in mossy fibers (Benveniste et al., 2010). Here, we
demonstrate that pilocarpine (300 nM), a muscarinic acetylcholine receptor (mAChR)
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agonist that preferentially binds to M1 mAChRs, produced a depression in KAR fEPSPs
at the mossy fiber – CA3 synapse (Pilo: 63.6 ± 6.9% of baseline fEPSP amplitude, n = 8,
p < 0.05) (Figure 4.1A). We previously demonstrated that ACET (1 μM), a previously
characterized GluK1 KAR subunit – selective antagonist, inhibits current at heteromeric
receptors containing either the GluK4 or GluK5 subunits (Chapter 3). Additionally, we
demonstrated that ACET (1 μM) was sufficient at completely inhibiting KAR current at
the mossy fiber – CA3 synapse (Chapter 3). Thus, we applied ACET (1 μM) after each
experiment as a control to verify that we were measuring the KAR fEPSP. Any further
depression induced by ACET application indicated the remaining KAR fEPSPs. After
pilocarpine administration, ACET (1 μM) application completely blocked the KAR
fEPSP, such that a competitive AMPA/KAR antagonist (CNQX, 50 μM) did not produce
any additional inhibition of the KAR fEPSP current (Figure 4.1A). Thus, by using both
controls (ACET and CNQX) we are confident that we measured the KAR fEPSP in its
entirety.
There a several ways mAChRs can modulate KAR fEPSPs. Muscarinic
acetylcholine receptors, specifically M1, co-localize with KARs on CA3 pyramidal
neurons. There are two potential ways these receptors can interact. Activation of
mAChRs can either 1) initiate a G-protein to begin a signaling cascade that would
eventually cause phosphorylation of the KARs, or 2) directly binding to KARs. Both of
these scenarios are a direct postsynaptic mechanism and require mAChRs and KARs to
be co-localized. Alternatively, mAChRs could affect KAR fEPSPs by affecting the
amount of glutamate released from presynaptic terminals. If activation of mAChRs
reduced glutamate release from mossy – fiber terminals, then the KAR fEPSPs would be
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reduced because less glutamate is binding to KARs postsynaptically. This scenario does
not require mAChRs to be co-localized with KARs, and thus, is an indirect presynaptic
mechanism by which activation of mAChRs can affect KAR fEPSPs. To determine
whether mAChR depression of fEPSPs at the mossy fiber – CA3 synapse is postsynaptic
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Figure 4.1 mAChR activation depresses kainate, but not AMPAR-mediated fEPSPs
A. A graph illustrating the peak amplitude of KAR fEPSP as it changes over time as
a result of drug application. Trains were evoked by stimulation of the mossy fiber
– CA3 pathway. Application of pilocarpine (300 nM) depresses the kainate
fEPSP. ACET (1 µM), a drug we previously characterized as an antagonist at
GluK4 and GluK5 receptors, completely inhibited the KAR-fEPSP, as verified by
an AMPA/KAR antagonist (CNQX, 50 µM)
B. Pilocarpine (300 nM) does not depress the AMPA fEPSP. Subsequent application
of CNQX (50 μM) completely block synaptic transmission, confirming the
presence of AMPA receptors.
C. Bar graph illustrating peak amplitude for KAR and AMPA fEPSP normalized to
the peak amplitude recorded during baseline. Pilocarpine significantly depresses
the kainate, but not the AMPA fEPSP measured after 10 min. of pilocarpine
application.

or presynaptic, we tested whether the AMPA fEPSP is also affected by mAChR
activation. To isolate the AMPA fEPSPs, we perfused an antagonist cocktail (same as
Chapter 3) to block NMDA, GABAA, GABAB, and KAR synaptic transmission
throughout the experiment (Figure 4.1B). Application of pilocarpine (300 nM) did not
inhibit the AMPA fEPSP (Pilo: 100.9 ± 9.7% of baseline fEPSP amplitude, n = 7, p <
0.05). Subsequent application of CNQX (50 μM) served as a control and completely
inhibited the AMPA fEPSP. The inhibition of KAR fEPSPs by pilocarpine (300 nM) was
significantly more than AMPA fEPSPs.

4.3.2 MACHR DEPRESSION OF KARS IS A FORM OF SHORT-TERM PLASTICITY
Next we wanted to determine whether this mAChR – induced depression of KAR
fEPSPs was a form of short-term plasticity or long-term plasticity. Plasticity is a change
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Figure 4.2 mAChR depression of KAR is short term
A. Pilocarpine (300 nM) transiently depresses the kainate fEPSP.
B. Pilocarpine (300 nM) significantly depresses the kainate fEPSP, but not 45
minutes after pilocarpine is washed out.

in the way one neuron communicates with another neuron. This change in
communication can persist longer than 1 hour (long-term plasticity) or less than 1hour
(short-term plasticity). Both forms of plasticity have important implication in the brain
(Martin et al., 2000). Inhibition of either short-term or long-term plasticity in the
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hippocampus causes significant deficits in learning and memory (Morris et al., 1986;
Silva et al., 1996). To test which form of synaptic plasticity is exemplified, we applied
pilocarpine (300 nM) as previously described. Then, we washed out the pilocarpine for
45 minutes and recorded the KAR fEPSP amplitude as a percent to the baseline
amplitude (Figure 4.2A). Pilocarpine (300 nM) produced a similar depression to KAR
fEPSPs as we reported previously (Pilo: 60.0 ± 4.3% of baseline fEPSP amplitude, n = 5,
p < 0.05). However, this depression went away as pilocarpine (300 nM) was washed out
(Washout: 108.7 ± 5.5% of baseline fEPSP amplitude, n = 5, p < 0.05). Thus, the
mAChR depression of the KAR fEPSP did not last longer than 1hour, and resembles a
short-term plasticity. Subsequent application of ACET (1 µM) and CNQX (50 µM)
produced complete inhibition of the measured KAR fEPSP. As stated previously,
pilocarpine (300 nM) induced a significant depression of KAR fEPSPs. However, the
KAR fEPSP amplitude was not significantly different from baseline 45 min. after
pilocarpine (300 nM) application (washout) (Figure 4.2B).

4.3.3 ACTIVATION M1 MACHRS DEPRESS KAR FEPSPS AT MOSSY FIBER – CA3
SYNAPSES

Our previous data demonstrated that activation of mAChRs transiently depresses
KAR fEPSP at mossy fiber – CA3 synapses through a direct postsynaptic mechanism.
The next step in elucidating this mechanism is to determine the mAChR necessary for
KAR fEPSP depression. Pilocarpine at low concentrations is considered an M1 preferring
agonist (Fisher et al., 1993). Additionally, M1 mAChRs are abundantly expressed in CA3
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pyramidal neurons (Cortes et al., 1984; Cortés et al., 1986; Rodríguez-Puertas et al.,
1997; Scarr et al., 2007). Thus, we sought to determine whether M1 mAChRs are

Figure 4.3 M1 mAChRs mediate the pilocarpine-induced depression of KAR
fEPSPs
A. Telenzepine (100 nM), an M1 mAChR antagonist, prevents pilocarpine-induced
depression of KAR fEPSPs at mossy fiber – CA3 synapses.
B. There is no significant difference in KAR fEPSP amplitude in the presence of
telenzepine (100 nM) with or without pilocarpine (300 nM) co-application.

responsible for the pilocarpine – induced depression of KAR fEPSPs. To test this, we
isolated the KAR fEPSP as previously described and preapplied an M1 mAChR
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antagonist (telenzepine, 100 nM) for a minimum of 15 min before administering
pilocarpine (300 nM). In the presence of telenzepine (100 nM), pilocarpine (300 nM)
failed to depress the KAR fEPSP (Figure 4.3A). The presence of a KAR fEPSP was
verified by complete inhibition of synaptic transmission by subsequent applications of
ACET (1 µM) and CNQX (100 µM). A bar graph illustrates that neither application of
telenzepine (100 nM) nor co-application of telenzepine (100 nM) and pilocarpine (300
nM) produced significant inhibition of the KAR fEPSP amplitude as compared to
baseline KAR fEPSP amplitude prior to telenzepine (100 nM) application (97.9 ± 4.7%, n
= 7) (Figure 4.3B).

4.3.4 PKC PHOSPHORYLATION IS NOT REQUIRED FOR MACHR – INDUCED
DEPRESSION OF KAR FEPSPS

We discovered earlier that M1 mAChRs depresses KAR fEPSPs more than likely
through a postsynaptic mechanism. One potential mechanism is by M1 mAChRs eliciting
a G-protein mediated second messenger signaling cascade resulting in the
phosphorylation of KARs. M1 mAChRs can coupled to Gαq and are thought to initiate a
second messenger cascade involving protein kinase C (PKC). To test whether PKC
phosphorylation is necessary for M1 mAChR – induced depression of the KAR fEPSPs,
we bath applied a PKC inhibitor (chelerythrine. 5 µM) at least 15 min. prior to and during
pilocarpine (300 nM) application (Figure 4.4 A,B). In the presence of chelethryine (5
µM), pilocarpine still depressed the average KAR fEPSP amplitude to levels similar to
that of pilocarpine application alone (67.9 ± 13.7%, n = 6). However, the depression in
KAR fEPSPs was not statistically significant. Thus, PKC mediated phosphorylation of
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KARs may not be fully responsible for M1 mAChR depression of KAR fEPSPs.
Subsequent bath application of ACET (1 µM) and CNQX (100 µM) verified the presence
of KAR fEPSPs.

Figure 4.4 mAChRs depression of KARs is not mediated through PKC
A. Chelerythrine (5 μM), a PKC inhibitor, does not prevent pilocarpine-induced
depression of KAR fEPSPs at mossy fiber – CA3 synapses.
B. Pilocarpine (300 nM) depression of KAR fEPSPs is not significant in the presence
of chelerythrine.
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4.3.5 M1 MACHR DEPRESSION OF KAR FEPSP IS DEVELOPMENTALLY REGULATED
Kainate receptor expression and function is fundamentally different in the
adolescent brain than the adult brain (Bahn et al., 1994). All data collected previously
was using adolescent aged rats (P21 – P28). However, it is not known whether this
regulation changes during further development. Thus, we examined whether this same
phenomenon (M1 mAChR activation depresses KAR fEPSP) happens in an ‘adult’ aged
brain. In this experiment, we used rats aged P65 – P80. The experimental set up was

Figure 4.5 mAChR depression of KARs is developmentally regulated
A. Pilocarpine (300 nM) fails to depress the kainate fEPSP in 65 days old rats.
B. Pilocarpine (300 nM) significantly suppresses kainate fEPSP in 22 days old rats,
but not 65 days old rats.
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identical to previous experiments by isolating the KAR fEPSP with an antagonist
cocktail. Then, we recorded a minimum of 20 min. of stable baseline (Figure 4.5A). Bath
application of pilocarpine (300 nM) did not depress the KAR fEPSP. Subsequent bath
application of ACET (1 µM) and CNQX (100 µM) confirmed the presence of KAR
synaptic transmission. A bar graph illustrates that pilocarpine (300 nM) application
significantly depressed the KAR fEPSPs in “adolescent” rat brains (22 days); however,
pilocarpine (300 nM) failed to produce a significant depression of KAR fEPSPs in the
“adult” rat brain (65 days) (87.6 ± 5.3%, n = 5).

4.3.6 D1-LIKE DOPAMINE RECEPTORS DO NOT ALTER KAR FEPSP AT THE MOSSY
FIBER – CA3 SYNAPSE

Dopamine receptors (DARs) are another GPCR with important modulatory
affects in the brain (Ehringer and Hornykiewicz, 1960; Robinson and Berridge, 1993;
Goto and Grace, 2007; Del Campo et al., 2011; Lodge and Grace, 2011). DARs are
separated into two groups based upon the G protein in which they associate: D1 and D5
DARs (D1-like) couple to Gs proteins and stimulate adenylate cyclase activity, leading to
PKA phosphorylation, while D2, D3, and D4 DARs (D2-like) couple to Gq proteins and
inhibit adenylate cyclase activity. Specifically, the D1 DARs in the hippocampus are
necessary for learning and memory (Huang and Kandel, 1995; Lemon and ManahanVaughan, 2006; Bethus et al., 2010; Clausen et al., 2011; da Silva et al., 2012). Previous
studies have shown that D1-like DARs can mediate other ionotropic glutamate receptors,
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Figure 4.6 Activation of D1-like dopamine receptors did not alter KAR fEPSP
Activation of D1-like (D1 and D5) dopamine receptors (SKF38393, 50 µM) did
not alter KAR fEPSPs at the mossy fiber – CA3 synapse. Subsequent bath
application of ACET (1 µM) and then CNQX (100 µM) verified the presence of
KAR potentials and the lack of AMPAR potentials.

such as NMDAR and AMPAR, through either a classical PKA-mediated second
messenger signaling pathway or a direct protein-protein interaction (Price et al., 1999;
Lee et al., 2002b; Hallett et al., 2006; Paoletti et al., 2008). However, it is not known
whether KAR activity is mediated by dopamine receptors. Recombinant data demonstrate
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that KARs can be phosphorylated by PKA, yielding an increase in KAR current
(Raymond et al., 1993; Wang et al., 1993; Kornreich et al., 2007). There is no data to
demonstrate whether this can happen in the brain.
In this experiment, we sought to determine whether D1 dopamine receptors
modulate KAR function in the brain. As previously described, we isolated KAR fEPSPs
at the mossy fiber – CA3 synapse by stimulating the hilus of the dentate gyrus and
recording in CA3 stratum lucidum in the presence of an antagonist cocktail to block
AMPA, NMDA, GABAA, and GABAB synaptic potentials. After recording a stable
baseline for a minimum of 20 min., we bath applied a selective D1-like DAR agonist
(SKF38393, 50 μM) (Figure 4.6). Activation of D1-like DARs did not significantly alter
the KAR fEPSP (101.9 ± 16.3, n = 4). To verify the presence of a KAR fEPSP, we
subsequently bath applied the selective KAR antagonist, ACET (1 μM). Furthermore, to
ensure that we did not inadvertently measure AMPAR fEPSPs, we bath applied an
AMPAR/KAR antagonist, CNQX (100 μM), which did not produce any further reduction
of the measured KAR fEPSP. These data demonstrate a lack of D1 DAR modulation of
KAR activity in the mossy fiber – CA3 synapse.

4.4 DISCUSSION

The major findings of our study are that M1 mAChRs, but not D1-like dopamine
receptors, activation depresses KAR fEPSPs. This effect is likely through a postsynaptic
mechanism, because the AMPAR fEPSP was unaffected by M1 mAChR activation by
pilocarpine. M1 mAChRs are the major muscarinic receptor located in the hippocampus
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(Cortes et al., 1984; Cortés et al., 1986; Rodríguez-Puertas et al., 1997; Scarr et al.,
2007). It binds to the Gαq protein to signal PKC phosphorylation. Inhibition of PKC
phosphorylation prevented the significant depression of KAR fEPSPs by pilocarpine.
However, a depression in the KAR fEPSP did occur. This suggests that PKC
phosphorylation has some affect on the magnitude of the depression. Interestingly, this
depression of KAR fEPSPs by M1 mAChRs is developmentally regulated and goes away
with age (‘adult’ P65 – P80).

4.4.1 M1 MACHRS DEPRESS KAR, BUT NOT AMPAR, AT MOSSY FIBER – CA3
SYNAPSES

This report is the first demonstration that M1 mAChRs can alter KARs activity in
the brain. We demonstrated that pilocarpine, an M1 preferring agonist, depresses KAR
fEPSPs at the mossy – fiber CA3 synapse. This depression was completely blocked by an
M1 antagonist. In other studies, it was reported in a recombinant receptor that muscarinic
activation by pilocarpine potentiated GluK2 containing heteromeric, but not homomeric,
KARs, suggesting that potentiation of KARs by mACh receptors also requires the highaffinity KAR subunits (Benveniste et al., 2010). The difference in M1 mAChRs
potentiating instead of inhibiting KAR activity, as in what we saw in our studies, could
result from the experimental model being used. It is possible that the mACh receptors
could

increase

channel

conductance

and

receptor

trafficking

simultaneously.

Recombinant experimental models are more sensitive to changes in channel conductance
than trafficking. HEK-239T cell do not express synapse scaffolding proteins, and thus,
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those experiments would not undergo changes in receptor trafficking that would resemble
that in the actual brain slice. In the brain, it is possible that the amount of receptor
trafficking away from the synapse could outperform the increase in channel conductance.
Indeed, M1 mAChRs have been shown to alter NMDAR and AMPAR synaptic
transmission primarily through trafficking of the receptors in or out of the synapse
(Zheng et al., 1998; Dickinson et al., 2009; Nomura et al., 2012).
Although my research has yielded several interesting results, there are several
questions that must be addressed. It was interesting to us that activation of M1 mAChRs
can produced a significant depression of postsynaptic KAR fEPSPs but not AMPAR
fEPSPs located in the same cell populations and synapses. Even more interesting is that
both KARs and AMPARs can be phosphorylated by mAChRs and specifically M1
mAChRs. Thus, it seems interesting how there is a significant effect on KARs but not
AMPARs. Further looking in the literature reveals that we are not the only laboratory to
find such interesting divergence in the effect of muscarinic activation on glutamate
receptors. Grishin et al. demonstrated that M1 mAChR activation depressed NMDAR
currents on postsynaptic CA3 pyramidal neurons, but did not affect AMPAR currents at
the same synapse (Grishin et al., 2005). Alternatively, other studies have shown that the
same signaling cascade can elicit different effects on KARs and AMPARs due to the
receptor association with the PDZ domain – interacting proteins PICK1 and GRIP
(Hirbec et al., 2003). Dissociation of PICK1 with KARs caused a loss of KAR synaptic
function, while the dissociation of PICK1 with AMPARs caused an increase in AMPAR
synaptic function.

129

4.4.2 M1

MACHR DEPRESSION OF

KAR

ACTIVITY IS A FORM OF SHORT-TERM

PLASTICITY

Another interesting result that deserves some explanation is that M1 mAChR
depression of KAR fEPSP was a form of short-term plasticity. Short-term plasticity, as
opposed to long-term plasticity, lasts for less than 1 hour after the initial stimulus. This
form of plasticity is thought to be important for the dynamic regulation of synaptic
function (Silva et al., 1996). Other studies have suggested that the determinate factor
between a short-term versus long-term plasticity phenotype is the association with a
second messenger system. Previous studies have reported that PICK1 plays an important
role in the expression of long-term depression, and disruption of glutamate receptor
interaction with PICK1 turns long-term plasticity into short-term plasticity (Xue et al.,
2010). Thus, one mechanism that might explain the short-term effect is a dissociation of
KARs with a PICK1 complex (Xue et al., 2010).

4.4.3 M1 MACHR DEPRESSION OF KAR ACTIVITY IS NOT MEDIATED BY PKC
PHOSPHORYLATION

Another interesting result was that M1 mAChR depression of KAR fEPSPs at the
mossy fiber – CA3 synapse was not prevented by application of the PKC inhibitor,
chelethryine. M1 mAChRs couple to Gq proteins and are primarily thought to regulate
other proteins, including glutamate receptors, through a PKC-dependent signaling
cascade. We found this not to be true for M1 mAChR depression of KARs fEPSPs at the
mossy fiber – CA3 synapse. As we previously discussed, Grishin et al demonstrated that
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M1 mAChRs postsynpatically depressed NMDAR, but not AMPAR, current at CA3
pyramidal neurons (Grishin et al., 2005). This depression was mediated not through PKC
phosphorylation but was dependent upon protein tyrosine phosphatases. Thus it is
possible that our M1 mAChR depression of KARs located also on CA3 pyramidal
neurons is mediated through protein tyrosine phosphatases.
An alternative explanation for the inability of chelethryine to inhibit the
pilocarpine-induced depression of KAR fEPSPs at the mossy fiber – CA3 synapse is that
chelethryine did not block PKC activity. Unlike the other drugs used in this chapter
whose ligand binding sites are extracellular, chelethryine must maneuver inside the cell
to inhibit PKC activity. We did not incorporate a positive control into our experiments to
verify the inhibition of PKC activity by chelethryine.

4.4.4 M1 MACHR DEPRESSION OF KAR ACTIVITY IS DEVELOPMENTALLY
REGULATED

We also discovered that M1 mAChR – induced depression of KAR fEPSPs was
developmentally regulated. In rats around adolescent age (P21 – P28), the KAR fEPSP
depression was robust; however, in rats around adult age (P65 – P80) we no longer saw a
M1 mAChR depression of KAR fEPSP. Although we did not directly test the reason for
this development ‘switch’, there are several possible mechanisms that we can speculate to
be responsible. One such mechanism is the age-dependent change in mAChR expression.
Previous studies have demonstrated that although mRNA expression of mAChRs does
not change in the hippocampus, mAChR protein expression is age-dependently
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downregulated in the hippocampus (Lee et al., 1994; Narang, 1995; Tice et al., 1996).
Specifically, M1 mAChRs expression in the CA3 field of the hippocampus is
significantly reduced in the aged rat brain compared to the young rat brain. A reduction in
the expression of M1 mAChRs in the adult rat brain would occlude the M1 –dependent
depression KAR fEPSPs.
Another possible explanation is the expression level of KARs. KARs are
necessary for the correct integration of mossy fiber – CA3 synapse (Tashiro et al., 2003;
Lanore et al., 2012). Early in development KARs expression is high, peaking at P9 (Bahn
et al., 1994). After P9 the expression of KARs steadily declines. In the transition from
adolescent to adulthood, the ratio of GluK2 expression to GluK4 and GluK5 become
higher (Bahn et al., 1994). Thus, it may be possible that the relative concentration of
ACET-sensitive KAR responses decline with aging. However, the persistence of an
ACET-sensitive KAR response in the adult mossy fiber – CA3 synapse verifies that the
KARs necessary for mAChR regulation is present.
Lastly, another possible difference is the relative expression of proteins associated
with translocation of KARs to the synapse, such as GRIP and PICK1. GRIP association
has been shown to increase more than 100% from P7 to P11, while PICK1 remains
unchanged (Xue et al., 2010). An age - induced increase in GRIP expression relative to
PICK1 expression was demonstrated to cause a switch from a depressive plasticity to
facilitation plasticity at the same synapse (Xue et al., 2010). If this trend continues
through adulthood, we can contend that our M1 mAChR – induced depression of KAR
fEPSPs would not persist with aging.
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These data demonstrate that muscarinic cholinergic receptors can modulate KARs
in the brain. Acetylcholine is released in the brain, specifically in the hippocampus,
during different brain states, such as during exercise (Nakajima et al., 2003; Uchida et al.,
2006) and just before a seizure (Hillert et al., 2014). Understanding what happens to the
glutamate receptors, especially KARs, during these brain states can provide a better
understanding for how the brain functions to improve cognition while exercising, and it
will allow us to elucidate critical mechanism involved in the genesis of a seizure, which
will lead to potential therapies.

4.4.5 KAINATE

RECEPTOR ACTIVITY IN THE MOSSY FIBER

– CA3

SYNAPSE IS NOT

MEDIATED BY D1-LIKE DOPAMINE RECEPTORS

In contrast to our M1 mAChR data, we found that D1-like dopamine receptors did
not alter KAR activity in the mossy fiber – CA3 synapse. D1-like dopamine receptors
couple to Gs proteins to stimulate adenylate cyclase activity and PKA mediated
phosphorylation pathways. Thus, these data suggest that KAR activity is more sensitive
to M1 mAChR regulation than D1-like DAR mediated regulation. Indeed, there are few
PKA phosphorylation sites on the C-terminus domain of KARs (GluK2, S856 and S868)
(Rojas and Dingledine, 2013). These PKA phosphorylation at residues S856 and S868
have only been shown to potentiate kainate-evoked currents of recombinant receptor
(Raymond et al., 1993; Wang et al., 1993). There is no evidence demonstrating that PKA
phosphorylation can alter KAR activity in the brain.
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CHAPTER 5
ALTERED DOPAMINERGIC REGULATION IN A CHRONIC MODEL OF TEMPORAL
LOBE EPILEPSY

5.1 INTRODUCTION

Dopamine receptors in the hippocampus are important for modulating learning
and memory (Packard and White, 1991; Gasbarri et al., 1996; Bernabeu et al., 1997;
O’Carroll et al., 2006). The hippocampus receives dense dopaminergic innervation from
the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) (Simon et
al., 1979; Scatton et al., 1980; Swanson, 1982), where dopamine is synthesized through
the rate-limiting enzyme, tyrosine hydroxylase (TH). Dopamine released from these
neurons can bind to two main types of dopamine receptors: D1-like (D1 and D5) and D2like (D2L/S, D3, and D4), which are categorized based on pharmacological agonists and
second messenger coupling. Particularly D1-like receptors have been shown to be
important in learning and memory consolidation (Frey et al., 1990, 1991; Huang and
Kandel, 1995; Otmakhova and Lisman, 1996, 1998; Navakkode et al., 2007; Granado et
al., 2008; Ortiz et al., 2010). Pharmacological blockage of D1-like receptors prevents
early and late phase long-term potentiation, a cellular model of learning, and blocks longterm memory storage (Frey et al., 1990, 1991). Additionally, D1 knockouts and adult rats
undergoing D1 receptor reduction in the CA1 region of the hippocampus exhibited
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significant decline in spatial learning, fear learning, classical conditioning of the eyelid
response, as well as the associated activity-dependent synaptic plasticity in the
hippocampal CA1-CA3 synapse (Ortiz et al., 2010). These studies provided compelling
evidence that a reduction in D1-like receptors in the hippocampus is correlated with
deficits learning and memory.
In temporal lobe epilepsy, D1-like receptors are also implicated in seizure
generation, as previous studies have shown that a D1-like receptor agonist can elicit
seizures in and of itself (O’Sullivan et al., 2008). Furthermore, a D1-like antagonist can
prevent seizures (al-Tajir et al., 1990a, 1990b; Barone et al., 1990; Turski et al., 1990;
DeNinno et al., 1991; Starr, 1996). To date, it is unknown whether temporal lobe
epilepsy alters D1 and D5 dopamine receptor protein expression in the hippocampus. The
chronic epilepsy model we use is clinically relevant as rats experience chronic
spontaneous seizures with comorbid cognitive decline (Rice et al., 1998). However, it is
not known whether dopamine receptors in this model have been pathologically altered.
One potential mechanism by which D1-like dopamine receptors mediate learning
and memory and temporal lobe epilepsy is by altering ionotropic glutamate receptor
function. D1-like dopamine receptors can alter both AMPAR and NMDAR function
through

either

a

phosphorylation-signaling

cascade

or

direct

protein-protein

heterodimerization (Price et al., 1999; Snyder et al., 2000; Lee et al., 2002b; Dunah et al.,
2004; Gao et al., 2006; Hallett et al., 2006). Although we previously did not see an
interaction between D1-like dopamine receptor activation and KAR receptor – mediated
synaptic transmission at the mossy fiber – CA3 synapse (Figure 4.6), evidence exists for
a potential interaction in epilepsy. Previous studies have demonstrated that a D1-like
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dopamine receptor antagonist can reduce the severity of seizures initiated by kainate
receptor agonists (Bourne et al., 2001). Before we can investigate whether D1-like
dopamine receptors regulate KAR function in the epileptic hippocampus, we must first
determine how D1-like dopamine receptors are altered in the epileptic hippocampus.
The goal of this study was to compare and contrast the dopaminergic system
between the normal and chronically epileptic brain. We were particularly interested in
evaluating differences known to regulate learning and memory. Thus, we evaluated the
effects of chronic epilepsy on D1 and D5 dopamine protein expression, dopamine
concentration, dopamine metabolites, and dopamine transporter protein expression in the
hippocampus. Our study provides further detail for one mechanism that may explain the
cognitive decline commonly experienced by TLE patients.

5.2 MATERIALS AND METHODS

5.2.1 ANIMALS
Adult male Sprague Dawley rats (40-45 days old; 200-250 gm) were purchased
from Harlan and were housed two-three per cage. Rats were kept in a temperaturecontrolled facility with access to food and water ad libitum. All experimental procedures
were approved by the University of South Carolina Animal Care and Use Committee in
accordance with the NIH Guide for the Care and Use of Laboratory Animals. Every
effort was made to minimize animal suffering and to reduce the number of animals used.
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5.2.2 INDUCTION OF STATUS EPILEPTICUS (SE)
The pilocarpine model of TLE is widely used in rodents (Cavalheiro, 1990) and
reproduces the human condition closely (Curia et al., 2008). Specifically, rodents treated
with pilocarpine exhibit spontaneous generalized and partial seizures, behavioral
abnormalities, as well as the pathologic and histological signs commonly observed in
human patients with TLE (Goffin et al., 2007). The mechanism by which pilocarpine
administration causes spontaneous recurrent seizures and epilepsy is fairly well
understood (Hamilton et al., 1997) and the stereotypic set of behavior produced by this
cholinergic agonist is well characterized (Goffin et al., 2007).
For detailed methods on the pilocarpine model of induced status epilepticus,
please see section 2.4.2.

5.2.3. IMMUNOHISTOCHEMISTRY
For detailed immunohistochemistry methods, please see section 2.6.

5.2.4. CELL COUNTS
Sections containing dorsal hippocampus (approximately 3.14-3.6 mm caudal to
bregma; Paxinos and Watson, 1998) were selected for manual cell counts of GAD-67positive somata. An area was selected encompassing all regions (stratum oriens [SO],
stratum pyramidale [SP], and striatum radiatum [SR]) of CA1 at 2X magnification, and
all immunopositive cells were counted using a Nikon ECLIPSE 80i microscope equipped
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with Neurolucida software (v.9, MicroBrightField, Inc., Williston, VT, USA) at 20X
magnification. For all counts, no hemispheric differences were noted in either sham or
epileptic tissue in any neuronal marker, cells or terminals. Therefore, we unilaterally
counted and averaged across two sections for each animal.

5.2.5. IMMUNOBLOT ANALYSIS
Please see section 2.5 for detailed immunoblot analysis methods.

5.2.6. SPECIFICITY OF THE ANTISERA
The D1 dopamine receptor antibody used in this study (#D2944, Sigma, St. Louis,
MO, USA) is a rat monoclonal (clone 1-1-F11 s.E6) which recognizes the C-terminal 97
amino acid of D1 dopamine receptor. The immunogen was affinity purified. The
specificity of this antibody, which does not cross-react with fusion proteins derived from
the same regions of D2, D3, D4, D5 receptors, has been well documented (Levey et al.,
1993).
The polyclonal D5 receptor antiserum (#SC-1441, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) was raised in goat and is a widely used antiserum to D5
receptors. Previous absorption studies demonstrate that it recognizes D5 dopamine
receptors, but not other dopamine receptor homologues (D1, D2, D3, D4) (Bodei et al.,
2009).
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5.2.7. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
Please see section 2.7 for a detailed description of the high performance liquid
chromatography methods.

5.2.8. STATISTICAL ANALYSES
Data are presented as mean ± standard error. Student’s t-test for independent
samples was used to compare the difference between means. Two sample sets were
considered significantly different when p < 0.05. All statistical data were analyzed and
graphical representations made in Origin version 7.5 software (OriginLab Corp,
Northampton, MA).

5.3 RESULTS

5.3.1 D1 DOPAMINE RECEPTORS ARE LOCALIZED DISTINCTLY IN INTERNEURONS,
AND LESS APPARENT IN PYRAMIDAL NEURONS

To determine how D1-like dopamine receptors are altered in the chronic epileptic
CA1 region of the hippocampus, we first sought to determine the localization of both D1
and D5 dopamine receptors in the control ‘naïve’ brain. A previous study identifies D1
dopamine receptor localization primarily in non-parvalbumin GABAergic interneurons
(Gangarossa et al., 2012). Indeed, our immunostaining for D1 dopamine receptor clearly
revealed interneurons in all layers (stratum oriens, stratum pyramidale, and stratum
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radiatum) of hippocampal area CA1 (Fig. 5.1, B-D). Less distinct labeling was seen in the
pyramidal cell body layer and proximal dendrites. No staining was observed in the ‘no
primary’ control (Fig. 5.1, A).

Figure 5.1 D1 dopamine receptors are located primarily in interneurons and less
apparently in pyramidal neurons.
A. Representative normal CA1 demonstrating lack of immunostaining in the absence
of primary antiserum.
B. Representative D1 dopamine receptor labeled CA1 illustrating D1 labeling
prominently in interneurons throughout the stratum oriens (S.O.), striatum
pyramidale (S.P.), and striatum radiatum (S.R.). Faint labeling was observed
diffused throughout the pyramidal cell body layer.
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5.3.2. D5 DOPAMINE RECEPTORS ARE LOCALIZED PREDOMINANTLY IN PYRAMIDAL
NEURONS

D5 dopamine receptor pattern of labeling was substantially different from D1
dopamine receptors. Previous studies report D5 labeling in pyramidal cell bodies and
apical dendrites (Khan et al., 2000). Indeed, our D5 labeling was almost exclusive to
pyramidal neurons (Fig. 5.2, B-D). Labeling extended from the pyramidal cell soma
surface down the length of the dendrites into the stratum lacunocum-molecularis (Fig.
5.2, B-D). This resulting pattern of labeling suggests that D5 DARs may elicit its
functional effects predominantly through excitatory inputs.

5.3.3. REMAINING INTERNEURONS CONTAIN MORE D1 DOPAMINE RECEPTORS

To investigate whether D1-like receptor protein expression and/or localization are
altered in the chronically TLE CA1 region of the hippocampus, we performed western
blots from microdissected CA1 and immunohistochemistry from sham-treated and
epileptic animals. Immunoblot analysis revealed that D1 protein expression in the
epileptic CA1 (113.326 ± 6.832%, n = 8) was not significantly different from shamtreated animals (Fig. 5.3, D). This result was particularly interesting based on previous
reports that interneurons are selectively susceptible to neuron loss in epilepsy (Houser
and Esclapez, 1996; Morin et al., 1998; André et al., 2001; Cossart et al., 2001; Dinocourt
et al., 2003). Immunostaining with D1 receptor antibody revealed no change in labeling
pattern between sham-treated and epileptic animals (Fig. 5.3, A-C). However, D1 DAR
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labeled interneurons appeared more intensely stained in the epileptic condition than
sham-treated (Fig. 5.3, A-C). These results suggest that the remaining interneurons are
more tightly regulated by D1 dopamine receptors.

Figure 5.2 D5 dopamine receptors are located primarily on pyramidal neuron soma
surface and dendrites.
A. Representative CA1 from a naïve rat demonstrating lack of immunostaining in the
absence of D5 primary antiserum.
B. Representative D5 dopamine receptor labeled CA1 illustrating D5 labeling
exclusively to pyramidal neuron soma surface and dendrites that extend
throughout stratum radiatum (S.R.) and terminate in the stratum lacunosum
molecular (SLM). Striatum oriens (S.O.), striatum pyramidale (S.P.)
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Figure 5.3 D1 dopamine receptor expression does not change in epilepsy CA1, but
the intensity of interneuron labeling increases.
A. Immunohistochemistry for D1 dopamine receptor labeling in area CA1 of shamtreated rats.
B. Immunohistochemistry for D1 dopamine receptor labeling in area CA1 of
epileptic rats reveal no difference in labeling pattern.
C. However, closer analysis suggests that D1 dopamine receptor labeling in
interneurons are more intense in the epileptic CA1 area than sham-treated.
D. Western blot analysis demonstrated no significant change in total D1 dopamine
protein expression between epileptic and sham-treated CA1.
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5.3.4 DOPAMINE D5 RECEPTORS ARE REDUCED IN EPILEPSY
We then sought to determine whether the localization and/or protein expression of
D5 dopamine receptors were altered in the chronically epileptic CA1 region of the
hippocampus. Immunoblot analysis of D5 protein expression in microdissected CA1
revealed a 72% significant reduction in epilepsy (27.701 ± 4.574%, n = 10, p < 0.0001)
compared to sham-treated animals (Fig. 5.4, E). This result was reproduced by an
unbiased colleague. Immunostaining also confirmed the immunoblot analysis. D5
labeling in the epileptic condition was visibly reduced predominately in the pyramidal
dendrites (Fig. 5.4, A-D). Instead of dense D5 dopamine receptor labeling extending
down into the stratum lacunocum-molecularis as in the sham condition (Fig. 5.4, A,C), in
the epileptic conditions D5 labeled staining was less dense and remained proximal to the
pyramidal cell body layer (Fig. 5.4, B,D).

5.3.5 INTERNEURONS IN STRATUM ORIENS ARE SELECTIVELY LOSS IN EPILEPSY
To ensure that GABAergic interneurons are selectively lost in our chronic TLE model,
we completed immunostaining for GAD67 and counted the positively labeled neurons.
Results were normalized to sham-treated animals. As previously reported, we observed a
significant reduction in GAD67 positively labeled interneurons, particularly in stratum
oriens, in epilepsy (27.19 ± 0.809%, n = 5) when compared to sham. No significant
difference was observed in the epileptic stratum pyramidale (82.895 ± 6.644%, n = 5) or
stratum radiatum (82.915 ± 8.814%, n = 5) when compared to sham-treated animals (Fig.
5.4). This data confirms previous reports that interneurons are selectively lost in epilepsy
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(Houser and Esclapez, 1996; Morin et al., 1998; André et al., 2001; Cossart et al., 2001;
Dinocourt et al., 2003). Thus, knowing that D1 expression in located primarily in
interneurons and interneurons are selective loss in epilepsy, demonstrating that total D1
expression does not change suggests that D1 expression in remaining interneurons may
have increased.

Figure 5.4 D5 dopamine receptor expression is reduced in the epileptic CA1
A. Immunohistochemistry for D5 dopamine receptor labeling in area CA1 of shamtreated rats
B. Immunohistochemistry for D5 dopamine receptor labeling in area CA1 of
epileptic rats revealed a substantial decrease in immunostaining in the pyramidal
neuron soma and dendrites.
C. Higher magnification of D5 dopamine receptors labeled dendrites in striatum
radiatum in sham-treated rats.
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D. Higher magnification of D5 dopamine receptors labeled dendrites in striatum
radiatum in epileptic rats.
E. Western blot analysis confirmed immunohistochemistry results, revealing a
significantly reduction in D5 expression in microdissected CA1 area.

Figure 5.5 Epilepsy reduces the number of GABAergic interneurons in CA1.
A. Immunohistochemistry for glutamate decarboxylase (GAD)-67 labeling in area
CA1 of sham-treated rats.
B. Immunohistochemistry for glutamate decarboxylase (GAD)-67 labeling in area
CA1 of epileptic rats revealed seizure-related decreases in inhibitory neurons in
stratum oriens (S.O.).
C. Higher magnification of GABAergic labeling CA1 interneurons in sham treated
rats.
D. Higher magnification of GABAergic labeling CA1 interneurons in epileptic rats.
E. Epilepsy was associated with a significant decrease in the number of GAD-67
immunoreactive cells in CA1 limited to S.O.
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5.3.6 LOCALIZATION OF D1 DOPAMINE RECEPTORS IS UNCHANGED IN THE EPILEPTIC
DENTATE GYRUS

D1 dopamine receptors are expressed more abundantly in the dentate gyrus than
any other region in the hippocampus (Gangarossa et al., 2012), where they impact neuron
excitability and learning and memory. Indeed, D1-like dopamine receptors activate
during a “novel” or “rewarding” signal in freely moving animals, and consequentially
increases DG excitability (Hamilton et al., 2010). Furthermore, inhibition of D1-like
dopamine receptors inhibits LTP in the DG (Yanagihashi and Ishikawa, 1992; Kusuki et
al., 1997; Swanson-Park et al., 1999). Thus, we investigated whether D1 dopamine
receptor expression is altered in the epileptic dentate gyrus. In agreement with previous
studies, D1 dopamine receptors demonstrated diffused labeling throughout the molecular
layer (MOL) and hilus (H) of the dentate gyrus (Figure 5.6A). We also observed abundant
D1 dopamine receptor labeling in the stratum lucidum. Notably, D1 dopamine receptor
labeling was absent from granule cell layer (GCL). This pattern of labeling suggests that
D1 dopamine receptors are expressed on dentate granule cell dendrites and axons (mossy
fibers), but absent from dentate granule cell soma.
D1 dopamine receptor expression in the epileptic dentate gyrus demonstrated no
observable difference in D1 dopamine receptor labeling pattern or strength in labeling
signaling (Figure 5.6B). Thus, these results illustrate that D1 dopamine receptor
expression is unchanged in the epileptic dentate gyrus.
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Figure 5.6 D1 dopamine receptor expression in the dentate gyrus does not change in
epilepsy.
A. Immunohistochemistry for D1 dopamine receptor labeling in the dentate gyrus of
sham-treated rats. D1 dopamine receptors are localized throughout the molecular
layer (MOL) and hilus (H) of the dentate gyrus but absent from the granule cell
layer (GCL).
B. Immunohistochemistry for D1 dopamine receptor labeling in the dentate gyrus of
epileptic rats revealed a similar labeling pattern to sham-treated controls.

5.3.7 LOCALIZATION OF D1 DOPAMINE RECEPTORS IS UNCHANGED IN THE EPILEPTIC
CA3 REGION
In the CA3 region, previous studies have demonstrated spare localization of D1
dopamine receptors on GABAergic interneurons (Gangarossa et al., 2012). In this study,
we also found that D1 dopamine receptors are scattered on interneurons (Figure 5.7A, B).
However, in addition to D1 labeled interneurons, we also saw prominent labeling in the
stratum lucidum, resembling mossy fiber axon labeling.
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Mossy fiber sprouting and hyperexcitability is a hallmark symptom of chronic
epilepsy (Tauck and Nadler, 1985; Sutula et al., 1988, 1989; Houser et al., 1990; Babb et
al., 1991; Cronin et al., 1992). Thus, we investigated whether D1 dopamine receptor
expression is altered in the epileptic CA3 region compared to sham-treated controls
(Figure 5.7C, D). Our immunostaining demonstrated no observable differences in D1
dopamine receptor labeling in the epileptic CA3 region (Figure 5.7C) when compared to
sham-treated control (Figure 5.7D).
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Figure 5.7 D1 dopamine receptor expression does not change in the epileptic CA3
region.
A. Representative normal hippocampus illustrating the CA1, CA3, and dentate gyrus
(DG) regions. The black box indicates the CA3 region.
B. Magnification of the CA3 region from a naïve rat. D1 dopamine receptor
immunobloting prominently labeled mossy fiber axons in the stratum lucidum
(S.L.). D1 dopamine receptors were also expressed on spare interneurons
throughout the stratum oriens (S.O.), stratum radiatum (S.R.), stratum pyramidale
(S.P.), and stratum lucidum (S.L.).
C. Immunohistochemistry for D1 dopamine receptor labeling in the CA3 region of
sham-treated rats.
D. Immunohistochemistry for D1 dopamine receptor labeling in the CA3 region of
chronically epileptic rats demonstrates similar labeling pattern and intensity to the
sham-treated rats.

5.3.8 TOTAL DOPAMINE AND DOPAMINE METABOLITE LEVELS REMAIN UNCHANGED
IN TLE HIPPOCAMPUS

We next sought to better understand how changes in the D1-like receptor
expression and localization might alter overall dopaminergic function. Our leading
hypothesis was overall D1-like receptor expression in the TLE hippocampal was
suppressed due to homeostatic compensation for upregulated dopamine. Thus, we used
HPLC to measure dopamine, dopamine metabolites, and norepinephrine concentration in
whole TLE hippocampus and sham-treated controls. Several experimental controls were
applied to ensure we identified the correct peak as dopamine. In addition to running
standard controls at various concentrations, sample from a sham-treated hippocampus
was also spiked with DA standard. The solemn differentiating peak was considered
dopamine (Fig. 5.6, C).
Total dopamine (DA), dopamine metabolites (DOPAC), and norepinephrine (NE)
in whole hippocampus were unaffected by TLE (Fig. 5.6, A-B,D). Monoamine levels
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Figure 5.8 Total dopamine and dopamine metabolite levels remain unchanged in the
TLE hippocampus.
A. High performance liquid chromatography (HPLC) chromatorgrams for shamtreated (black line) superimposed with epileptic (gray line) illustrated no change
in total hippocampus concentration of dopamine (DA), dopamine metabolite (3,4dihydroxyphenylacetic acid (DOPAC)), or norepinephrine (NE, downstream
synthesized catecholamine).
B. Chromatographs of a combination standard (100 nM of NE, DOPAC, and DA;
black dash line), sham-treated sample (black solid line), and sham-treated sample
“spiked” with 100 nM combination standard (gray line) superimposed to
demonstrate correct identification of each monoamine.
C. Quantification of DA, DOPAC, dopamine utilization (DOPAC/DA, a measure of
released dopamine), and NE revealed no significant differences in monoamine
concentrations between the epileptic and sham-treated hippocampus.
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were reported as a percentage of Sham-treated controls. Total levels of DA in epileptic
animals were 86.376 ± 8.114% of that in sham-treated animals (n = 4 sham-treated, n = 7
epileptic) (Fig. 5.6, A-B,D). Total DOPAC levels in epileptic animals were 105.466 ±
23.817% of that in sham-treated animals. Total NE levels in epileptic animals were
100.609 ± 3.115% of that in sham-treated animals. Dopamine utilization was calculated
by dividing total DOPAC by DA concentration as a measure of released dopamine. No
difference was observed in the epileptic hippocampus (125.133 ± 27.885%) from shamtreated animals. Thus, the amount of dopamine produced is not different between the
sham and epileptic hippocampus. These results suggest that changes in dopamine
receptor expression are more significant.

5.3.9. REDUCED DOPAMINE CLEARANCE IN THE EPILEPTIC HIPPOCAMPAL CA1
REGION

After observing that dopamine concentration did not change in epilepsy, we then
evaluated whether dopamine clearance is altered in the chronically epileptic
hippocampus. Western blots for COMT in microdissected CA1 from epileptic and shamtreated animals displayed two bands (35kD and 25kD) (Fig. 7, B). Immunoblot analysis
revealed no significant difference at either protein size (35kD, 109.921 ± 10.073%; 25kD,
98.658 ± 12.286%; n = 11) when compared to sham-treated animals (Fig. 7, B).
Immunoblots for DAT also displayed a band at two protein sizes (80kD and
55kD) (Fig. 7, A). Epilepsy demonstrated a significant reduction in DAT protein
expression in the 80kD protein size (50.588 ± 10.867%, n = 11, p = 0.03) but not the
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55kD protein size (84.534 ± 8.287%, n = 11), when compared to sham-treated animals
(Fig. 7, A). Thus, we observed reduced dopamine clearance in the epileptic hippocampal
CA1 region.

Figure 5.9 Reduced dopamine clearance in the epileptic hippocampal CA1 region.
A. Antigen for DAT recognized bands at 80 kilodaltons (kD) and 55 kD. Western
blot analysis revealed a significant reduction in dopamine transporter (DAT)
protein expression in the epileptic CA1 area only at 80 kD when compared to
sham-treated rats.
B. Antigen for COMT recognized bands at 35 kD and 25 kD. Western blot analysis
revealed no difference in catechol-O-methyl transferase (COMT) protein
expression in the epileptic CA1 area when compared to sham-treated rats.
Immunoblot analyses were corrected for actin.
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5.3.10 NO

CHANGE IN DOPAMINERGIC FIBER EXPRESSION IN THE EPILEPTIC

HIPPOCAMPAL CA1 REGION

To determine whether dopaminergic fibers expression and/or localization were
altered in the epileptic condition, we performed immunoblots with microdissected
hippocampal CA1 and immunohistochemistry with epileptic and sham-treated animals.
Immunoblot analysis revealed no significant change in epileptic tyrosine hydroxide (TH)
expression (97.047 ± 15.919%, n = 8) from sham-treated animals (Fig. 8, C). This result
was confirmed by immunostaining. TH labeled catecholamine fibers that dispersed
randomly throughout all CA1 layers (Fig. 7, A-B). Thus, no change was observed in the
amount of dopaminergic fibers.
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Figure 5.10 No change in dopaminergic fiber expression in the epileptic
hippocampal CA1 region.
A. Immunohistochemistry for tyrosine hydroxylase (TH) labeling in area CA1 of
sham-treated rats.
B. Immunohistochemistry for tyrosine hydroxylase (TH) labeling in area CA1 of
epileptic rats revealed no difference in dopaminergic fiber innervation.
C. Western blots confirmed immunostaining results, demonstrating no difference in
TH protein expression when comparing epileptic to sham-treated CA1. TH
protein expression was normalized to actin.

5.4 DISCUSSION

The principal finding of this study is that the dopaminergic system is altered in a
chronic model of temporal lobe epilepsy. In our study we have identified differential
patterns of labeling between D1 and D5 receptors. D1 DARs were located primarily on
interneurons, diffused throughout the molecular layer of the dentate gyrus, and on mossy
fiber axons, while D5 receptors were located predominately in pyramidal neurons
dendrites. D5 DAR protein expression was significantly reduced in proximal dendrites of
the epileptic hippocampal CA1 area. No change in protein expression was seen in D1
DARs; however we did observe a possible increase in interneuron D1 DAR expression in
the epileptic CA1. These results were accompanied by a reduction in dopamine clearance,
but no change in overall dopamine content.
We identify that D5 dopamine receptors are significantly reduced in the epileptic
hippocampus. This deficit in D1-like receptor may result in the cognitive decline
associated with epilepsy. To date the role of D5 dopamine receptors are not well
characterized. However, previous studies have elucidated a role for D5 dopamine
155

receptors in learning and memory. D5 dopamine receptors are particularly important in
regulating plasticity of the medial perforant path onto dentate granule cells (Yang and
Dani, 2014) Furthermore, a rat model of ADHD that demonstrates impaired learning also
has significantly lower D5 dopamine receptor expression than healthy controls (Medin et
al., 2013).
Previous studies have identified D1 DARs primarily on interneurons (Mansour et
al., 1990, 1991; Fremeau et al., 1991; O’Sullivan et al., 2008; Gangarossa et al., 2012).
However, other studies suggest that D1 DARs are predominately in pyramidal neurons
(Bergson et al., 1995). We identify D1 DARs to be predominately located on
interneurons, with diffuse labeling throughout the stratum pyramidal cell body layer and
dendrites. In our hands, we identified no change in D1 DAR expression. This was of
particular interest to us because we identified D1 DARs to be primarily located on
interneurons. It has been widely demonstrated in previous literature and also replicated in
this study that interneurons, particularly in the stratum oriens, are susceptible to cell death
in epilepsy (Dinocourt et al., 2003). Thus, no change in D1 DAR expression may indicate
that the remaining interneurons have upregulated D1 DAR expression.
There is not a consensus on how the dopaminergic system is altered in epilepsy.
Some studies indicated that dopamine concentration increases (Cavalheiro et al., 1994),
while others indicate no change dopamine content but an increase in dopamine
metabolites (Freitas et al., 2004). We identified no significant change in dopamine
concentration. We went to great lengths to identify the correct peak for each monoamine
measured. Not only were various concentration of each monoamine standard used to
complete the standard curves for measuring accurate concentration and retention times,
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but a hippocampus sample was “spiked” with a combination of each monoamine
standard. The spiked sample, original hippocampus sample, and the monoamine standard
were all superimposed onto each other, and the peaks in common were identified as the
respective monoamine.
We demonstrated a significant reduction of dopamine clearance in the epileptic
hippocampal CA1 region. This reduction in dopamine clearance suggests that even
though dopamine concentration is unchanged in the epileptic hippocampus, the dopamine
may be allowed to diffuse further away for the synapse. This would allow dopamine to
bind to receptors it would not normally interact with, in effect, increasing its sphere of
influence. Immunoblots for both COMT and DAT produced two bands. COMT
immunoblots produced bands at 35kD and 25kD. The 35kD band represents the
phosphorylated form of COMT, which is transported to the cell surface where it can be
more active. The 25kD COMT band represents the non-phosphorylated from of COMT,
which is left in the cytoplasm and is considered the less active form. DAT immunoblots
demonstrated bands at 80kD and 55kD. The 80kD band represents the glycosylated,
mature form of DAT, which is packaged and transported to the cell membrane. The 55kD
band is thought to be the non-glycosylated, immature form of DAT, which is left in the
endoplasmic reticulum.
Based on our findings, we suggest that dopamine D1-like receptor expression is
differentially regulated in the epileptic hippocampus. A decrease in D5 dopamine
receptors located in CA1 hippocampus pyramidal neurons and reduction in dopamine
clearance may speak to the deficits in learning and memory seen is patients with temporal
lobe epilepsy.
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CHAPTER 6
GENERAL DISCUSSION AND SIGNIFICANCE

6.1 FINDINGS OF THE STUDY

1. ACET selectively inhibits the GluK4 and GluK5 subunits in GluK2/K4 and GluK2/K5
heteromeric receptor. Kynurenate selectively inhibits the GluK2 subunits. We used both
drugs to determine that glutamate binding to either the “high-affinity” subunits (GluK4 or
GluK5) or the GluK2 subunit is sufficient to activate the heteromeric receptor. However,
desensitization occurred only when three or more subunits are bound to glutamate.
Furthermore, we demonstrated that perfusing ACET onto brain slices inhibits kainate
receptor synaptic transmission at the mossy fiber – CA3 synapse. See Figure 6.1 for an
illustration of these conclusions.

2. Activation of M1 mAChRs, but not D1 dopamine receptors, depressed KAR synaptic
transmission at the mossy fiber – CA3 synapse. This effect is mediated through colocalized M1 and KARs on the postsynaptic CA3 neuron. However, PKC
phosphorylation does not explain this depression. Furthermore, M1 mAChR depression
of KAR synaptic transmission goes away in adulthood. See Figure 6.2 for an illustration
of these conclusions.
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3. Dopamine D5 receptor is significantly reduced in the epileptic CA3 region of the
hippocampus, while D1 dopamine receptor expression in remaining interneurons is
upregulated. Additionally, dopamine transporter and COMT were significantly reduced
although tyrosine hydroxylase and dopamine content were unchanged. Thus, total
dopamine in the epileptic hippocampus is unchanged but dopamine clearance is reduced.
This suggests that more dopamine is floating in the extrasynaptic space. See figure 6.3 for
an illustration of these conclusions.

6.2 MUSCARINIC MODULATION OF KAINATE RECEPTORS: IMPLICATIONS FOR
EXERCISE AND EPILEPSY

Exercise alters the cholinergic system in healthy and diseased brains. Particularly,
in the hippocampus, exercise has been shown to double acetylcholine release during
moderate intensity exercise (Nakajima et al., 2003; Uchida et al., 2006), while inhibiting
acetylcholine degradation by inhibiting acetylcholinesterase (Tsakiris et al., 2006). Thus,
more acetylcholine is released and remains in the extrasynaptic space in the exercising
brain. This increase in acetylcholine content would increase binding and activation of
acetylcholine receptors, including abundantly expressed M1 muscarinic acetylcholine
receptors (Cortes et al., 1984; Cortés et al., 1986; Rodríguez-Puertas et al., 1997; Scarr et
al., 2007). In the CA3 region, we proved that M1 mAChR activation depressed KARmediated synaptic transmission, where they are co-localized on CA3 pyramidal neurons
(Chapter 4). Thus, an exercise-induced increase in acetylcholine in the hippocampus
would increase binding to M1 mAChRs in principal neurons, including in the CA3. This
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Figure 6.1 Illustration of the receptor occupancy model for KAR activation and desensitization. When no glutamate is
present, the kainate receptor is closed and no current is produced. If either GluK2 or the GLuK5 subunits in the GluK2/K5
heteromeric tetramer are bound to glutamate, the receptor opens to a non-desensitzing current. However, when three or more
subunits in the tetramer are bound to glutamate, the kainate receptor will desensitize.
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Figure 6.2 Illustration of M1 mAChR depression of kainite receptor EPSPs. During normal synaptic
transmission, depolarization of mossy fibers causes release of glutamate from mossy fiber terminals. This released
glutamate binds to GluK2/K4 and/or GluK2/K5 receptors located postsynaptically on CA3 pyramidal neurons and
produces a KAR EPSP. Bath application of pilocarpine activates M1 mAChRs located on CA3 pyramidal neurons,
which elicits a signaling cascade that either phosphorylates or dephosphorylates GluK2/K4 and GluK2/K5
receptors. The end result is KARs trafficking away from the synapse and smaller KAR fEPSP amplitudes.

Figure 6.3 Illustration of dopaminergic system alteration in the epileptic CA1
compared to the normal brain. We discovered that D5 dopamine receptors and
dopamine clearance is reduced in the epileptic hippocampus, while dopamine
concentration and the amount of dopaminergic fiber is unchanged. Thus, we reasoned
that released dopamine remains in the extrasynaptic space longer in the epileptic brain
compared to the normal brain.
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increased M1 mAChR activation would subsequently depress KAR synaptic
transmission.
Overactivation of KARs have been implicated in epilepsy (Ben-Ari and Cossart,
2000; Vincent and Mulle, 2009; Contractor et al., 2011; Lerma and Marques, 2013).
First, due to their slow deactivation kinetics, KARs facilitate temporal summation of
postsynaptic excitatory potentials and epileptiform bursting (Castillo et al., 1997; Vignes
and Collingridge, 1997; Frerking et al., 1998; Kidd and Isaac, 2008). Secondly,
postsynaptic

KARs

elicits

a

metabotropic

function

that

reduces

the

slow

afterhyperpolarization, causing an increase in spike firing and neuronal excitability
(Melyan et al., 2002, 2004). Furthermore, a hallmark symptom of chronic epilepsy in
both human and animal models is mossy fiber sprouting, where mossy fibers in the CA3
make aberrant synaptic connections onto dentate granule cell neurons (Buckmaster et al.,
2002). This sprouting creates an excitatory feed forward circuit that is susceptible to
epileptiform bursting. KARs also located on these sprouted mossy fibers and can respond
to glutamate (Epsztein et al., 2005). Lastly, KARs are also located presynaptically on
principal and interneurons where they facilitate glutamate release and inhibit GABA
release (Contractor et al., 2011; Carta et al., 2014). Overactivation of presynaptic KARs
would tilt the excitatory/inhibitory brain balance to being more excitatory. Thus, an
exercised-induced suppression of KARs activity on CA3 pyramidal neurons would be
beneficial for patients with epilepsy. Indeed, humans and animals with a chronic model
of temporal lobe epilepsy have demonstrated reduced seizure frequency and susceptibility
to developing seizures when engaged in exercise training (Westerberg et al., 1984; Arida
et al., 1999, 2004, 2009a, 2013; de Lima et al., 2011; Gomes da Silva et al., 2011; Nyberg
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et al., 2013). Acutely, seizures susceptibility is higher during rest than during or
immediately after bouts of physical activity, which has been shown to silence
epileptiform discharges (Camilo et al., 2009; Vancini et al., 2010; de Lima et al., 2011).

6.3 ALTERATIONS IN THE DOPAMINERGIC SYSTEM IN TEMPORAL LOBE
EPILEPSY: IMPLICATIONS FOR EXERCISE

Forty years ago, epilepsy was thought to be a disease of dopaminergic
hypoactivity versus schizophrenia (Lamprecht, 1977; Starr, 1996), which is thought to be
a disease of dopaminergic hyperactivity. This theory was conceived as a result of studies
demonstrating that application of a general dopamine receptor agonist reduces seizure
susceptibility (Lamprecht, 1977; Lal, 1988), whereas blockage of dopamine receptors
induced seizures (Laird et al., 1984; Jann et al., 1993). We now known that there are two
subtypes of dopamine receptors: D1-like and D2-like. These dopamine receptors have
opposite effects on seizure susceptibility. D1-like dopamine receptor activation
precipitates seizures (Starr et al., 1987; al-Tajir et al., 1990a, 1990b), while D2-like
dopamine receptors reduce seizure susceptibility (al-Tajir et al., 1990a; Al-Tajir and
Starr, 1991).
In the chronically epileptic brain, we found that D5 dopamine receptor expression
is reduced in CA1, while total D1 dopamine receptor expression is unchanged but likely
upregulated in remaining interneurons in CA1. Additionally, we discovered that total
dopamine concentration remains unchanged, while dopamine clearance is reduced in the
whole hippocampus. Taken together, these results suggest that more dopamine is
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remaining in the extrasynaptic space. An increase in extrasynaptic dopamine would allow
more dopamine binding to both D1-like and D2-like dopamine receptors. In theory, these
anatomical changes of increased extrasynaptic dopamine and reduced D1-like dopamine
receptor expression are beneficial for the epileptic condition.
Interestingly, these changes mimic exercise’s effects on the dopaminergic system.
Briefly, exercise also increased dopamine concentration in the brain while reducing D1
DA receptor density (de Castro and Duncan, 1985; MacRae et al., 1987; Greenwood et
al., 2011). Exercise also decreases dopamine turnover (a ratio of dopamine metabolites to
dopamine concentration) in Parkinson patients (Aguiar et al., 2015), suggesting that a
higher percentage of released dopamine remains in the extrasynaptic space. Also,
exercise has been shown to increase the sensitivity of dopamine receptors to dopamine
(Zigmond et al., 2012). As stated in the previous section, exercise is beneficial for people
with epilepsy and can be used as an alternative therapy in conjunction with
pharmaceutical therapies to help patients manage their seizures.

6.4 FUTURE DIRECTIONS

1.

We used ACET and kynurenate to discover that binding to either the GluK2 or

GluK5 subunit is sufficient to activate the receptors, and that binding or both are required
for desensitization. However, we did not investigate the subunit contribution to
deactivation, which is fundamentally different mechanism than desensitization. Also,
deactivation has significant physiological relevance. Therefore, it would be important to
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use the pharmaceutical tools, ACET and kynurenate, to delineate the function roles of
GluK2 and GluK5 to deactivation.

2.

We found that M1 mAChRs depresses postsynaptic KAR-mediated synaptic

transmission at the mossy fiber – CA3 synapse. Epilepsy has been shown to modulate
both the cholingeric system and kainate receptor expression. Thus, it would be important
to determine whether a chronic model of epilepsy alters this M1 mAChR-mediated
depression of KARs.

3.

The dopaminergic system is altered in a chronic model of temporal lobe epilepsy.

Exercise is a potent therapy demonstrated to both reduce seizure frequency and alter the
dopaminergic system. Thus, it would be important to evaluate the anatomical and
functional differences between the dopaminergic system in a chronically epileptic rat and
a chronically epileptic rat that is allowed to undergo physical activity.
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